Page last updated: 2024-12-05

fenofibrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenofibrate is a lipid-lowering medication that belongs to the fibrate class of drugs. It is a synthetic compound that acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. When fenofibrate binds to PPARα, it modulates gene expression, leading to increased levels of lipoprotein lipase, which breaks down triglycerides. This results in reduced levels of triglycerides and very low-density lipoproteins (VLDL) in the blood, while also raising levels of high-density lipoprotein (HDL), known as good cholesterol. Fenofibrate is primarily used to treat high levels of triglycerides in the blood, especially in combination with other measures like diet and exercise. It may also be used to lower LDL cholesterol and slightly increase HDL cholesterol. Research on fenofibrate focuses on its efficacy in various conditions, including cardiovascular disease, diabetes, and metabolic syndrome. Studies have shown that fenofibrate can reduce the risk of heart attacks and strokes in individuals with high triglyceride levels. However, it is important to note that fenofibrate may have side effects, such as muscle pain, liver problems, and gallstones. It is generally well-tolerated, but it's crucial to discuss potential risks and benefits with a healthcare professional before taking fenofibrate.'

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5269
CHEMBL ID86537
CHEBI ID75272
SCHEMBL ID2544804
MeSH IDM0017618
PubMed CID3339
CHEMBL ID672
CHEBI ID5001
SCHEMBL ID4670
MeSH IDM0017618

Synonyms (325)

Synonym
1,2-dihydro-3h-benzo[f]chromen-3-one
chebi:75272 ,
HMS3268C11
BRD-K27710560-001-02-6
splitomicin ,
splitomicin, >=98% (hplc), powder
NCGC00025208-01
BIO2_000878 ,
BIO2_000398
tocris-1542
BSPBIO_001116
IDI1_002153
NCGC00025208-02
1,2-dihydro-3h-naphtho[2,1-b]pyran-3-one
KBIOGR_000456
KBIO2_003024
KBIOSS_000456
KBIO3_000851
KBIO3_000852
KBIO2_005592
KBIO2_000456
NCGC00025208-03
HMS1990H17
chembl86537 ,
bdbm29590
EC-000.2450
HMS1792H17
HMS1362H17
5690-03-9
1,2-dihydrobenzo[f]chromen-3-one
AKOS006288326
1h-benzo[f]chromen-3(2h)-one
1,2-dihydro-3h-naphtho[2,1-b]-pyran-3-one
S7593
gtpl8101
CCG-208679
S0892
SCHEMBL2544804
AC-35443
3h-naphtho[2,1-b]pyran-3-one, 1,2-dihydro-
ISFPDBUKMJDAJH-UHFFFAOYSA-N
splitomycin
1-naphthalenepropionic acid, 2-hydroxy-, .delta.-lactone
HB4091
HMS3403H17
mfcd08705254
SR-01000597607-1
sr-01000597607
1h,2h,3h-naphtho[2,1-b]pyran-3-one
HY-100585
CS-0019737
splitomicin - cas 5690-03-9
HMS3676J05
Q27088853
BCP10432
HMS3412J05
DTXSID201017436
A14221
T72636
AS-56331
NCGC00025208-05
1-naphthalen propanoic acid
AC-4227
BIDD:GT0574
MLS001148191
HY-17356
AB00052196-15
AB00052196-16
BRD-K50388907-001-05-6
MLS000028515 ,
KBIO1_000557
DIVK1C_000557
CHEBI:5001 ,
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
fnf ,
finofibrate
propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate
EU-0100486
fenofibrate, >=99%, powder
fenofibrate (micronized)
isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
ankebin
lipantil
triglide
lipidex
fenotard
SPECTRUM_001250
brn 2062462
einecs 256-376-3
c20h21clo4
procetofen
tricor (micronized)
lipoclar
protolipan
nsc 281319
lipofene
lipirex
isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
lf-178
isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
phenofibrate
lipsin
lipifen
nolipax
fenofibratum [inn-latin]
tricor
liposit
antara
elasterin
propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester
luxacor
secalip
procetofene
ccris 7282
2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
fenobrate
fenofibrato [inn-spanish]
elasterate
fenogal
lipidil
lipanthyl
BSPBIO_000150
PRESTWICK_217
lopac-f-6020
NCGC00015437-01
cas-49562-28-9
NCGC00015437-02
IDI1_000557
SPECTRUM5_001479
nsc281319
sedufen
nsc-281319
proctofene
PRESTWICK2_000275
BPBIO1_000166
LOPAC0_000486
BSPBIO_003162
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester
fulcro
lipofen
fenoglide
lcp-feno
cip-fenofibrate
fenomax
pharmavit
lcp-fenochol
grs-027
fenofibrate idd-p
AB00052196
fenofibrate ,
C07586
49562-28-9
DB01039
antara (tn)
tricor (tn)
lipofen (tn)
triglide (tn)
fenofibrate (jan/usp/inn)
lipantil (tn)
D00565
PRESTWICK3_000275
NCGC00021475-05
NCGC00021475-04
NCGC00021475-07
smr000058299
KBIOSS_001730
KBIOGR_000706
KBIO2_001730
KBIO2_004298
KBIO3_002382
KBIO2_006866
SPECTRUM2_001390
SPBIO_002369
SPECTRUM3_001431
SPBIO_001380
PRESTWICK1_000275
PRESTWICK0_000275
NINDS_000557
SPECTRUM4_000413
SPECTRUM1501010
NCGC00021475-08
NCGC00015437-03
NCGC00021475-03
NCGC00021475-06
lofibra
lf 178
supralip
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
NCGC00015437-06
HMS2090G20
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methyl-ethyl ester
HMS2092B05
F 6020 ,
NCGC00015437-12
bdbm50085042
isopropyl (4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
fenofibrate micronized
fenofibrate delayed release
CHEMBL672 ,
HMS501L19
AKOS005107777
FT-0654669
HMS1568H12
HMS1921B17
NCGC00015437-10
BRD-K50388907-001-18-9
HMS3259K03
HMS2095H12
HMS3261B13
F0674
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionate
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionic acid isopropyl ester
NCGC00253945-01
tox21_300151
isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate;fenofibrate
A827746
nsc-757822
pharmakon1600-01501010
nsc757822
MLS002548878
tox21_110147
dtxcid209874
dtxsid2029874 ,
HMS2231B14
CCG-38996
NCGC00015437-07
NCGC00015437-08
NCGC00015437-13
NCGC00015437-04
NCGC00015437-14
NCGC00015437-09
NCGC00015437-05
NCGC00015437-11
ec 256-376-3
hsdb 7736
antara (micronized)
u202363uos ,
unii-u202363uos
fenofibratum
fenofibrate [usan:usp:inn:ban]
fenofibrato
FT-0626400
NCGC00015437-16
LP00486
AB03716
fenofibrate [usan]
fenofibrate [jan]
fenofibrate [who-dd]
fenofibrate [orange book]
fenofibrate [inn]
fenofibrate [usp monograph]
fenofibrate [ema epar]
fenofibrate [usp impurity]
fenofibrate [hsdb]
fenofibrate [mart.]
fenofibrate [usp-rs]
fenofibrate [mi]
fenofibrate [ep monograph]
fenofibrate [vandf]
CS-0892
S1794
HMS3369M13
gtpl7186
isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
NC00452
SCHEMBL4670
NCGC00015437-17
tox21_110147_1
MS-2223
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoicacidisopropylester
tox21_500486
NCGC00261171-01
Q-201111
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester
isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
procetoken
HMS3649D20
AB00052196_18
AB00052196_17
OPERA_ID_328
mfcd00133314
propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate
SR-01000000091-5
sr-01000000091
fenofibrate, united states pharmacopeia (usp) reference standard
fenofibrate, analytical reference material
fenofibrate, european pharmacopoeia (ep) reference standard
HMS3655K12
fenofibrate, pharmaceutical secondary standard; certified reference material
SR-01000000091-2
SR-01000000091-6
SR-01000000091-8
SBI-0050470.P003
HMS3712H12
SW196525-4
BCP21243
Q419724
fenofibrate (micronized) (fenofibrate
fenofibrate (tricor, trilipix)
fenofibrate,(s)
SR-01000000091-16
BRD-K50388907-001-20-5
SDCCGSBI-0050470.P004
NCGC00015437-31
1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethylester
isopropyl 2-(4-(4-chlorobenzoyl)-phenoxy)-2-methylpropanoate
SY052561
CS-0695026
HY-17356R
fenofibrate (standard)
Z1501485369
c10ab05
fenofibrate (usp impurity)
fenofibrate (usan:usp:inn:ban)
fenofibrate (usp-rs)
fenofibratum (inn-latin)
fenofibrato (inn-spanish)
propan-2-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
fenofibrate (ep monograph)
fenofibrate (mart.)
lipidax
fenofibratefilm coated
fenofibrate (usp monograph)

Research Excerpts

Overview

Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. It is an agonist drug for peroxisome proliferator-activated receptor alpha (PPAR. Fe is an antilipidemic drug that increases the activity of the lipoprotein lipase enzyme.

ExcerptReferenceRelevance
"Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. "( Short-term fenofibrate treatment improves ultrastructure of hepatocytes of old rats.
Kmiec, Z; Wronska, A; Zauszkiewicz-Pawlak, A; Zubrzycki, A, 2021
)
2.45
"Fenofibrate is an agonist drug for peroxisome proliferator-activated receptor alpha (PPAR"( Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Butler, AE; Jamialahmadi, T; Mahmoudi, A; Sahebkar, A, 2021
)
1.65
"Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury."( Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis.
Aizawa, F; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kanda, M; Maegawa, A; Miyata, K; Niimura, T; Okada, N; Sakurada, T; Yagi, K; Yanagawa, H; Yoshida, A; Yoshioka, T; Zamami, Y, 2022
)
1.44
"Fenofibrate, which is an agonist of peroxisome proliferator-activated receptor α, has been used primarily in hypercholesterolemia and mixed dyslipidemia."( The effect of fenofibrate, a peroxisome proliferator-activated receptor α agonist, on cardiac damage from sepsis in BALB/c mice.
Long, X; Lv, M; Xie, D, 2022
)
1.8
"Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. "( Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.
AboKamer, AM; Al-Gareeb, AI; Al-Kuraishy, HM; Alkhayyat, SS; Batiha, GE; El-Bouseary, MM; Simal-Gandara, J, 2022
)
3.61
"Fenofibrate (FEN) is an antilipidemic drug that increases the activity of the lipoprotein lipase enzyme, thus enhancing lipolysis; however, it may cause myopathy and rhabdomyolysis in humans. "( Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?
AbdElfattah, AA; Ayuob, NN; El-Bassouny, DR; Ellakkany, AS; Mansour, AA, 2023
)
2.61
"Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in clinical therapy to effectively ameliorate the development of NAFLD, but its mechanism of action is incompletely understood."( Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice.
Chen, H; Chen, Y; Geng, Z; Huang, M; Li, L; Liu, J; Ma, L; Ma, Y; Wang, D; Wang, H; Wang, X; Wen, D; Zhang, D; Zhu, X; Zou, C, 2023
)
3.07
"Fenofibrate is a hypolipidemic peroxisome proliferator-activated receptor α (PPARα) agonist used clinically to reduce hypercholesterolemia and hypertriglyceridemia."( Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Jeon, S; Lee, J; Lee, M; Yoon, M, 2023
)
3.8
"Fenofibrate (FF) is a good candidate for the treatment of lipid abnormalities in patients with type 2 diabetes."( Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat.
Barman, RK; Ghosh, MK; Habib, A; Khan, RI; Wahed, MII, 2020
)
1.57
"Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. "( Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Buschard, K, 2020
)
3.44
"Fenofibrate is an effective lipid-lowering drug; however, its poor solubility and high log p (5.2) result in insufficient absorption from the gastrointestinal tract, leading to poor bioavailability. "( A One-Step Twin-Screw Melt Granulation with Gelucire 48/16 and Surface Adsorbent to Improve the Solubility of Poorly Soluble Drugs: Effect of Formulation Variables on Dissolution and Stability.
Ajjarapu, S; Bandari, S; Butreddy, A; Janga, KY; Kallakunta, VR; Murthy, SN; Repka, MA; Sarabu, S; Zhang, F, 2021
)
2.06
"Fenofibrate is a marketed fibric acid derivative for lipid-lowering in patients with lipid disorders. "( Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis.
Chen, Y; Dong, Z; Ji, X; Li, C; Li, R; Lu, J; Zhang, J; Zhao, Y, 2021
)
2.47
"Fenofibrate is a lipid-regulating agent and exhibits species-related hazards in fish."( Microparticle formulations alter the toxicity of fenofibrate to the zebrafish Danio rerio embryo.
Böhmer, W; Eilebrecht, E; Fenske, M; Günday-Türeli, N; Heng, PWS; Hering, I; Modh, H; Parnham, MJ; Schäfers, C; Türeli, AE; Wacker, MG; Weiler, M, 2021
)
1.6
"Fenofibrate is a fibric acid derivative known to have a lipid-lowering effect. "( The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
Dai, X; Huang, B; Ni, S; Nyalali, AMK; Sun, J; Xu, F; Zhang, K; Zhao, H; Zhu, W, 2021
)
2.37
"Fenofibrate is a PPAR-α agonist In the present study, we investigate the effects and relevant mechanism of fenofibrate on experimental myocardial ischemia-reperfusion (I/R) injury in rats."( Fenofibrate protects against acute myocardial I/R injury in rat by suppressing mitochondrial apoptosis as decreasing cleaved caspase-9 activation.
Cui, Z; Li, Q; Sheng, X; Tao, M; Xu, C; Xu, H; Zhao, Q; Zheng, Y, 2017
)
2.62
"Fenofibrate (FF) is a drug for regulating lipids."( Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation.
Kumar, R; Siril, PF, 2018
)
1.5
"Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended."( Identification and Characterization of Fenofibrate-Induced Liver Injury.
Ahmad, J; Barnhart, H; Chalasani, N; Cirulli, ET; Fontana, RJ; Hayashi, PH; Hoofnagle, JH; Kleiner, DE; Odin, JA, 2017
)
2.17
"Fenofibrate is a peroxisome proliferator-activated receptor (PPAR)-α activator that lowers triglycerides and influences cytochrome P-450 (CYP-450) epoxygenase-dependent arachidonic acid (AA) metabolism. "( Protective effect of fenofibrate against ischemia-/reperfusion-induced cardiac arrhythmias in isolated rat hearts.
Al-Masri, AA; Almotrefi, AA; Bukhari, IA; Mohamed, OY; Sheikh, SA, 2018
)
2.24
"Fenofibrate is a fibric acid derivative indicated for use in hypertriglyceridemia and mixed dyslipidemia treatment among adults. "( Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.
Wang, D; Wang, Y, 2018
)
3.37
"Fenofibrate is a safe and inexpensive orally administered fibric acid derivative conventionally used to treat dyslipidemia. "( Fenofibrate for Diabetic Retinopathy.
Lois, N; Stewart, S,
)
3.02
"Fenofibrate is a fibric acid derivative which exhibits a role of peroxisome proliferator-activated receptor-alpha agonist. "( Fenofibrate inhibits the growth of prostate cancer through regulating autophagy and endoplasmic reticulum stress.
Shen, Q; Shen, Z; Tao, T; Xiao, J; Xuan, Q; Zhao, F, 2018
)
3.37
"Fenofibrate (Fb) is a known treatment for elevated triglyceride (TG) levels. "( Detecting responses to treatment with fenofibrate in pedigrees.
Bickeböller, H; Cantor, RM; Cherlin, S; Wang, MH, 2018
)
2.19
"Fenofibrate (Fbt) is a prodrug that has been used to reduce low-density-lipoprotein cholesterol, triglycerides, and increase high-density-lipoprotein cholesterol. "( Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
Li, G; Qiu, F; Sun, Y; Zhao, L; Zhao, M, 2019
)
2.18
"Fenofibrate (FNB) is an effective drug for the treatment of hypertriglyceridemia, hypercholesterolemia as well as mixed hyperlipidemia. "( Fenofibrate Solid Dispersion Processed by Hot-Melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism.
Niu, B; Pan, X; Quan, G; Wen, T; Wu, C; Wu, Q; Zhou, Y, 2019
)
3.4
"Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR). "( Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K, 2019
)
3.4
"Fenofibrate is an agonist of peroxisome proliferator-activated receptor α and can reduce the incidence of cardiovascular events in diabetic patients."( Fenofibrate improves vascular endothelial function in diabetic mice.
An, D; Fu, J; Huang, F; Li, Y; Xin, R; Zhu, Q, 2019
)
2.68
"Fenofibrate is a hypolipidemic drug, which acts by activating the transcription factor PPARα."( Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.
Alhousseiny, S; Ding, H; Jameel, M; Majeed, Y; Musthak, A; Shaheen, Y; Taha, T; Triggle, CR; Upadhyay, R, 2019
)
1.46
"Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia."( Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.
Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012
)
2.54
"Fenofibrate is a prototypical agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) which is well known to be associated with species related carcinogenesis. "( Metabolism of fenofibrate in beagle dogs: new metabolites identified and metabolic pathways revealed.
Chen, L; Dai, R; Liu, A; Luo, W; Yang, J, 2013
)
2.19
"Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance. "( Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014
)
3.29
"Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has antiinflammatory actions and regulates bile acid detoxification."( Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
Ananthanarayanan, M; Boyer, JL; Ghonem, NS; Soroka, CJ, 2014
)
1.12
"Fenofibrate is a serum lipid-lowering agent used as an adjunct to diet in patients with hypercholesterolemia and hypertriglyceridemia. "( Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.
Chachad, SS; Gole, M; Malhotra, G; Naidu, R, 2014
)
2.12
"Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceridemia. "( ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity.
Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014
)
2.06
"Fenofibrate (FF) is a common lipid-lowering drug and a potent agonist of the peroxisome proliferator-activated receptor alpha (PPARα). "( Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.
Culicchia, F; Dean, M; Grabacka, M; Marrero, L; Mullinax, J; Ochoa, A; Parsons, C; Peruzzi, F; Reiss, K; Wilk, A; Wyczechowska, D; Zapata, A, 2015
)
2.17
"Fenofibrate is a lipid-lowering agent that has been shown to be capable of preventing DR progression."( Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats.
Hsu, YJ; Wang, LC; Yang, CH; Yang, CM; Yang, WS, 2014
)
1.51
"Fenofibrate is a specific agonist of PPARα, and is characterized by relatively low systemic toxicity. "( Enhancement of radiosensitivity in human esophageal carcinoma cells by fenofibrate and its potential mechanism.
Li, XQ; Meng, XJ; Wu, JC; Yu, J; Zhou, JD; Zou, ST,
)
1.81
"Fenofibrate is a potential novel therapy for primary biliary cirrhosis (PBC). "( Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
Corpechot, C; Grigorian, AY; Levy, C; Mardini, HE; Poupon, R, 2015
)
3.3
"Fenofibrate is a lipid-lowering drug and an agonist of the peroxisome proliferator-activated receptor alpha (PPARα)."( NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells.
Chen, X; Han, D; Hu, Q; Liu, N; Wang, X; Wang, Y; Wei, W; You, Y; Yu, T; Zhang, J; Zhang, Y, 2015
)
1.39
"Fenofibrate is a potent agonist of PPARα and is used in the treatment of hyperlipidemia."( Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation.
Bae, SH; Kang, DH; Lee, DH; Park, JS, 2015
)
2.58
"Fenofibrate is a lipophilic drug used in hypercholesterolemia and hypertriglyceridemia as a lipid-regulating agent; however, it is characterized by poor water solubility and low dissolution rate, which result in a low oral bioavailability. "( Sericin/Poly(ethylcyanoacrylate) Nanospheres by Interfacial Polymerization for Enhanced Bioefficacy of Fenofibrate: In Vitro and In Vivo Studies.
Cappello, AR; Dolce, V; Fiorillo, M; Iacopetta, D; Parisi, OI; Puoci, F; Scrivano, L; Sinicropi, MS, 2015
)
2.07
"Fenofibrate is an orally administered, poorly water-soluble active pharmaceutical ingredient (API), used clinically to lower lipid levels."( Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide.
Badens, E; Bouledjouidja, A; Masmoudi, Y; Schueller, L; Van Speybroeck, M, 2016
)
1.5
"Fenofibrate is a clinical lipid-lowering agent and an effective anticancer drug."( Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential Drug Repurposing for Oral Cancer.
Chang, NW; Chiu, CF; Huang, YP; Jan, CI; Liu, CJ; Tsai, MH, 2016
)
2.6
"Fenofibrate is a synthetic ligand for peroxisome proliferator-activated receptors subtype alpha (PPARa); it is used for the treatment of a wide range of metabolic diseases such as hypertriglyceridemia, dyslipidemia, diabetes and various neurodegenerative diseases. "( [The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes].
Bashmakov, VY; Gureev, AP; Popov, VN; Shmatkova, ML; Starkov, AA, 2016
)
2.23
"Fenofibrate is a selective agonist of PPAR-α."( Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway.
Huang, C; Jiang, B; Song, L; Wang, H; Wang, YJ; Wu, F; Zhang, W; Zhu, Q, 2017
)
1.46
"Fenofibrate is a PPAR-alpha agonist indicated for the treatment of hypertriglyceridemia and mixed dyslipidemia, and is approved for the treatment of hypercholesterolemia, lipid abnormalities commonly observed in patients at high risk of cardiovascular disease, including Type 2 diabetes and/or metabolic syndromes. "( Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson, RS, 2008
)
3.23
"Fenofibrate is a peroxisome proliferator-activated receptor-alpha (PPARalpha) activator that has been clinically used to treat dyslipidemia and insulin resistance. "( Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Bao, Y; Huang, P; Jia, W; Liu, Y; Lu, J; Wei, L; Wu, H; Xiang, K, 2009
)
3.24
"Fenofibrate is a synthetic ligand for the nuclear receptor peroxisome proliferator-activated receptor (PPAR) alpha and has been widely used in the treatment of metabolic disorders, especially hyperlipemia, due to its lipid-lowering effect. "( Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells.
Araki, H; Charnock-Jones, DS; Doi, A; Dunmore, B; Humphrey, S; Imoto, S; Kuhara, S; Miyano, S; Nagasaki, M; Nakanishi, Y; Print, C; Sanders, D; Tamada, Y; Tashiro, K; Tomiyasu, Y; Yasuda, K, 2009
)
2.02
"Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood."( Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
Belfort, R; Berria, R; Cornell, J; Cusi, K, 2010
)
3.25
"Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist that has been widely used to treat dyslipidemia. "( Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis.
Do, MH; Joe, Y; Kang, S; Lee, HJ; Park, HT; Seo, E; Yun, J, 2010
)
3.25
"Fenofibrate is a lipid-lowering agent and supposed to have anti-inflammatory properties. "( The modulatory mechanisms of fenofibrate on human primary T cells.
Cheng, SM; Chu, KM; Lai, JH, 2010
)
2.09
"Fenofibrate is a potent agonist of peroxisome proliferator activated receptor alpha (PPARalpha) that can switch energy metabolism from glycolysis to fatty acid beta-oxidation, and has low systemic toxicity."( ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.
Del Valle, L; Drukala, J; Grabacka, M; Madeja, Z; Reiss, K; Urbanska, K; Wilk, A; Wybieralska, E, 2010
)
1.33
"Fenofibrate is a generally safe and useful agent for the treatment of mixed dyslipidemia and hypertriglyceridemia in people with HIV infection though limited data are available particularly on clinical outcomes."( Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Fichtenbaum, CJ; Samineni, D, 2010
)
3.25
"Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals."( Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.
Arnett, DK; Borecki, I; Chung, BH; Gao, G; Hopkins, PN; Lai, CQ; Ordovas, JM; Parnell, L; Wojczynski, MK, 2010
)
1.33
"Fenofibrate is a fibric acid postulated to regulate immune response and cell proliferation."( Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Cabrera, R; Clark, V; Firpi, RJ; Keach, J; Levy, C; Lindor, K; Morelli, G; Nelson, DR; Peter, JA; Petz, J; Soldevila-Pico, C, 2011
)
1.46
"Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. "( Pleiotropic actions of fenofibrate on the heart.
Balakumar, P; Mahadevan, N; Rohilla, A, 2011
)
2.12
"Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α. "( Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating, GM, 2011
)
3.25
"Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety."( Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Davis, MW; Digiacinto, J; Godfrey, AR, 2011
)
1.32
"Fenofibrate is an antilipemic agent that exerts its therapeutic effects through activation of peroxisome proliferator-activated receptor α (PPAR α)."( Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Chang, CJ; Chang, YS; Liou, SS; Liu, IM; Tzeng, TF, 2011
)
1.09
"Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. "( Fenofibrate: a review of its use in dyslipidaemia.
Keating, GM; McKeage, K, 2011
)
3.25
"Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. "( Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012
)
3.26
"Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. "( Role of the PPAR-α agonist fenofibrate in severe pediatric burn.
Børsheim, E; Elijah, IE; Finnerty, CC; Herndon, DN; Maybauer, DM; Maybauer, MO, 2012
)
2.12
"Fenofibrate is a peroxisome proliferator-associated receptor alpha agonist (PPARα) used clinically for the management of dyslipidemia and is a myocardial fatty acid oxidation stimulator. "( Fenofibrate reduces cardiac remodeling and improves cardiac function in a rat model of severe left ventricle volume overload.
Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Roussel, É, 2013
)
3.28
"Fenofibrate is a peroxisome proliferator-activated receptor (PPAR)-α agonist that showed beneficial effects on total cardiovascular risk in patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study."( Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Barter, PJ; Brown, C; Jenkins, AJ; Keech, AC; O'Connell, R; Ong, KL; Rye, KA; Sullivan, DR; Xu, A, 2012
)
2.22
"Fenofibrate is a drug used to treat hyperlipidaemia that works by inhibiting hepatic triacylglycerol synthesis. "( cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis.
Choi, YK; Go, Y; Jeong, JY; Kim, YD; Lee, IK; Min, AK; Park, KG, 2013
)
2.09
"Fenofibrate is a hypolipidemic drug that prevents body weight gain in diet-induced obese rats and enhances lipid metabolism by activating peroxisome proliferator-activated receptors (PPARs)."( De novo expression of uncoupling protein 3 is associated to enhanced mitochondrial thioesterase-1 expression and fatty acid metabolism in liver of fenofibrate-treated rats.
Colantuoni, V; De Rosa, G; Franco, R; Goglia, F; Lanni, A; Mancini, FP; Sabatino, L; Silvestri, E, 2002
)
1.24
"Fenofibrate is a potent hypolipemic agent, widely used in patients with renal insufficiency in whom dyslipidemia is frequent. "( Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
Achard, JM; El Esper, N; Fournier, A; Hottelart, C; Rose, F, 2002
)
3.2
"Fenofibrate is a fibric acid derivative that has been marketed since the mid-1970's (1998 in the United States). "( Update on fenofibrate.
Guay, DR, 2002
)
2.16
"Fenofibrate is an effective, well-tolerated treatment for hypertriglyceridemia associated with HLS."( Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy.
Balasubramanyam, A; D'Amico, S; Maldonado, M; Rao, A, 2004
)
3.21
"Fenofibrate is a reasonable second-line therapy for dyslipidaemia in diabetes and safe in combination therapy."( FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Wierzbicki, AS, 2006
)
1.06
"Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures. "( Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Croom, KF; Keating, GM, 2007
)
3.23
"Fenofibrate is a drug that has been suggested to inhibit weight gain by increasing the catabolism of fatty acid in the hepatic mitochondria. "( The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.
Choi, SS; Hong, SH; Kim, DK; Lee, HJ; Lee, KI; Park, MK; Yoo, YH, 2007
)
2.05
"Fenofibrate is an efficient serum lipid-lowering drug with few clinical side effects. "( Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
Orö, L; Rössner, S,
)
3.02
"Fenofibrate is a broad spectrum lipid-lowering agent able to produce substantial reductions in plasma triglyceride and low density lipoprotein (LDL) and an increase in high density lipoprotein (HDL). "( Overview of fenofibrate.
Packard, CJ, 1998
)
2.12
"Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent. "( [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Achard, JM; el Esper, N; Fournier, A; Hottelart, C; Pruna, A, 1999
)
2.66
"Fenofibrate is an effective cholesterol- and triglyceride-lowering agent which has been shown to be beneficial in the treatment of atherosclerosis."( Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.
Bellamy, FD; Chaput, E; Edgar, AD; Maubrou-Sanchez, D, 1999
)
2.47
"Fenofibrate is a new lipid-lowering agent for adults with very high triglyceride levels that was administered to two HIV-positive patients who were taking protease inhibitors and developed hypertriglyceridemia."( Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities.
Bultemeier, NC; Cerveny, JD; Del Bene, VE; Lopes-Virella, MF; McWhorter, LS; Taylor, KB; Thomas, JC, 2000
)
1.48
"Fenofibrate, which is a potent inducer of the ALDR gene in the liver of adult rats, could not induce the ALDR gene in suckling rats."( Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression.
Albet, S; Bentejac, M; Berger, J; Bugaut, M; Gondcaille, C; Netik, A; Savary, S; Szpirer, C; Troffer-Charlier, N, 2001
)
1.03
"Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. "( Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
Bodkin, NL; Brown, HR; Brown, PJ; Hansen, BC; Kliewer, SA; Lehmann, JM; Lewis, MC; Ott, RJ; Plunket, KD; Tong, WQ; Way, JM; Wilkison, WO; Winegar, DA, 2001
)
2.14
"Fenofibrate is a potent hypolipidemic agent that lowers plasma lipid levels and may thus decrease the incidence of atherosclerosis. "( Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.
Burton, CA; Chao, Y; Guo, Q; Hernandez, M; Ippolito, MC; Milot, DP; Wang, PR; Wright, SD, 2001
)
2
"Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase (LPL) metabolism. "( Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Bossé, Y; Brisson, D; Gaudet, D; Hudson, TJ; Julien, P; Ledoux, K; Perron, P; St-Pierre, J; Vohl, MC, 2002
)
1.96
"Fenofibrate is a lipid-regulating drug which is structurally related to other fibric acid derivatives, such as clofibrate. "( Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Balfour, JA; Heel, RC; McTavish, D, 1990
)
3.16
"Fenofibrate is a fibric acid derivative that has been available in much of the world for over 10 years."( Treatment of hypercholesterolaemia with fenofibrate: a review.
Brown, WV, 1989
)
1.27
"Fenofibrate is a fibric acid derivative that lowers both triglycerides and LDL-cholesterol in combined hyperlipidaemia."( A review of combined hyperlipidaemia and its treatment with fenofibrate.
Superko, HR,
)
1.09
"Fenofibrate is a fibric acid derivative with enhanced potency and specificity of action on lipids. "( Safety of fenofibrate--US and worldwide experience.
Roberts, WC, 1989
)
2.12
"Fenofibrate is a well-tolerated drug in the fibric acid series and has putatively beneficial effects on triglyceride, very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein cholesterol concentrations in both type II A and type II B hyperlipidemic patients."( Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Brown, WV; Dujovne, CA; Farquhar, JW; Feldman, EB; Goldberg, AC; Grundy, SM; Knopp, RH; Lasser, NL; Mellies, MJ; Palmer, RH, 1987
)
1.38

Effects

Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. It has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL.

Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA) It has been used for decades against hypercholesterolemia and has no serious side effects.

ExcerptReferenceRelevance
"Fenofibrate has a well-known efficacy to reduce cholesterol and triglycerides."( Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein.
Kazdová, L; Kůdela, M; Landa, V; Malínská, H; Marková, I; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Trnovská, J; Zídek, V, 2016
)
1.47
"Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha."( Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Steiner, G, 2008
)
2.51
"Fenofibrate has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL, and thus it is used to manage dyslipidemia."( Pleiotropic actions of fenofibrate on the heart.
Balakumar, P; Mahadevan, N; Rohilla, A, 2011
)
1.4
"Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g."( Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating, GM, 2011
)
2.53
"Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. "( Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003
)
3.2
"Fenofibrate also has antioxidant, anti-inflammatory, and anticoagulant properties while also having a beneficial effect on the vasomotor function of the endothelium."( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021
)
1.58
"Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). "( Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Deng, J; Ding, D; Guo, C; Guo, G; Han, Y; Jia, G; Liu, Y; Shang, Y; Sun, R; Wang, X; Zheng, L, 2022
)
2.47
"Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects."( Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Buschard, K, 2020
)
2.72
"Fenofibrate (FF) has been suggested as a second-line therapy for primary biliary cholangitis (PBC) with suboptimal response to ursodeoxycholic acid (UDCA). "( Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Han, Y; Liu, Y; Sun, K; Tian, A; Wang, L; Zhang, M; Zhou, X, 2022
)
3.61
"Fenofibrate has received great attention as it benefits diabetic patients by reducing retinal laser requirement."( Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.
Cheng, R; Li, J; Liu, Q; Ma, JX; Yi, J; Zhang, F; Zhang, X, 2018
)
2.64
"Fenofibrate has been shown to reduce serum and tissue levels of the proinflammatory protein osteopontin, as well as reducing macrophage recruitment to the aortic wall, both of which are integral processes in the development and progression of AAAs."( Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm.
Golledge, J; Krishna, SM; Moran, CS; Rowbotham, SE, 2018
)
2.64
"Fenofibrate has been shown to improve the short-term biochemical response in this group of patients."( Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan, W; Jia, J; Ma, H; Ou, X; Wang, Q; Wang, X; Wang, Y; Wu, X; You, H; Zhang, W; Zhao, X, 2018
)
1.51
"Fenofibrate has been demonstrated to exert a promising therapeutic effect against diabetic retinopathy. "( Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway.
Han, C; Wang, N; Wang, Y; Zhao, S; Zheng, Z; Zou, C, 2018
)
3.37
"Fenofibrate has been approved for its lipid-lowering effects in patients with hypercholesterolemia and hypertriglyceridemia."( Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle Toxicity.
D'mello, AP; Fauty, SE; Kochansky, CJ; Lyman, MJ; Vlasakova, K, 2018
)
1.54
"Fenofibrate has also been shown to suppress arrhythmias in isolated rat hearts subjected to ischemic/reperfusion-induced cardiac injury."( Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits.
Alsayari, A; Balakumar, P; Dhanaraj, SA; Mahadevan, N; Muhsinah, AB; Sambathkumar, R; Venkateswaramurthy, N, 2019
)
1.55
"Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years. "( Fenofibrate and the kidney: an overview.
Elisaf, MS; Florentin, M; Kostapanos, MS, 2013
)
3.28
"Fenofibrate (FF) has been suggested as a second-line agent in primary biliary cholangitis (PBC) patients who do not achieve adequate biochemical response to ursodeoxycholic acid (UDCA) monotherapy. "( Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Dyson, JK; Hegade, VS; Jones, DEJ; Khanna, A; Walker, LJ; Wong, LL, 2016
)
2.28
"Fenofibrate treatment has neuroprotective effects on middle cerebral artery infarcts."( Neuroprotective Effects of Chronic Fenofibrate Treatment via Modulating the Immunoreactivity of Cleaved Caspase-3 in Stroke Induced by Transient Middle Cerebral Artery Occlusion Rat Model.
Altintas, MO; Altintas, O; Antar, V; Asil, T; Aydin, MS; Baran, O; Esrefoglu, M, 2017
)
2.17
"Fenofibrate has a well-known efficacy to reduce cholesterol and triglycerides."( Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein.
Kazdová, L; Kůdela, M; Landa, V; Malínská, H; Marková, I; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Trnovská, J; Zídek, V, 2016
)
1.47
"Fenofibrate (FF) has previously been shown to induce hepatocellular neoplasia in a conventional mouse bioassay (NDA 1993), but there has been no report to examine the carcinogenic susceptibility of rasH2 mice to this chemical. "( Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.
Dewa, Y; Jin, M; Kawai, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saegusa, Y; Shibutani, M; Taniai, E, 2008
)
2.06
"Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha."( Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Steiner, G, 2008
)
2.51
"Fenofibrate has been widely used for the treatment of dyslipidaemia with a long history. "( New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.
Chen, Y; Dai, R; Feng, Y; Gonzalez, FJ; Liu, A; Liu, Y; Luo, W; Rui, W; Yang, Z, 2009
)
2.12
"Fenofibrate have been illustrated to stimulate nitric oxide (NO) pathway, which plays pivotal roles in neovascularization. "( Fenofibrate enhances neovascularization in a murine ischemic hindlimb model.
Fujihara, S; Harada, S; Hisatome, I; Kaetsu, Y; Katayama, A; Matsubara, K; Sugitani, M; Tanaka, K; Yamamoto, Y; Yoshida, A, 2009
)
3.24
"Fenofibrate has been proven to reduce adiposity. "( Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms.
Bocos, C; Gonzalez, MC; Herrera, E; Vidal, H, 2009
)
3.24
"Fenofibrate has been evaluated in the ACCORD trial, in combination with a statin, to prevent vascular complications in patients with type 2 diabetes. "( [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
Scheen, AJ; Van Gaal, LF, 2010
)
2.03
"Fenofibrate has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL, and thus it is used to manage dyslipidemia."( Pleiotropic actions of fenofibrate on the heart.
Balakumar, P; Mahadevan, N; Rohilla, A, 2011
)
1.4
"Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g."( Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating, GM, 2011
)
2.53
"Fenofibrate also has nonlipid, pleiotropic effects (e.g."( Fenofibrate: a review of its use in dyslipidaemia.
Keating, GM; McKeage, K, 2011
)
2.53
"Fenofibrate has been noted to cause an elevation in serum creatinine in some individuals. "( Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
Bonds, DE; Buse, J; Craven, TE; Crouse, JR; Cuddihy, R; Elam, M; Ginsberg, HN; Kirchner, K; Marcovina, S; Mychaleckyj, JC; O'Connor, PJ; Sperl-Hillen, JA, 2012
)
3.26
"Fenofibrate therapy has been associated with increases in serum aminotransferase levels, and clinical monitoring of these markers of liver function should be performed regularly."( Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Najib, J, 2002
)
2.48
"Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. "( Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003
)
3.2
"But fenofibrate has no effect on drug-induced fatty liver."( [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].
Jia, XQ; Lu, RJ; Meng, FL; Yan, M; Zhao, XC, 2003
)
1.12
"Only fenofibrate has significant beneficial effects on the fibrinogen levels."( The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S, 2005
)
0.99
"Fenofibrate has shown to reduce major cardiovascular events and slow angiographic progression of coronary atherosclerosis. "( Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI.
Badimon, JJ; Corti, R; Fallon, JT; Fuster, V; Hutter, R; Mizsei, G; Osende, J; Valdivieso, C; Viles-Gonzalez, JF; Zafar, U, 2007
)
3.23
"Fenofibrate also has nonlipid (i.e."( Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Croom, KF; Keating, GM, 2007
)
2.5
"Fenofibrate has beneficial effects on the progression and clinical emergence of atherosclerosis in normoglycemic and in diabetic patients. "( Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.
Barazzoni, R; Bossi, F; Bosutti, A; Cattin, L; Dapas, B; Farra, R; Giansante, C; Grassi, G; Guarnieri, G; Stocca, A; Tedesco, F; Uxa, L; Zanetti, M, 2008
)
2.1
"Fenofibrate has been reported to regulate lipid homeostasis and is involved in insulin secretion in pancreatic beta-cells."( Chronic palmitate exposure inhibits AMPKalpha and decreases glucose-stimulated insulin secretion from beta-cells: modulation by fenofibrate.
Gao, GQ; Gao, L; Gong, B; Guo, H; Ren, M; Sun, Y; Xin, W; Zhang, XJ; Zhao, JJ, 2008
)
1.27
"Fenofibrate has favorable pleiotropic effects on several features of the metabolic syndrome, which are likely to explain the clinical benefits of fibrate therapy, beyond an impact on HDL-C levels."( Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Després, JP, 2001
)
1.27
"Fenofibrate has also been shown to raise plasma high density lipoprotein concentrations."( Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.
Goldberg, DM; Hahn, SE, 1992
)
1.25
"Fenofibrate also has three other actions that may result in the prevention or at least slowing of atherogenesis, namely inhibition of cholesterol esterification, platelet aggregation, and platelet-derived growth factor."( The biochemical pharmacology of fenofibrate.
Caldwell, J, 1989
)
1.28

Actions

Fenofibrate can enhance the radiosensitivity of human esophageal carcinoma cells by increasing G2/M phase arrest. Fenofibrates increase mitochondrial fatty acid beta-oxidation in liver but not in skeletal muscle and lower plasma levels of triglyceride and free fatty acid.

ExcerptReferenceRelevance
"Fenofibrate (FNB) can activate peroxisome proliferator-activated receptor α (PPARα) to increase fatty acid oxidation and ameliorate NAFLD."( Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease.
Chen, D; Du, K; Huang, X; Peng, A; Qi, R; Yang, Q; Zhang, J, 2023
)
2.02
"Fenofibrate could inhibit CNV formation."( Impact of fenofibrate on choroidal neovascularization formation and VEGF-C plus VEGFR-3 in Brown Norway rats.
Chen, QB; Geng, Y; Guan, M; Hua, HR; Li, Y; Xi, XT; Yang, JH; Zhao, JF, 2018
)
1.6
"Fenofibrate can enhance the radiosensitivity of human esophageal carcinoma cells by increasing G2/M phase arrest. "( Enhancement of radiosensitivity in human esophageal carcinoma cells by fenofibrate and its potential mechanism.
Li, XQ; Meng, XJ; Wu, JC; Yu, J; Zhou, JD; Zou, ST,
)
1.81
"Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients."( Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015
)
3.3
"Fenofibrate seems to produce a complex beneficial effect on hemostasis in this group of patients."( Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.
Handzlik, G; Krysiak, R; Okopień, B,
)
1.17
"The fenofibrate induced increase in HCY did not, however, explain the risk associated with fenofibrate therapy."( Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.
Ehnholm, C; Herrmann, M; Keech, AC; Sullivan, DR; Veillard, AS; Whiting, MJ, 2012
)
0.86
"Fenofibrate increase mitochondrial fatty acid beta-oxidation in liver but not in skeletal muscle and lower the plasma levels of triglyceride and free fatty acid."( Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
An, YJ; Choi, SS; Garber, AJ; Hong, SH; Hwang, TH; Kang, DY; Kim, DK; Kim, MC; Lee, HJ; Park, MK; Seo, SY, 2002
)
2.48
"Fenofibrate-induced increase of daily creatinine production is neither readily explained by accelerated muscular cell lysis."( Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
Achard, JM; El Esper, N; Fournier, A; Hottelart, C; Rose, F, 2002
)
2.48
"Fenofibrate failed to increase eNOS activity within 1 hour."( Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
Goya, K; Kasayama, S; Kawase, I; Kitamura, T; Kouhara, H; Kurebayashi, S; Saito, H; Sumitani, S; Xu, X; Yamamoto, H, 2004
)
1.04
"Fenofibrate could inhibit the PAI-1 mRNA and protein expression and reduce PAI-1 antigenic content dependently."( Inhibitory effects of fenofibrate on plasminogen activator inhibitor-1 expression in human endothelial cells.
Dong, C; He, W; Hu, Y; Sun, C; Wang, H; Wang, Y; Zhang, X, 2006
)
1.37
"Fenofibrate could increase the proliferation and decrease the apoptosis, and up-regulate eNOS mRNA expression and enhance NO production in HUVECs."( [Effects of fenofibrate on the proliferation and apoptosis and nitric oxide synthase expression of cultured human umbilical vein endothelial cells induced by lysophosphatidylcholine].
Sun, GJ; Xie, XM; Xing, Y; Yan, WH; Yang, TL; Yu, GL, 2006
)
1.43
"Fenofibrate did not inhibit mechanical allodynia or paw edema induced by phorbol-12,13-didecanoate (PDD), a protein kinase C activator, in rats."( Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT, 2007
)
1.31
"Fenofibrate impeded the increase in atrial natriuretic peptide, brain natriuretic peptide, and endothelin-1 plasma levels."( The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Brigadeau, F; Duriez, P; Fruchart, JC; Gelé, P; Lacroix, D; Marquié, C; Martin-Nizard, F; Staels, B; Torpier, G; Wibaux, M, 2007
)
1.37
"Fenofibrate caused an increase in LDL size (Delta 0.80 nm, p < 0.001)."( Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Ehnholm, C; Hiukka, A; Jauhiainen, M; Keech, AC; Leinonen, E; Sundvall, J; Taskinen, MR, 2007
)
1.38
"Fenofibrate promotes the oxygenation of fatty acids by up-regulating the CPT-1 mRNA expression in the liver and skeletal muscles, thus improving the insulin sensitivity."( [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].
Bai, XP; Du, RQ; Li, HL; Lou, DJ; Wang, B; Xiao, JZ; Yang, WY, 2008
)
2.17
"Fenofibrate may enhance the effect of oral anticoagulants."( Micronized fenofibrate: a new fibric acid hypolipidemic agent.
Guay, DR, 1999
)
1.41
"Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats."( Fenofibrate lowers blood pressure in two genetic models of hypertension.
Quest, DW; Shatara, RK; Wilson, TW, 2000
)
2.47
"A fenofibrate-induced increase of HDL-C in 20 low-HDL subjects was associated with a significant reduction of plasma sICAM-1 and sE-selectin concentrations."( Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.
Calabresi, L; Dmitrieff, C; Franceschini, G; Gomaraschi, M; Omoboni, L; Villa, B, 2002
)
0.87

Treatment

Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing. Treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.

ExcerptReferenceRelevance
"Fenofibrate treatment returned myofibre function by inhibiting the expressions of myostatin, MuRF1, and atrogin-1 protein in the gastrocnemius muscle and diaphragm, while leaving the mRNA level of myostatin unaffected."( A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation.
Huang, X; Jiang, Z; Li, C; Li, S; Li, X; Liu, B; Sun, L; Sun, Z; Xu, D; Zhang, L; Zhao, L, 2022
)
1.74
"fenofibrate treatment) in LT-associated cardiac injury."( Targeting PPARα in low ambient temperature exposure-induced cardiac dysfunction and remodeling.
Chen, XY; Jiao, Y; Zhang, FY, 2021
)
1.34
"Fenofibrate-treated NOD mice had a more stable blood glucose, which was associated with reduced non-fasting and increased fasting blood glucose."( Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice.
Bilgin, M; Buschard, K; Giacobini, JD; Hasselby, JP; Haupt-Jorgensen, M; Holm, LJ, 2019
)
2.68
"Fenofibrate treatment lowered the plasma C24:0/C16:0 ceramide ratio and minimally altered oxidative stress markers but did not alter measures of inflammation."( Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes.
Chen, L; Farmer, MS; Goldberg, AC; Jiang, X; Ory, DS; Peterson, LR; Schaffer, JE, 2020
)
1.28
"Fenofibrate treatment activated autophagy and TFEB/TFE3 and reduced hepatic fat accumulation in an mTOR-independent manner. "( Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy.
Ahn, KJ; Chung, HY; Hwang, YC; Jeong, IK; Yoo, J, 2021
)
3.51
"Fenofibrate treatment reduced adiposity and attenuated obesity-induced dysfunctions of glucose metabolism in obese mice fed a high-fat diet."( The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
Aizawa-Abe, M; Aoki, Y; Ebihara, K; Goto, T; Hirata, M; Itoh, N; Iwase, M; Jheng, HF; Kawada, T; Kim, CS; Kim, M; Li, Y; Matsuda, H; Nomura, W; Seno, S; Takahashi, H; Takahashi, N; Yu, R, 2017
)
1.18
"Fenofibrate treatment restored EPC function, increased NO production, and decreased O2- level in EPCs of diabetic mice."( PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway.
Cai, J; Deng, Y; Han, F; Han, X; Jiang, G; Ren, G; Sun, Y; Yao, Z; Yu, J, 2017
)
1.18
"Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time."( Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017
)
1.53
"Fenofibrate treatment effect was estimated in 17,142 T2DM patients from FIELD, ACCORD, and SMART."( Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.
Ginsberg, HN; Keech, AC; Koopal, C; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2018
)
1.51
"Fenofibrate treatment significantly increased liver and pancreas volumes vs placebo treatment, and the changes in liver and pancreas volumes were positively correlated (rho 0.45, P = .02)."( Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
Eriksson, JW; Jansson, PA; Johansson, L; Lind, L; Moris, L; Nilsson, PM; Önnerhag, K; Oscarsson, J; Risérus, U; Sundén, M,
)
1.11
"Fenofibrate treatment produced a marked increase in ADH1 protein levels (396% ± 18%, p < 0.001) and enzymatic activity (425% ± 25%, p < 0.001)."( Fenofibrate -a PPARα agonist- increases alcohol dehydrogenase levels in the liver: implications for its possible use as an ethanol-aversive drug.
Flores-Bastías, O; Karahanian, E; Muñoz, D; Quintanilla, ME; Rivera-Meza, M, 2020
)
2.72
"Fenofibrate treatment was associated with significant decreases in pain score, tender joint count, duration of morning stiffness, disease activity score, Cochin index, and ESR."( Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study.
Shirinsky, IV; Shirinsky, VS, 2014
)
1.34
"Fenofibrate treatment increased fatty acid metabolism further, which reduced postburn hepatic steatosis (burn versus sham P < 0.05, burn + fenofibrate versus sham not significant)."( Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress.
Arno, A; Hiyama, Y; Jeschke, MG; Kraft, R; Marshall, AH, 2013
)
2.55
"Fenofibrate treatment significantly increased serum vaspin levels of dyslipidemic patients, which correlated with reduced body weight and increased insulin sensitivity."( Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014
)
2.57
"Fenofibrate treatment further stimulates biliary phosphatidylcholine secretion in rat hepatocytes, thereby providing a functional correlate."( Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
Ananthanarayanan, M; Boyer, JL; Ghonem, NS; Soroka, CJ, 2014
)
1.12
"Fenofibrate treated mice gained less body weight (BW) and had lower serum amyloid A (SAA) levels, but higher Interleukin (IL)-1α and MIP1α than other mice."( Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice.
Bastiaansen-Jenniskens, YM; Bierma-Zeinstra, SM; Botter, SM; Clockaerts, S; Gierman, LM; Kloppenburg, M; van Osch, GJ; Verhaar, JA; Wei, W; Weinans, H; Zuurmond, AM, 2014
)
1.12
"Fenofibrate treatment increased PPARα and PPARγ protein abundance in adipose tissue. "( Increased expression of oxidative enzymes in adipose tissue following PPARα-activation.
Botion, LM; Delpuerto, HL; Ferreira, AV; Mario, EG; Martins, AS; Menezes-Garcia, Z, 2014
)
1.85
"Fenofibrate treatment of HGG cells robustly diminished the expression of key signaling pathways, including NF-κB and cyclin D1."( Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells.
Binello, E; Emdad, L; Germano, IM; Kothari, H; Mormone, E, 2014
)
1.45
"The fenofibrate-treated group also showed a significantly higher level of hepatic SOD content (untreated model: 67.00+/-4.65 vs."( [Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis].
Jiang, JJ; Li, L; Xie, C; Xu, YP; Zhu, YY, 2013
)
1.17
"Fenofibrate treatment induced mature SREBP-1c expression via the direct binding of PPARα to the DR1 motif of the SREBP-1c gene."( Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Cao, M; Chen, W; Gao, L; Jing, F; Wang, Q; Wang, T; Xu, C; Yan, F; Yu, C; Zhao, J; Zhou, X, 2014
)
1.12
"Fenofibrate treatment exacerbated inflammation and tissue injury in acute colitis, and this was dependent on PPARα activation."( PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.
Bredell, BX; Brocker, CN; Fang, ZZ; Gonzalez, FJ; Jiang, C; Krausz, KW; Qi, Y; Shah, YM; Tanaka, N, 2014
)
1.35
"Fenofibrate treatment opposed the development of obesity, hypertriglyceridemia, and insulin resistance."( ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity.
Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014
)
1.34
"Fenofibrate treatment was initiated after the clinical onset once daily for 14 days."( Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate.
Kohno, H; Kuroyanagi, K; Osada, M; Sakai, T; Tsuneoka, H, 2014
)
1.34
"Fenofibrate treatment abrogated these changes."( Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway.
Gu, Q; Li, J; Li, T; Wang, N; Xu, X; Zhao, S; Zheng, B; Zheng, Z, 2015
)
0.42
"Fenofibrate treatment often induces the production of intracellular reactive oxygen species (ROS), leading to cell death."( Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation.
Bae, SH; Kang, DH; Lee, DH; Park, JS, 2015
)
2.58
"Fenofibrate treatment partially reverses dyslipidemia in these subjects."( Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE, 2016
)
1.35
"Fenofibrate treatment decreased hepatic triglyceride (TG) content and FSP27/CIDEC protein expression in mice fed an HFD diet."( Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX, 2016
)
1.16
"Fenofibrate treatment has neuroprotective effects on middle cerebral artery infarcts."( Neuroprotective Effects of Chronic Fenofibrate Treatment via Modulating the Immunoreactivity of Cleaved Caspase-3 in Stroke Induced by Transient Middle Cerebral Artery Occlusion Rat Model.
Altintas, MO; Altintas, O; Antar, V; Asil, T; Aydin, MS; Baran, O; Esrefoglu, M, 2017
)
2.17
"Fenofibrate treatment in type 2 diabetes patients reduces progression of diabetic retinopathy independent of its peroxisome proliferator-activated receptor (PPAR)α agonist lipid lowering effect."( Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Burnim, SB; Edin, ML; Fu, Z; Gong, Y; Hellström, A; Liegl, RG; Lih, FB; Liu, CH; Meng, SS; SanGiovanni, JP; Shao, Z; Smith, LEH; Sun, Y; Wang, Z; Zeldin, DC, 2016
)
2.6
"Fenofibrate treatment significantly attenuated the course of malignant hypertension in I3C-induced CYP1a1-Ren-2 transgenic rats, and the mechanism responsible for antihypertensive action was fenofibrate-induced suppression of renin-angiotensin system activity."( Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats.
Červenka, L; Doleželová, Š; Jíchová, Š; Kompanowska-Jezierska, E; Kopkan, L; Sadowski, J, 2016
)
3.32
"Fenofibrate treatment significantly decreased serum RBP4 levels of dyslipidemic patients, which correlated with reduced body weight and increased insulin sensitivity."( Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Bao, Y; Huang, P; Jia, W; Liu, Y; Lu, J; Wei, L; Wu, H; Xiang, K, 2009
)
2.52
"Fenofibrate treatment was not associated with beneficial changes in IMT, augmentation index, or biomarkers of inflammation and endothelial function. "( Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Hiukka, A; Hulten, LM; Keech, AC; Leinonen, ES; Salonen, JT; Taskinen, MR; Tuomainen, TP; Watanabe, H; Westerbacka, J; Wiklund, O; Yki-Järvinen, H, 2008
)
2.11
"Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level. "( Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes.
Bukowska, H; Chełstowski, K; Jastrzebska, M; Klimek, K; Mierzecki, A, 2009
)
2.19
"Fenofibrate treatment preserved AdipoR2 and phosphorylated AMPK (pAMPK) levels in palmitate-treated cells accompanied by reduced triglyceride (TG) accumulation and less activation of ER stress markers CCAAT/enhancer binding (C/EBPbeta) and eukaryotic translation initiation factor 2 alpha."( Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.
Friedman, JE; Janssen, RC; Qadri, I; Rahman, SM, 2009
)
2.52
"Fenofibrate treatment slightly increased plasma transaminase activities in rats with the findings directly related to the pharmacological action of the drug."( Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats.
Kobayashi, A; Kuno, H; Sakakibara, H; Shimoi, K; Sugai, S; Suzuki, Y, 2009
)
1.46
"Fenofibrate treatment significantly lowered serum triglyceride levels."( Fenofibrate enhances neovascularization in a murine ischemic hindlimb model.
Fujihara, S; Harada, S; Hisatome, I; Kaetsu, Y; Katayama, A; Matsubara, K; Sugitani, M; Tanaka, K; Yamamoto, Y; Yoshida, A, 2009
)
2.52
"Fenofibrate treatment strongly induced hepatic de novo lipogenesis and chain elongation (+/-300, 150, and 600% for C16:0, C18:0, and C18:1 synthesis, respectively) in parallel with an increased expression of lipogenic genes."( Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice.
Grefhorst, A; Groen, AK; Havinga, R; Kuipers, F; Oosterveer, MH; Reijngoud, DJ; Staels, B; van Dijk, TH, 2009
)
2.52
"Fenofibrate treatment did not modify plasma free fatty acid (FFA) concentration in virgin rats, it greatly increased it in pregnant animals."( Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms.
Bocos, C; Gonzalez, MC; Herrera, E; Vidal, H, 2009
)
2.52
"Fenofibrate treatment significantly induced mRNA expression of AOX and UCP-2, but not of PPARalpha."( Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice.
Arai, T; Chiba, H; Kim, HJ; Matsumoto, A, 2009
)
1.33
"The fenofibrate-treated group did not have significantly altered levels of hepatic human APOA-I mRNA and plasma ApoA-I compared with the control group."( Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.
Drosatos, K; Duka, A; Hayes, KC; Sanoudou, D; Zannis, VI, 2010
)
0.84
"Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver."( Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.
Aizawa, M; Goda, N; Kondo, K; Morimoto, M; Shimizu, K; Suematsu, M; Sugioka, T; Takizawa, M; Tsukada, K, 2010
)
2.52
"Fenofibrate treatment overrode nocodazole-induced G2/M cell cycle arrest in a PPARalpha-independent manner. "( Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis.
Do, MH; Joe, Y; Kang, S; Lee, HJ; Park, HT; Seo, E; Yun, J, 2010
)
3.25
"Fenofibrate treatment significantly reduced the percentage of time with SpO(2) <90% (from 9.0% to 3.5% vs. "( Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?
Ansquer, JC; Bonnefont-Rousselot, D; Bruckert, E; Dubois, A; Duchêne, E; Gaymard, B; Hansel, B, 2010
)
2.09
"Fenofibrate treatment did not result in significant changes in small HDL subclass particle concentration. "( Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.
Arends, VL; Arnett, D; Hanson, NQ; Li, N; Ordovas, JM; Straka, RJ; Tsai, MY, 2010
)
2.21
"Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma. "( Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.
Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M, 2010
)
3.25
"Fenofibrate treatment also decreased HOMA in IFG and IGT patients, fasting plasma glucose in IFG subjects and 2-h post-glucose load plasma glucose in IGT patients."( Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
Krysiak, R; Okopień, B; Stachura-Kułach, A,
)
1.11
"Fenofibrate treatment attenuated IGF-I signaling responses and repressed cell motility of LN-229 and T98G Glioma cell lines. "( ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.
Del Valle, L; Drukala, J; Grabacka, M; Madeja, Z; Reiss, K; Urbanska, K; Wilk, A; Wybieralska, E, 2010
)
2.05
"Fenofibrate co-treatment reduced weight loss in amiodarone treated PPARα(-/-) mice, but not PPARα(+/+) mice."( Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Ernst, MC; Pollak, PT; Sinal, CJ, 2010
)
1.08
"Fenofibrate-treated mice exhibited increases in AMPK phosphorylation and a decrease in PEPCK expression in the liver but not in skeletal muscles, suggesting that unmetabolized fenofibrate accumulated and affected AMPK only in the liver."( Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes.
Cheng, XW; Kataoka, H; Murakami, H; Murakami, R; Murohara, T; Numaguchi, Y; Okumura, K; Takahashi, R, 2010
)
1.44
"Fenofibrate treatment further elevated homocysteine level, which was reduced by telmisartan in combination with fenofibrate."( Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.
Bhalodia, Y; Jivani, N; Sheth, N; Vaghasiya, J, 2010
)
1.52
"Fenofibrate-treated group showed a significant reduction in neointimal formation (0.07±0.04mm(2)) from the control (0.13±0.04mm(2))."( Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.
Kim, DW; Kim, TJ; Kwon, JS; Lee, JJ; Lim, Y; Myung, CS; Yu, JY; Yun, YP; Zhang, WY, 2011
)
1.41
"0.3% fenofibrate treatment suppressed the incidence rate of tongue lesions, reduced the multiplicity of squamous cell carcinoma (SCC), decreased the tumor size, and increased the immunoreactivity of EGFR and COX2 in oral dysplasia but decreased EGFR and COX2 expressions in SCC."( Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model.
Chang, NW; Chiu, CF; Chu, PY; Hsu, HT; Lin, C; Tsai, MH; Yeh, CM; Yeh, KT, 2011
)
2.27
"Fenofibrate treatment resulted in significant reductions in TG concentrations by 24.2% (p<0.0001), 41.9% (p < 0.0001), and 46.6% (p < 0.0001) in tertiles 1, 2, and 3, respectively."( Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.
Arnett, D; Cao, J; Dong, Y; Hanson, NQ; Kabagambe, E; Ordovas, J; Steffen, BT; Straka, R; Tsai, AK; Tsai, MY; Zhou, X, 2011
)
1.48
"And fenofibrate pretreatment reverses these changes."( [Effects of fenofibrate on the expression of peroxisome proliferator-activated-gamma coactivator-1α in skeletal muscle of rats infused with intralipid].
Bai, XP; Li, HL; Wang, B; Xiao, JZ; Yang, WY, 2010
)
1.22
"Fenofibrate treatment restored the impaired endothelium-dependent relaxation and increased basal nitric oxide availability in diabetic aorta, enhanced erythrocyte/liver superoxide dismutase and catalase levels, ameliorated the abnormal serum/aortic thiobarbituric acid reactive substances, and prevented the increased aortic myeloperoxidase without a significant change in serum total cholesterol and triglyceride levels."( Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats.
Cınar, GM; Olukman, M; Sezer, ED; Sözmen, EY; Ulker, S, 2010
)
2.52
"Fenofibrate treatment prevented arthritis-induced increase in atrogin-1 and MuRF1 expression in the gastrocnemius."( Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy.
Castillero, E; Fernández-Galaz, C; Granado, M; López-Calderón, A; López-Menduiña, M; Martín, AI; Nieto-Bona, MP; Villanúa, MA, 2011
)
2.53
"Fenofibrate treatment led to minor modifications of the urinary proteomic profile in a way that does not create safety issues affecting glomerular and tubular functions. "( Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers.
Ansquer, JC; Foucher, C; Mischak, H; Schiffer, E; Wilbraham, D, 2011
)
2.21
"Fenofibrate treatment decreased IGF1 and Igf1 mRNA in the liver and gastrocnemius."( Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1.
Castillero, E; López-Calderón, A; López-Menduiña, M; Martín, AI; Villanúa, MÁ, 2011
)
1.31
"Fenofibrate treatment resulted in a 30.1% mean increase in Lp-PLA(2) mass (P = 0.0003) and a 14.7% mean increase in sVCAM-1 levels (P = 0.0096) but only in tertile1 of either target."( Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.
Arnett, D; Hanson, NQ; Ordovas, JM; Steffen, BT; Straka, R; Tsai, AK; Tsai, MY; Zhou, X, 2011
)
1.48
"Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing."( The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.
Almad, A; Lash, AT; Lovett-Racke, AE; McTigue, DM; Wei, P, 2011
)
1.09
"Fenofibrate treatment significantly attenuated oxidative damage, cytokines and improved mitochondrial complexes enzyme activity in brain."( Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.
Bhateja, DK; Dhull, DK; Gill, A; Padi, SS; Reddy, BV; Sharma, S; Sidhu, A, 2012
)
1.1
"Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive."( Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012
)
1.38
"Fenofibrate-based treatment was associated with improved insulin sensitivity. "( Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B, 2012
)
1.82
"Fenofibrate treatment increased sulfatides and CST mRNA levels in the kidney, heart, liver, and small intestine in a PPARα-dependent manner."( Peroxisome proliferator-activated receptor α mediates enhancement of gene expression of cerebroside sulfotransferase in several murine organs.
Aoyama, T; Hara, A; Kamijo, Y; Kimura, T; Kyogashima, M; Nakajima, T; Nakamura, K; Sugiyama, E; Tanaka, N; Yuzhe, H, 2013
)
1.11
"Fenofibrate treatment was associated with 52 % higher risk, but the change in HCY with fenofibrate was not significantly associated with VTE after adjustment for baseline HCY."( Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.
Ehnholm, C; Herrmann, M; Keech, AC; Sullivan, DR; Veillard, AS; Whiting, MJ, 2012
)
1.1
"Fenofibrate treatment also reduced plasma-oxidized low-density lipoprotein, a systemic marker of oxidative stress, compared with placebo (P<0.05)."( Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults.
Eckel, RH; Kaplon, RE; Lucking, SM; Russell-Nowlan, MJ; Seals, DR; Walker, AE, 2012
)
2.54
"Fenofibrate treatment had no detectable effect on serum A-FABP level (P > 0.05)."( Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Barter, PJ; Brown, C; Jenkins, AJ; Keech, AC; O'Connell, R; Ong, KL; Rye, KA; Sullivan, DR; Xu, A, 2012
)
1.5
"Fenofibrate treatment reduced high triglycerides in the fructose-fed HTG rat and subsequently restored the cardioprotective effect of IPC."( Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart.
Babbar, L; Balakumar, P; Mahadevan, N, 2013
)
2.55
"Fenofibrate treatment for 2 weeks did not change blood pressure but significantly improved the M-value, sTG and mTG."( Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle.
Furuhashi, M; Higashiura, K; Hyakukoku, M; Murakami, H; Shimamoto, K; Ura, N; Yamaguchi, K, 2002
)
2.48
"Fenofibrate treatment dose-dependently reduced plasma concentration of malonyldialdehyde and 4-hydroxydialkenals."( The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity.
Bełtowski, J; Jamroz, A; Mydlarczyk, M; Wójcicka, G, 2002
)
1.26
"Fenofibrate treatment resulted in hepatic induction of PPARalpha target genes encoding enzymes for fatty acid beta-oxidation, the magnitudes of which were much higher in males compared to females, as evidenced by results for acyl-CoA oxidase, a first enzyme of the beta-oxidation system."( Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism.
Han, M; Jeong, S; Kim, JJ; Lee, H; Nicol, CJ; Oh, GT; Ryu, C; Seo, YJ; Yoon, M, 2002
)
2.48
"Fenofibrate treatment reduced total plasma cholesterol and low-density lipoprotein (LDL)-cholesterol levels by 24% and 35%, respectively."( Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue.
Cabrero, A; Carrera, MV; Jové, M; Laguna, JC; Novell, F; Planavila, A; Ros, E; Zambón, D, 2003
)
1.3
"In fenofibrate-treated rats, plasma acetoacetate was significantly elevated."( Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Jensen, PB; Larsen, LK; Larsen, PJ; Sørensen, RV; Vrang, N; Wassermann, K; Wulff, EM, 2003
)
0.83
"Fenofibrate treatment decreased body weight and visceral fat, whereas rosiglitazone treatment increased body weight."( Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY, 2003
)
1.04
"Fenofibrate-treated rats also showed decreased concentrations of FFA and CH with concomitant decrease of catecholamine-induced lipolysis in adipocytes, but also hyperinsulinemia and the highest insulin/glucose ratio."( Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome.
Kazdova, L; Kren, V; Krenova, D; Seda, O; Sedova, L, 2004
)
1.38
"Fenofibrate pretreatment, 1 microM, 24 h prior to palmitate, significantly (p < 0.05) reduced palmitate-induced apoptosis."( Reduction of palmitate-induced cardiac apoptosis by fenofibrate.
Kong, JY; Rabkin, SW, 2004
)
1.3
"Fenofibrate treatment did not change serum lipid levels during the feeding period, but decreased high cholesterol diet-induced increases in body weight by 19% and serum TNF-alpha concentration by 44.7% in fenofibrate treated group compared with high cholesterol group (P<0.05)."( Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits.
Wu, J; Zhao, SP, 2004
)
2.49
"Fenofibrate treatment decreased body weight gain and WAT mass in OVX, but not in Sham mice."( Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.
Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004
)
1.43
"Fenofibrate treatment enhanced the (125)I-OxLDL uptake and degradation and up-regulated CD36 mRNA expression in adipocytes and suppressed PPARgamma mRNA expression in adipose tissue from hypercholesterolemia rabbits."( Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit.
Li, JQ; Liu, L; Wu, J; Ye, HJ; Zhang, DQ; Zhao, SP, 2004
)
2.49
"Fenofibrate treatment improved the OxLDL uptake and degradation in adipocytes from hypercholesterolemia rabbits."( Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit.
Li, JQ; Liu, L; Wu, J; Ye, HJ; Zhang, DQ; Zhao, SP, 2004
)
2.49
"Fenofibrate treatment improved endothelium-dependent vasorelaxation at only high carbamycholine concentrations (10 microM)."( Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats.
Fatani, S; Naderali, EK; Williams, G, 2004
)
2.49
"Fenofibrate treatment led to decreased content of saturated fatty acids in phosphatidylethanolamines."( Hypolipidemic drugs can change the composition of rat brain lipids.
Novák, F; Nováková, O; Stanková, B; Tvrzická, E; Vecka, M; Zák, A, 2004
)
1.04
"Fenofibrate treatment in the presence of TGF-beta1 inhibited the incorporation of [(35)S]-sulphate into secreted and cell-associated proteoglycans synthesised by human VSMCs by 59.2% (p<0.01) and 39.8% (p<0.01) respectively."( Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding.
Ballinger, ML; Dilley, RJ; Jennings, GL; Little, PJ; Nigro, J; Wight, TN, 2004
)
2.49
"Fenofibrate treatment did not cause any change in the serum xanthine and hypoxanthine concentrations."( Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.
Fuse, M; Noguchi, Y; Otsuka, Y; Saito, Y; Shibata, T; Suyama, K; Takeo, C; Tatsuno, I; Yoshida, T, 2004
)
1.45
"Fenofibrate treatment increased whole-body fatty acid oxidation, and in liver, the expression of carnitine palmitoyl transferase I only in OP rats, but enhanced expression of acyl-CoA oxidase in both OP and OR rats."( Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
Friedman, MI; Ji, H; Outterbridge, LV, 2005
)
1.28
"Fenofibrate treatment showed significant inhibition of [3H]thymidine incorporation in both endothelin-1-stimulated and non-stimulated fibroblasts."( The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation.
Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Takanashi, M; Yamaguchi, I, 2004
)
1.28
"Fenofibrate treatment in apo E-KO mice paradoxically increased total cholesterol and TG by 65% and 44%, respectively, and decreased HDL-cholesterol levels by 35% as compared with controls."( Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice.
Bahadori, B; Declercq, V; Khademi, H; Moghadasian, MH; Moshtaghi-Kashanian, GR; Yeganeh, B, 2005
)
1.36
"Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity."( PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005
)
1.05
"Fenofibrate treatment corrected metabolic changes."( The effects of fenofibrate on metabolic and vascular changes induced by chocolate-supplemented diet in the rat.
Fatani, S; Naderali, EK, 2005
)
1.4
"Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (-49%) and triglycerides (-82%) and a significant increase in low-density lipoprotein (LDL) size (251.5+/-1.8 versus 263.5+/-0.7 A). "( Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Badellino, KO; Cohn, JS; Couture, P; Lamarche, B; Marcil, M; Mauger, JF; Ruel, IL, 2005
)
2.17
"Fenofibrate treatment led to an increase of the activity of antioxidant enzyme glutathione peroxidase (GPx) by 80% from baseline values (p = 0.001)."( Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity.
Javorský, M; Kozárová, M; Molcányiová, A; Tkác, I, 2006
)
2.5
"Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis."( Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006
)
1.06
"Fenofibrate (0.2g/kg) treatment, when in combination with schisandrin B (0.2g/kg), for 4 days significantly reduced the schisandrin B-induced increase in serum triglyceride level (by 81%, P<0.001)."( A novel experimental model of acute hypertriglyceridemia induced by schisandrin B.
Dong, H; Han, YF; Ko, KM; Li, WY; Pan, SY; Zhao, XY, 2006
)
1.06
"Fenofibrate treatment dramatically reduced fasting blood glucose (P<0.001) and HbA1c levels (P<0.001), and was associated with decreased food intake (P<0.01) and slightly reduced body weight."( PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006
)
1.39
"Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only."( Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Dolinkova, M; Haluzik, M; Haluzik, MM; Haluzikova, D; Horinek, A; Housa, D; Kumstyrova, T; Lacinova, Z; Vernerova, Z, 2006
)
1.06
"In fenofibrate treated rats, only plasma triglyceride concentrations were lowered by 82%, while the other lipid parameters were not significantly changed indicating that this aqueous herb extract may contain products that lower plasma lipid concentrations and might be beneficial in treatment of hyperlipideamia."( The hypolipidaemic activity of aqueous Erica multiflora flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparison with fenofibrate.
Amrani, S; Aziz, M; Bouanani, Nel H; Ghalim, N; Harnafi, H; Serghini Caid, H, 2007
)
1.06
"Fenofibrate treatment was associated with less albuminuria progression and less retinopathy needing laser treatment."( Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Vergès, B, 2006
)
2.5
"Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration."( Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Anderlová, K; Bosanská, L; Dolezalová, R; Haluzík, M; Haluzíková, D; Housová, J; Kremen, J; Skrha, J, 2007
)
1.34
"Fenofibrate treatment started within 1 week postburn and continued for 2 weeks significantly decreased plasma glucose concentrations by improving insulin sensitivity, insulin signaling, and mitochondrial glucose oxidation. "( Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Aarsland, A; Cree, MG; Fram, R; Herndon, DN; Morio, B; Qian, T; Sanford, AP; Wolfe, RR; Zwetsloot, JJ, 2007
)
1.99
"Fenofibrate pretreatment (fenofibrate + LPS group) did not alter signs of endotoxemia but prevented reductions in both cardiac contractility and myofilament Ca2+ sensitivity."( Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
Bordet, R; Brisson, H; Callebert, J; Gelé, P; Jozefowicz, E; Lebuffe, G; Mebazaa, A; Rozenberg, S; Tavernier, B; Vallet, B, 2007
)
1.3
"Fenofibrate treatment reduced acetylcholine relaxation. "( Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway.
Aras-López, R; Arroyo-Villa, I; Balfagón, G; Blanco-Rivero, J; Ferrer, M; Márquez-Rodas, I; Xavier, FE, 2007
)
2.18
"Fenofibrate treatment significantly lowered T-cho, triglyceride, and LDL-C levels."( Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Koide, J; Nakanishi, S; Nakashima, R; Oki, K; Yamane, K, 2007
)
2.5
"Fenofibrate treatment lowered fasting triglycerides (-46.1%, P < 0.0001) and postprandial (area under the curve) triglycerides (-45.4%, P < 0.0001) due to significant reductions in postprandial levels of large (-40.8%, P < 0.0001) and medium (-49.5%, P < 0.0001) VLDL particles. "( Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2007
)
3.23
"Fenofibrate treatment blunted reduction in left ventricular ejection fraction, reduced cardiac hypertrophy, and attenuated clinical signs of heart failure."( The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Brigadeau, F; Duriez, P; Fruchart, JC; Gelé, P; Lacroix, D; Marquié, C; Martin-Nizard, F; Staels, B; Torpier, G; Wibaux, M, 2007
)
1.37
"Fenofibrate treatment induced significant reductions in plasma triglycerides (P<0.001) and total cholesterol (P<0.001) in both groups."( Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
Aarsland, A; Chinkes, D; Cree, MG; Newcomer, BR; Paddon-Jones, D; Read, LK; Sheffield-Moore, M; Wolfe, RR, 2007
)
1.06
"Fenofibrate treatment also prevented the diet-induced decrease in cardiac function and improved post-ischemic functional recovery."( Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum, E; Berge, RK; Gudbrandsen, OA; How, OJ; Khalid, AM; Larsen, TS, 2008
)
2.51
"Fenofibrate treatment reduced concentrations of monohydroxy fatty acids (OH-FA) by 15.5% (p=0.001), lipopolysaccharide activated monocyte chemotactic protein-1 (MCP-1/CCL2) production in fasting blood samples by 3.4% (p=0.01 vs. "( Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2008
)
3.23
"Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice."( Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
Dong, H; Fang, HY; Fong, WF; Ko, KM; Pan, SY; Xiang, CJ; Yu, ZL; Zhao, XY, 2008
)
1.07
"Fenofibrate treatment lowered fasting Lp-PLA2 mass by 13.2% (-19.0 to -7.7) versus placebo (2.3% [-5.0 to 4.1], P = .0002) and total ox-FA by 15.5% (-34.2 to +1.4) versus an 11.5% increase with placebo (P = .0013). "( Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson, RS, 2008
)
3.23
"Fenofibrate treatment prevented fatty liver induction, caused an additional reduction on plasma lipids concentrations and caused a 40% decrease in the lipogenic rate in adipose tissue."( Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
Botion, LM; Delpuerto, HL; Ferreira, AV; Mario, EG; Martins, AS; Parreira, GG; Porto, LC, 2008
)
2.51
"Fenofibrate treatment reduced serum total sialic acid levels significantly in the control and hypercholesterolemic groups at the end of the 3rd week and only in the control group at the end of the 6th week."( Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.
Emekli, N; Oztürk, LK; Yarat, A, 2007
)
1.46
"Fenofibrate treatment decreased TAG and cholesterol concentrations in plasma, total lipids of the whole body and liver, and EPA and DHA contents in tissues."( Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp ( Ctenopharyngodon idella) fed a high-fat diet.
Clouet, P; Degrace, P; Du, ZY; Frøyland, L; Liu, YJ; Tian, LX; Zheng, WH, 2008
)
1.37
"Fenofibrate treatment resulted in decreases in total cholesterol, triglycerides (TG), and VLDL cholesterol of 19%, 48%, and 70%, respectively, and a 28% increase in HDL cholesterol, with no significant change in the proportion of Lp A-I and Lp A-I/A-II particles."( Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.
Agnani, G; Edgar, AD; Fruchart, JC; Lau, P; Marcel, YL; McPherson, R, 1996
)
1.21
"Fenofibrate-treated rats exhibited a natriuresis."( Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998
)
1.02
"Fenofibrate treatment also caused the attenuation of impairment of endothelium-dependent relaxation by the oxidized LDL from these patients."( The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.
Arthur, G; Choy, PC; Dembinski, T; Hatch, GM; Kroeger, EA; Liang, B; Man, RY; McMaster, JC; Mymin, D; Shen, G, 2000
)
1.39
"Fenofibrate treatment reduces myocardial infarction size and improves post-ischaemic contractile dysfunction. "( Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.
Andriantsitohaina, R; Auwerx, J; Carpusca, I; Jesel, L; Schoonjans, K; Tabernero, A, 2002
)
1.76
"Fenofibrate treatment provoked a dose-dependent decrease in HL mRNA levels."( Down-regulation of hepatic lipase gene expression and activity by fenofibrate.
Auwerx, J; Peinado-Onsurbe, J; Staels, B, 1992
)
1.24
"Treatment with fenofibrate prior to LPS significantly decreased nuclear NF-κB p50 and p65 subunit binding by 49% and 31%, respectively."( Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis.
Alsuwayt, B; Assis, DN; Auclair, AM; Boyer, JL; Gallucci, GM; Ghonem, NS, 2022
)
2.5
"Treatment with fenofibrate and pioglitazone either alone or in combination markedly attenuated DOX-induced injury by suppression of oxidative stress, inflammation and apoptosis."( Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats.
Ali, AA; El-Raouf, OMA; El-Rhman, RHA; Gad, AM; Saad, EB, 2023
)
1.25
"Treatment with fenofibrate at low or high doses may downregulate the expression of Sirt1 and Sirt3 proteins in the rat liver. "( Age-related effects of fenofibrate on the hepatic expression of sirtuin 1, sirtuin 3, and lipid metabolism-related genes.
Kmieć, Z; Wierzbicki, PM; Wrońska, A; Zubrzycki, A, 2023
)
1.57
"Treatment with fenofibrate reduced tumor necrosis factor α (TNFα) mRNA levels in adipose tissue and lowered serum TNFα levels."( Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Jeon, S; Lee, J; Lee, M; Yoon, M, 2023
)
2.69
"Treatment with fenofibrate contributed to improve fibrosis in a rat model of renal transplantation."( Targeted changes in blood lipids improves fibrosis in renal allografts.
Li, G; Liu, B; Meng, Q; Wang, Y; Xu, ZX; Yang, H; Zhang, D; Zhang, YH; Zhou, H, 2023
)
1.25
"Treatment with fenofibrate did not cause brain mtDNA damage."( [The fenofibrate effect on genotoxicity in brain and liver and on the expression of genes regulating fatty acids metabolism of mice].
Gureev, AP; Khorolskaya, VG; Laver, DA; Popov, VN; Shaforostova, EA, 2019
)
1.37
"Treatment with fenofibrate, pioglitazone and their combination resulted in a significant improvement in the behavioural and neurochemical changes induced by βA injection."( Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases.
Assaf, N; El Sayed, NS; El-Shamarka, ME; Khadrawy, YA; Salem, NA, 2020
)
0.9
"Pre-treatment with fenofibrate and pioglitazone in addition to their combination improved neurobehavioral dysfunction, reduced cerebral infarct volume, attenuated inflammatory and apoptotic markers and ameliorated histopathological changes in I/R injured rats. "( The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF, 2020
)
0.89
"Treatment with fenofibrate in the diabetic group improved oxidative stress by potentiation of antioxidant elements and a reduction in nitrate and malondialdehyde production."( PPAR-α Agonist Fenofibrate Ameliorates Oxidative Stress in Testicular Tissue of Diabetic Rats.
Jamialahmadi, T; Mohammadi, MT; Sahebkar, A; Yaribeygi, H, 2020
)
1.25
"Treatment with fenofibrate attenuated AKI and associated hepatic dysfunction."( Fenofibrate attenuates ischemia reperfusion-induced acute kidney injury and associated liver dysfunction in rats.
Kaur, J; Kaur, T; Pathak, D; Sharma, AK; Singh, AP; Yadav, HN, 2021
)
2.4
"Treatment with fenofibrate, a peroxisome proliferators-activated receptor α (PPARα) agonist, was associated with a lower risk of amputations, particularly minor amputations without known large-vessel diseases, probably through non-lipid mechanisms."( PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway.
Cai, J; Deng, Y; Han, F; Han, X; Jiang, G; Ren, G; Sun, Y; Yao, Z; Yu, J, 2017
)
0.79
"Treatment by fenofibrate increased SOD and CAT activities and improved oxidative stress by decreasing pancreatic MDA and Nox levels."( PPAR-α Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System.
Mohammadi, MT; Sahebkar, A; Yaribeygi, H, 2018
)
0.83
"Post-treatment with fenofibrate significantly inhibits APAP-induced hepatotoxicity, as evidenced by decreased serum ALT and AST levels and hepatic necrosis in liver tissue as well as increased the surviving rate in response to APAP overdose, whereas this protective effect of fenofibrate is largely attenuated in FGF21 KO mice."( FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice.
Li, Q; Li, X; Pan, X; Pan, Y; Xiong, R; Yang, S; Zhang, S; Zhang, Y; Zheng, J, 2018
)
1.06
"Treatment with fenofibrate improved renal function by improving creatinine clearance (P = 0.01) and protein excretion (P = 0.001) and lowering plasma levels of blood urea nitrogen (P = 0.001), creatinine (P = 0.001), and uric acid (P = 0.01)."( Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy.
Mohammadi, MT; Rezaee, R; Sahebkar, A; Yaribeygi, H, 2018
)
2.26
"Treatment with fenofibrate significantly attenuated the propionic acid induced-social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity."( Selective modulator of peroxisome proliferator-activated receptor-α protects propionic acid induced autism-like phenotypes in rats.
Mirza, R; Sharma, B, 2018
)
0.82
"Treatment with fenofibrate significantly attenuated prenatal VPA-induced social impairment, repetitive behavior, hyperactivity, anxiety, and low exploratory activity."( Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats.
Mirza, R; Sharma, B, 2019
)
1.23
"Treatment with fenofibrate exerted a better effect on clinical scoring."( Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Jouzeau, JY; Koufany, M; Moulin, D, 2014
)
2.18
"Treatment with fenofibrate was associated with a significant decrease in alkaline phosphatase (-114IU/L, 95% CI: -152 to -76, P<0.0001); a significant decrease in GGT level (-92IU/L, 95% CI: -149 to -43; P=0.0004); significant decrease in total bilirubin (-0.11mg/dL, 95% CI: -0.18 to -0.08; P=0.0008); and a significant decrease in IgM level (-88mg/dL, 95% CI: -119 to -58; P<0.0001)."( Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
Corpechot, C; Grigorian, AY; Levy, C; Mardini, HE; Poupon, R, 2015
)
2.2
"Treatment with fenofibrate (100 mg kg(-1) BM mixed into the diet) lasted 5 weeks."( PPAR-α agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice.
Aguila, MB; Bringhenti, I; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A; Rachid, TL; Souza-Mello, V, 2015
)
0.76
"Treatment with fenofibrate significantly improved the renal function as revealed by the significant reductions in urinary albumin excretion and serum levels of creatinine and urea, in addition to the significant increase in creatinine clearance compared with the diabetic control group."( Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy.
Al-Ajmi, HN; Al-Amin, MA; Al-Rasheed, NM; Attia, HA; Hasan, IH; Mohamad, RA; Sinjilawi, NA, 2015
)
1.06
"Treatment with fenofibrate or ER niacin in patients with metabolic syndrome not only increased HDL-C levels but also improved the endothelial protective effects of HDL."( Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Adorni, MP; Benghozi, R; Calabresi, L; Damonte, E; Franceschini, G; Gomaraschi, M; Niesor, E; Ossoli, A; Veglia, F, 2015
)
2.21
"Treatment with fenofibrate significantly improved arterial endothelial function after 4 months. "( Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2015
)
2.21
"Cotreatment with fenofibrate blunts these processes."( Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.
Farris, RA; O'Brien, CE; Price, ET; Stolarz, AJ; Wiley, CA, 2015
)
2.19
"Treatment with fenofibrate, a PPARα agonist, normalized both FA and glucose uptake while reducing LV dilation caused by AR."( Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism.
Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Gascon, S; Lachance, D; Lecomte, R; Rousseau, JA; Roussel, E; Sarrhini, O; Walsh-Wilkinson, E, 2015
)
0.76
"Treatment with fenofibrate attenuated renal oxidative stress induced by FA-BSA as evidenced by decreased MDA level, increased SOD activity and catalase, GPx-1 expression."( Fenofibrate, a PPARα agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB.
Liu, H; Ma, X; Zheng, X; Zuo, N, 2015
)
2.2
"Pretreatment with fenofibrate significantly decreased inflammatory factors in both the intestine and the lung."( Protective effects of fenofibrate against acute lung injury induced by intestinal ischemia/reperfusion in mice.
Chen, W; He, G; Wang, J; Wang, Y; Zhu, Q, 2016
)
1.07
"Treatment with fenofibrate prevents intestinal mucosal damage and stimulates intestinal epithelial cell turnover following intestinal IR in a rat model."( Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat.
Ben Shahar, Y; Berkowitz, D; Bitterman, A; Bitterman, N; Coran, AG; Moati, D; Nissimov, N; Pollak, Y; Sukhotnik, I, 2016
)
2.23
"Treatment with fenofibrate significantly reduced triglycerides, non-high density lipoprotein cholesterol (non-HDL-C), insulin levels and insulin resistance index (HOMA-IR) in MetS animals."( Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II.
Carreón-Torres, E; Del Valle-Mondragón, L; Díaz-Díaz, E; Guarner-Lans, V; Ibarra-Lara, L; Rubio-Ruiz, ME; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Vázquez-Meza, H, 2016
)
2.22
"Treatment with fenofibrate reduced fasting and postprandial serum triglyceride levels, possibly through a mechanism related with an increase in the expression of RXRα and PPARα, by activating the pathways involved in the uptake and degradation of triglycerides and increasing the synthesis of apolipoprotein. "( Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome.
Cardona, F; Castellano-Castillo, D; Clemente-Postigo, M; Fernández-García, JC; Macias-Gonzalez, M; Moreno-Indias, I; Queipo-Ortuño, MI; Tinahones, FJ, 2017
)
1.13
"Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats."( Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Balakumar, P; Chakkarwar, VA; Singh, M, 2009
)
0.94
"Treatment with fenofibrate lowers triglycerides, raises HDL-cholesterol and decreases concentrations of small LDL-cholesterol particles and apolipoprotein B."( Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson, RS, 2008
)
2.13
"Treatment with fenofibrate did reduce all cardiovascular disease (CVD) events, the secondary end point (by 11%, p = 0.035)."( After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Sacks, FM, 2008
)
1.09
"Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms."( Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Baker, JR; Best, JD; Colman, PG; D'Emden, MC; Keech, AC; Laakso, M; Li, LP; Rajamani, K; Voysey, M, 2009
)
1.1
"Treatment with fenofibrate led to acceleration of revascularization of ischemic hindlimb relative to the contralatereal limb in wild-type (WT) mice, as measured by laser Doppler blood flow and capillary density analyses."( Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway.
Kondo, M; Li, P; Maruyama, S; Murohara, T; Ohashi, K; Ouchi, N; Shibata, R, 2010
)
2.14
"Mice treated with fenofibrate and administered with l-NAME exhibited similar reactivity to methacholine than vehicle-treated mice administered with the NOS inhibitor, suggesting that NO mediates fenofibrate-induced decrease in airway reactivity."( The peroxisome proliferator-activated receptor α agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung.
Becker, J; Delayre-Orthez, C; Frossard, N; Pons, F, 2012
)
0.95
"Pretreatment with fenofibrate for 4 but not 2 days reduced mortality by 80% and brain LTB(4) levels decreased concomitantly with the induction of Cyp4f15 and 4f18, which catalyze detoxification of LTB(4) through hydroxylation."( Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.
Basu, A; Kumawat, KL; Ravindranath, V; Sehgal, N, 2012
)
2.15
"Treatment with fenofibrate (80 mg/kg/day, p.o., 4 weeks) and telmisartan (10 mg/kg/day, p.o., 4 weeks) either alone or in combination did not affect the elevated glucose levels in diabetic rats."( The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Balakumar, P; Bishnoi, HK; Mahadevan, N, 2012
)
0.72
"Treatment with fenofibrate resulted in significant decrease in CRP and IL-6 concentrations and improvement in lipid profile."( The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.
Kalinovskaya, N; Polovnikova, O; Shirinsky, I; Shirinsky, V, 2013
)
1.08
"The treatment with fenofibrate or vehicle was started 7 days before the AB operation."( Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts.
Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002
)
0.63
"Treatment with fenofibrate (200 mg qd), however, was followed by a significant reduction of triglyceride and cholesterol concentrations to 12 mmol/L (1050 mg/dL) and 10 mmol/L (387 mg/dL)."( [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
Battegay, M; Hirsch, HH, 2003
)
0.66
"Treatment with fenofibrate did not alter plasma ADMA level, in contrast to serum triglycerides which were significantly lowered and plasma total homocysteine which was significantly increased."( Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
Bode-Böger, SM; Dierkes, J; Luley, C; Martens-Lobenhoffer, J; Westphal, S, 2004
)
2.11
"Treatment with fenofibrate, a potent PPARalpha agonist, markedly increased plasma levels of truncated FIAF, but not native FIAF, in humans."( The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.
Bakker, A; Escher, P; Kersten, S; Kleemann, R; Koenig, W; Mandard, S; Müller, M; Patsouris, D; Tan, NS; Veenman, F; Wahli, W; Zandbergen, F, 2004
)
0.85
"Treatment with fenofibrate for 24 h significantly increased the expression of leptin and TSHr genes."( Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy.
Bellastella, A; Colantuoni, V; De Bellis, A; Fusco, A; Pasquali, D; Pierantoni, GM; Sinisi, AA; Staibano, S, 2004
)
2.11
"Treatment with fenofibrate (30 or 100 mg/kg) significantly reduced the inhibition of vasodilator responses to acetylcholine, decreased the elevated levels of ADMA, MDA and TNF-alpha, and enhanced the decreased level of nitrite/nitrate in the rats treated with LDL."( Effect of fenofibrate on LDL-induced endothelial dysfunction in rats.
Chen, MF; Jiang, JL; Li, YJ; Luo, BL; Yang, TL; Yu, J, 2004
)
1.07
"Pretreatment with fenofibrate (3, 10 or 30 microM) significantly inhibited the increases in ADMA, LDH and TNF-alpha, attenuated the decreased levels of NO and the decreased activity of DDAH and prevented the activation of NF-kappaB."( Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.
Chen, MF; Jiang, JL; Li, YJ; Luo, BL; Xie, QY; Yang, TL, 2005
)
2.09
"Treatment with fenofibrate (given p.o."( Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.
Besson, VC; Chen, XR; Marchand-Verrecchia, C; Plotkine, M, 2005
)
2.11
"Treatment with fenofibrate led to reduction of total cholesterol by 18%, LDL cholesterol and apoB by 17%, triglycerides by 46%, as well as increase of HDL cholesterol level by 10%. "( Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity.
Javorský, M; Kozárová, M; Molcányiová, A; Tkác, I, 2006
)
2.13
"Treatment with fenofibrate significantly reduced the level of conjugated dienes, a measure of LDL oxidation, and increased GPx activity. "( Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity.
Javorský, M; Kozárová, M; Molcányiová, A; Tkác, I, 2006
)
2.13
"Treatment with fenofibrate or metformin ameliorated renal damage in OLETF rats through SREBP-1 and some enzyme regulated by it reduced fat deposit in kidney directly."( [Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS, 2006
)
1.06
"Treatment with fenofibrate suppressed the expression of PAI-I mRNA and its protein activity, and inhibited TGF-beta1 overexpression."( Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.
Chen, LL; Wang, BP; Zhang, JY, 2006
)
0.97
"Treatment with fenofibrate protected HRECs from apoptosis in response to serum deprivation in a dose-dependent manner."( Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.
Ahn, JH; Ha, J; Kim, HS; Kim, J; Kim, JH; Oh, YS; Shinn, SH; Yu, YS, 2007
)
2.12
"Treatment with fenofibrate and metformin in combination led to normalization of biochemical abnormalities associated with the MetS more effectively compared with either therapy alone, without additional adverse effects. "( Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007
)
0.96
"Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids."( Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007
)
1.1
"Treatment with fenofibrate (0.15-15 mg/day) during allergen challenge dose-dependently reduced airway inflammatory cell infiltrate induced by ovalbumin in C57BL/6 mice."( Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate.
Auwerx, J; Becker, J; Delayre-Orthez, C; Frossard, N; Pons, F, 2008
)
0.89
"Treatment with fenofibrate (0.5% wt/wt) for 7 d increased plasma human apo A-I levels up to 750% and HDL-cholesterol levels up to 200% with a shift to larger particles."( Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
Auwerx, J; Berthou, L; Branellec, D; Denèfle, P; Duverger, N; Emmanuel, F; Fruchart, JC; Guillouzo, A; Langouët, S; Rubin, E; Staels, B, 1996
)
0.63
"Treatment with fenofibrate reduced 7 alpha-hydroxycholesterol concentrations in six patients from 107 +/- 47 ng/ml to 61 +/- 12 ng/ml (p < 0.05)."( Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans.
Hahn, C; von Bergmann, K, 1996
)
0.63
"The treatment of fenofibrate (30 mg.kg(-1).day(-1)) significantly improved high fructose-induced metabolic derangements such as insulin resistance, hypertension, hyperlipidemia, and fat accumulation in the liver."( Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
Kashiwagi, A; Kikkawa, R; Maegawa, H; Nagai, Y; Nakamura, T; Nishio, Y, 2002
)
0.64
"Treatment with fenofibrate significantly reduced the linoleic acid (18:2n-6) in PC and TAG plasma, CE and TG LDL, in a higher ratio of palmitoleic acid (16:1n-7) in CE LDL, oleic (18:1n-9) in PC LDL, in significant concentration of total monoenic FA in PC and CE LDL and to a significant increase of the concentration of myristic acid (14:0) in CE and myristic and stearic acids (18:0) in TAG LDL."( [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
Konárková, M; Stípek, S; Tvrzická, E; Zák, A; Zeman, M, 2002
)
0.65

Toxicity

The most important and commonly observed adverse effects in the fenofibrate group were dermatological events, myalgia and asymptomatic increase in aminotransferase values. In the lovastatin group cardiovascular events (five patients) were the most common.

ExcerptReferenceRelevance
" Preclinical toxicology reveals minimal toxic effects; dose-related changes occurred seldom, with only hepatic effects in rodents (mainly enzyme changes), some renal effects in dogs, and no reactions in monkeys."( Safety of fenofibrate--US and worldwide experience.
Roberts, WC, 1989
)
0.68
" Our observations provide good evidence that lovastatin and simvastatin have no undesirable toxic effects on the lens and other ocular tissues, compared with fenofibrate."( Ocular drug safety and HMG-CoA-reductase inhibitors.
Hockwin, O; Paulus, U; Schmidt, J; Schmitt, C; von Bergmann, K, 1994
)
0.49
" This short-term study showed few adverse effects for both drugs."( Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Bonnefous, F; Debbas, N; Farnier, M; Irvine, A, 1994
)
0.55
" Each patient was followed up at Out-patient Clinic regularly for diet interview, compliance and possible adverse events."( Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997
)
0.61
" There was no obvious adverse event noted during each treatment period with either drug."( Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997
)
0.61
" The most important and commonly observed adverse effects in the fenofibrate group were dermatological events (three patients), myalgia (two patients) and asymptomatic increase in aminotransferase values (nine patients), while in the lovastatin group cardiovascular events (five patients) were the most common."( Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
Gholami, K; Maleki, M; Shafiee, A; Tavakoli, N, 1998
)
0.8
" There were no major clinical or biological adverse events in the dose interval from 200 mg to 400 mg of micronised fenofibrate per day."( Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Corda, C; Farnier, M; Gerlinger, C; Issa-Sayegh, M; Krempf, M; Masseyeff-Elbaz, MF; Rohmer, V; Sirugue, I, 2000
)
0.8
" The safety of the treatment was assessed by recording adverse events and measuring clinical laboratory parameters."( [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003
)
0.59
"Statin monotherapy is generally well tolerated, with a low frequency of adverse events."( Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Bellosta, S; Corsini, A; Paoletti, R, 2004
)
0.32
"An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis."( Risk of adverse events with fibrates.
Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004
)
0.55
"Fenofibrate at 300 mg per day is effective and safe in treating Thai patients with dyslipidemia."( Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Chawantanpipat, C; Jeamanukulkit, N; Khanacharoen, I; Koanantakul, B; Piamsomboon, C, 2004
)
2.02
" Lipid profiles, physical and laboratory investigations for adverse effects were assessed."( [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
Chen, H; Luo, Y; Ren, JY, 2005
)
0.57
" (3) All treatments were well tolerated with no increase in adverse events for combination therapy versus monotherapy."( [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
Chen, H; Luo, Y; Ren, JY, 2005
)
0.57
"The results of this study demonstrated that combination therapy with fenofibrate (200 mg/day) and low-dose simvastatin (10 mg/day) is more effective than monotherapy in patients with combined hyperlipidemia, and is generally safe and well tolerated."( [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
Chen, H; Luo, Y; Ren, JY, 2005
)
0.8
" The overall frequency of adverse events was similar in the 2 FF-muG groups and did not differ significantly from placebo (63."( Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005
)
0.61
" Both treatment regimens were safe and well tolerated."( Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.
Abby, S; Jones, M; McKenney, J, 2005
)
0.56
" There were few adverse events and no rhabdomyolysis reported."( A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA, 2005
)
0.58
"Cardiotoxicity is a treatment-limiting side effect of the anticancer drug doxorubicin (DOX)."( Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity.
Duan, Z; Furuhashi, K; Ichihara, G; Ichihara, S; Kawai, Y; Osawa, T; Yamada, Y, 2007
)
0.34
" We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period."( Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008
)
0.91
"Lipid-lowering drugs have been associated with severe adverse effects on skeletal muscle, including rhabdomyolysis."( Statins and fibrate target ClC-1 - from side effects to CLC pharmacology.
Zdebik, AA, 2009
)
0.35
"Mean percentage changes in lipid parameters, percentages of patients achieving optimal serum lipid/apolipoprotein levels, and incidence of adverse events."( Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010
)
0.36
" Incidence of adverse events was generally similar among treatments."( Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010
)
0.36
" According to the detected ethanol toxic response marked by reduced cell viability, 3D cultured hepatocytes in gel entrapment were suggested to be better than 2D hepatocyte in monolayer, but the cultures in either William's Medium E or DMEM exhibited comparable sensitivity to ethanol toxicity."( Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Meng, Q; Ruan, X; Shen, C, 2010
)
0.36
" Safety was evaluated based on data collected for adverse events (AEs), physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests."( Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Although amiodarone is the most effective antiarrhythmic agent currently available, concerns regarding adverse effects, including liver, lung and thyroid toxicity, often limit its use."( Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Ernst, MC; Pollak, PT; Sinal, CJ, 2010
)
0.36
" Combination therapy was generally well tolerated with incidences of clinical and laboratory adverse experiences similar between the 2 groups."( Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Bryniarski, L; Ducobu, J; Farnier, M, 2010
)
0.65
" Overall, adverse events were similar in the 2 treatment groups."( Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2010
)
0.36
"In conclusion, rosuvastatin 5 mg + fenofibric acid 135 mg resulted in comprehensive improvements in the lipid profile of patients with mixed dyslipidemia without unanticipated adverse events."( Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010
)
0.36
" In conclusion, these data suggest that a combination of fenofibric acid and a statin could be considered safe and efficacious for treating women with mixed dyslipidemia."( Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Bittner, V; Goldberg, AC; Kelly, MT; Lele, A; Pepine, CJ; Setze, CM; Sleep, DJ; Thakker, K, 2011
)
0.37
" Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded."( Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012
)
0.66
" ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment."( Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012
)
0.89
" Adverse events (AEs) and clinical laboratory values were also assessed."( One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM, 2012
)
0.38
" Adverse event (AE) profiles of FF/PRA 160 mg/40 mg (n=645 in the double-blind cohort) were evaluated relative to comparators (statins, n=519 or fenofibrate, n=122)."( Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
Bryniarski, L; Császár, A; De Niet, S; Ducobu, J; Farnier, M; Marcereuil, D; Retterstøl, K; Steinmetz, A; Vanderbist, F, 2012
)
0.85
" Discontinuation attributed to any adverse events (4."( Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
Ding, Z; Guo, J; Hou, R; Li, C; Ma, N; Meng, F; Qin, Y; Wang, H, 2012
)
0.62
" Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.39
" Thus BGL003 should be safe and suitable strategy to endow hydrophobic molecules with much hydrophilicity."( Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells.
Hattori, H; Ishizawa, K; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Tsuchiya, K; Watanabe, M, 2012
)
0.38
"Patients with mixed dyslipidemia can benefit from the combination of fenofibric acid (FA) with statins, but concerns about adverse events make physicians reluctant to prescribe the combination therapy."( Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
0.39
"In the present study, we performed a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and adverse events in patients taking statins and FA."( Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
0.39
"Medline, Embase and the Cochrane Library were searched to identify studies that reported adverse events."( Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
0.39
" The adverse events in the FA + moderate-dose statin group were almost identical to those in the FA + low-dose statin group."( Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
0.39
" However, we still need large-scale and long follow-up period RCTs to definitively confirm the adverse events of FA-statin therapy."( Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
0.39
"The combination of fenofibrate with statins is a beneficial therapeutic option for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) make physicians reluctant to use this combination therapy."( Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J, 2013
)
1
"Fenofibrate-associated nephrotoxicity is an underrecognized adverse effect that is being reported with increasing frequency in the medical literature."( Fenofibrate-associated nephrotoxicity: a review of current evidence.
Attridge, RL; Frei, CR; Koeller, J; Linn, WD; Ryan, L, 2013
)
3.28
"Fenofibrate-associated nephrotoxicity is an underrecognized adverse drug reaction."( Fenofibrate-associated nephrotoxicity: a review of current evidence.
Attridge, RL; Frei, CR; Koeller, J; Linn, WD; Ryan, L, 2013
)
3.28
" Mean percentage change from baseline in triglycerides (TGLs), non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and TC-HDL ratio, incidence of adverse effects, and cost-effectiveness were compared in both the groups."( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014
)
0.64
" Incidence of adverse events was reasonably less in alternate day therapy group."( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014
)
0.64
"Alternate day therapy with atorvastatin-fenofibrate combination is an effective and safe alternative to daily therapy in mixed dyslipidemia."( Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK, 2014
)
0.91
"Combined fenofibrate-statin treatment is generally safe and well tolerated, liver function should be monitored before and during and after therapy."( [A meta-analysis on the safety of combination therapy with fenofibrate and statins].
Chen, H; Geng, Q; Li, SF; Ren, JY, 2013
)
1.05
" Taken together, these findings indicate the molecular mechanism by which PPARα activation increases liver triglyceride accumulation and suggest an adverse effect of fibrates on the pathogenesis of hepatic steatosis."( Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Cao, M; Chen, W; Gao, L; Jing, F; Wang, Q; Wang, T; Xu, C; Yan, F; Yu, C; Zhao, J; Zhou, X, 2014
)
0.4
" However, this combination is often associated with adverse eff ects, especially muscular and hepatic."( [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares, A, 2014
)
0.69
"Current evidence regarding the adverse effects of fenofibrate/simvastatin combination is critically presented based on the results of large randomized controlled trials and other relevant studies."( Safety considerations with fenofibrate/simvastatin combination.
Elisaf, MS; Filippatos, TD, 2015
)
0.97
"Large randomized clinical trials show that the combined administration of fenofibrate with simvastatin is not associated with significantly increased incidence of serious adverse events compared with simvastatin monotherapy."( Safety considerations with fenofibrate/simvastatin combination.
Elisaf, MS; Filippatos, TD, 2015
)
0.94
"Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin."( Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
El-Mas, MM; Helmy, MM; Helmy, MW, 2015
)
0.68
" Fenofibrate use was associated with some changes in laboratory measurements, but there was no differential adverse effect between the combination therapy and fenofibrate monotherapy."( Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S, 2017
)
1.61
"The combination therapy with fenofibrate and ezetimibe substantially reduces concentrations of LDL cholesterol and triglycerides and is safe in a long-term treatment in Japanese patients with combined hyperlipidemia."( Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S, 2017
)
1
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Treatment-emergent adverse events occurred in 77."( Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF, 2016
)
0.43
"The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the combination of extended-release niacin and laropiprant versus placebo."( Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
Gagne, JJ; Hampp, C; Houstoun, M; Marshall, JH; Reichman, ME; Toh, S, 2018
)
0.48
" The incidence rates of adverse drug reactions in pemafibrate groups (2."( Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Arai, H; Araki, E; Ishibashi, S; Suganami, H; Yamashita, S; Yokote, K,
)
0.13
"To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety by assessing the incidence of adverse events (AEs) and adverse drug reactions (ADRs)."( Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai, H; Araki, E; Ishibashi, S; Suganami, H; Yamashita, S; Yokote, K, 2018
)
0.95
"The favorable safety profile of pemafibrate, with fewer adverse effects on kidney/liver-related laboratory tests and fewer AEs/ADRs, including those leading to treatment discontinuation, over fenofibrate 200 mg/day may justify the use of this novel and potent treatment option for reducing TG levels in a broader range of patients."( Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai, H; Araki, E; Ishibashi, S; Suganami, H; Yamashita, S; Yokote, K, 2018
)
0.93
" The overall rates of adverse events were not significantly different between the cirrhotic and non-cirrhotic group."( Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan, W; Jia, J; Ma, H; Ou, X; Wang, Q; Wang, X; Wang, Y; Wu, X; You, H; Zhang, W; Zhao, X, 2018
)
0.79
" Several studies have been conducted to attenuate the side effects of cisplatin; one such side effect in cancer patients undergoing cisplatin chemotherapy is ototoxicity."( Protective roles of fenofibrate against cisplatin-induced ototoxicity by the rescue of peroxisomal and mitochondrial dysfunction.
Kim, SJ; Lee, JN; Park, C; Park, R, 2018
)
0.8
" Safety was assessed by adverse events and laboratory parameters."( Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study.
Chen, SY; Fang, NY; Jiang, H; Jiao, QP; Lu, J; Sheng, J; Wang, HY; Zheng, SB, 2018
)
0.75
" There were no serious adverse events or significant changes in laboratory variables after any of the treatment regimens."( Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study.
Chen, SY; Fang, NY; Jiang, H; Jiao, QP; Lu, J; Sheng, J; Wang, HY; Zheng, SB, 2018
)
0.75
" These lipids are toxic to the retina and may drive the photoreceptor loss that occurs in MacTel patients."( Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery.
Eade, K; Friedlander, M; Giles, S; Harkins-Perry, S, 2021
)
0.62
" The toxic effects on the zebrafish embryo thus suggested that the formulation as well as the solvent increased the bioavailability of fenofibrate."( Microparticle formulations alter the toxicity of fenofibrate to the zebrafish Danio rerio embryo.
Böhmer, W; Eilebrecht, E; Fenske, M; Günday-Türeli, N; Heng, PWS; Hering, I; Modh, H; Parnham, MJ; Schäfers, C; Türeli, AE; Wacker, MG; Weiler, M, 2021
)
1.08
" Furthermore, the 5FU group showed toxic histopathological changes including marked cardiac damage and a significant decrease in reduced glutathione (GSH), total antioxidant capacity (TAC), and peroxisome proliferator-activated receptor alpha (PPARα) expression."( The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity.
Abdelzaher, WY; Bayoumi, AMA; El-Tahawy, NFG; Refaie, MMM; Shehata, S, 2022
)
0.93
" There were no additional serious adverse events in the combination therapy group compared with the statin monotherapy group."( Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study.
Han, KH; Kim, BJ; Kim, EJ; Kim, SH; Kwon, SU; Lee, SH; Park, MS; Ryu, KH; Youn, JC, 2021
)
0.93
" No significant adverse effects associated with additional FF therapy were observed in our cohort."( Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Deng, J; Ding, D; Guo, C; Guo, G; Han, Y; Jia, G; Liu, Y; Shang, Y; Sun, R; Wang, X; Zheng, L, 2022
)
1.03
" We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients."( Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023
)
0.91

Pharmacokinetics

The dissolution rate of fenofibrate nanosuspension was increased obviously, and the product was evaluated by pharmacokinetic characteristic in rats. Bezafibrate and fenfibrate had no significant effect on the peak concentration (Cmax) of repaglinide.

ExcerptReferenceRelevance
"ml-1), Cmax (812 ng."( Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.
Bizollon, CA; Boissonnat, P; deLorgeril, M; Dureau, G; Faucon, G; Guichard, JP; Guidollet, J; Levy-Prades-Sauron, R; Renaud, S, 1992
)
0.48
" All members of this class are primarily excreted via the kidneys and display some increase in plasma half-life in individuals with severe renal impairment."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.3
"This study was conducted to evaluate the potential pharmacokinetic interaction between fenofibrate and pravastatin."( Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
Achari, R; Gustavson, LE; Gutterman, C; Pan, WJ; Rieser, MJ; Wallin, BA; Ye, X, 2000
)
0.76
" This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions."( Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Bellosta, S; Corsini, A; Paoletti, R, 2004
)
0.32
" A 2-period, randomized, open-label, crossover study was conducted in 12 subjects to determine if fenofibrate and simvastatin are subject to a clinically relevant pharmacokinetic interaction at steady state."( Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman, AJ; Burke, J; Hartford, A; He, W; Lasseter, KC; Liu, L; Murphy, G; Paolini, JF; Prueksaritanont, T; Qiu, Y; Valesky, R; Vega, JM; Zhao, JJ, 2004
)
0.77
" Pharmacokinetic parameters were assessed on day 14."( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004
)
0.57
"The primary pharmacodynamic parameter was percentage change from baseline in LDL-C concentration following co-administration of ezetimibe and fenofibrate vs either drug alone, or placebo."( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004
)
0.77
" Bezafibrate and fenofibrate had no significant effect on the peak concentration (Cmax) of repaglinide."( Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, M; Neuvonen, PJ, 2004
)
0.94
" Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.55
"This study was conducted to evaluate the potential for pharmacokinetic interaction between fenofibrate and ezetimibe in healthy subjects."( Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD, 2006
)
0.79
" ABT-335 and rosuvastatin have different mechanisms of actions and exert complementary pharmacodynamic effects on lipids."( ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Awni, WM; Chira, TO; Hosmane, B; Kelly, MT; Pradhan, RS; Sleep, DJ; Stolzenbach, JC; Wan, K; Zhu, T, 2009
)
0.35
"The dissolution rate of fenofibrate nanosuspension was increased obviously, and the product was evaluated by pharmacokinetic characteristic in rats."( Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.
Gu, L; Li, X; Wang, Y; Xu, Y, 2009
)
1.01
" The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid."( Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011
)
0.91
"Management of a lipophilic-hydrophilic balance is a key element in drug design to achieve desirable pharmacokinetic characters."( A novel prodrug strategy for extremely hydrophobic agents: conjugation to symmetrically branched glycerol trimer improves pharmacological and pharmacokinetic properties of fenofibrate.
Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Taoka, C; Tomida, Y; Tsuchiya, K; Watanabe, M, 2013
)
0.58
" The findings imply that the observed pharmacokinetic interaction is unlikely clinically relevant, and support the combined use of simvastatin and fenofibrate not only given at staggered interval but also given simultaneously."( Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?
Ansquer, JC; Aubonnet, P; Beckmann, K; Driessen, S; Lehnick, D; Mihara, K; Olbrich, M; Piskol, G; van Amsterdam, P; van Assche, H; Winsemius, A, 2014
)
0.85
" The 90% CIs for the test/reference mean ratios of the ln-transformed pharmacokinetic variables Cmax, AUC0-t, and AUC0-∞ were within the conventional bioequivalence range of 80% to 125%."( Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.
Chachad, SS; Gole, M; Malhotra, G; Naidu, R, 2014
)
0.67
" Interactions between statins and other drugs are caused by pharmacokinetic mechanisms, mainly by changing the metabolism of statins in the CYP450 enzyme system, in the hepatic glucuronidation pathway or in the transporters responsible for statin distribution in tissues."( [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos, P, 2014
)
0.4
" A pharmacokinetic study was then undertaken on male BALB/cJRj mices."( Self-emulsifying drug delivery system developed by the HLB-RSM approach: Characterization by transmission electron microscopy and pharmacokinetic study.
Bahloul, B; Dhotel, H; Lai-Kuen, R; Lassoued, MA; Mignet, N; Seguin, J; Sfar, S, 2015
)
0.42
" The in vivo phototoxic risk of fenofibrate (FF) and its metabolites, fenofibric acid (FA) and reduced fenofibric acid, were evaluated based on photochemical and pharmacokinetic analyses."( New Photosafety Assessment Strategy Based on the Photochemical and Pharmacokinetic Properties of Both Parent Chemicals and Metabolites.
Kato, M; Ohtake, H; Onoue, S; Seto, Y; Suzuki, G, 2015
)
0.7
"With the purpose of carrying out pharmacokinetic interaction studies ofnberberine (BBR) and fenofibrate (FBT), an UPLC-MS/MS method has been developed and validated."( Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administrati
Li, G; Liu, M; Su, X; Yang, F; Zhao, L; Zhao, M, 2016
)
0.84
"Open-label, single-sequence pharmacokinetic study."( Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Alfaro, RM; Calderón, MM; Gordon, LA; Hadigan, C; Kovacs, JA; Malati, CY; McLaughlin, M; Penzak, SR, 2016
)
0.43
" Fenofibric acid pharmacokinetic parameter values were compared before and after concomitant ritonavir or lopinavir-ritonavir administration."( Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Alfaro, RM; Calderón, MM; Gordon, LA; Hadigan, C; Kovacs, JA; Malati, CY; McLaughlin, M; Penzak, SR, 2016
)
0.43
" This method was validated and successfully applied to pharmacokinetic study of nitrofibriate and fenofibrate after oral administration."( Comparisons of pharmacokinetics and NO-releasing of nitrofibriate and fenofibrate after oral administration in rats.
Cheng, Q; Jiang, X; Li, T; Liu, X; Liu, Z; Wang, L; Yang, Y, 2016
)
0.89
" Pharmacokinetic parameters of fenofibric acid was evaluated after oral (at doses of 20 mg/kg) administration of JW322 and fenofibrate in rats."( Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate.
Kim, TK, 2017
)
0.87
" Coadministration of Fbt and Svt with Bbr had no significant effect on the pharmacokinetic parameters of Bbr, except time to maximum concentration, apparent volume of distribution, and apparent clearance."( Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
Li, G; Qiu, F; Sun, Y; Zhao, L; Zhao, M, 2019
)
0.74
" No clinically obvious pharmacokinetic interactions between Bbr and Fbt/Svt were observed with combined administration."( Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
Li, G; Qiu, F; Sun, Y; Zhao, L; Zhao, M, 2019
)
0.74
" Pharmacokinetic (PK) parameters were estimated using noncompartmental methods."( Pharmacokinetics and bioequivalence of two fenofibrate choline formulations in healthy subjects under fed and fasted condition
.
Chae, SI; Chung, EK; Hwang, SJ; Lee, KT; Lee, SJ; Noh, YS; Park, JM; Shim, WS; Yoon, JM, 2019
)
0.78
"The reference and the test formulations of 135 mg choline fenofibrate show comparable pharmacokinetic profiles of fenofibric acid under both fed and fasted conditions and are considered bioequivalent."( Pharmacokinetics and bioequivalence of two fenofibrate choline formulations in healthy subjects under fed and fasted condition
.
Chae, SI; Chung, EK; Hwang, SJ; Lee, KT; Lee, SJ; Noh, YS; Park, JM; Shim, WS; Yoon, JM, 2019
)
1.02
" Potential risk factors affecting critical quality biopharmaceutical attributes of fenofibrate nanocrystals like size, zeta potential, in vitro release, crystallinity and intrinsic solubility were optimized to improve pharmacokinetic performance."( Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective.
Gite, S; Kakade, P; Patravale, V, 2021
)
1.16

Compound-Compound Interactions

The purpose of this study was to assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service.

ExcerptReferenceRelevance
"Recent trials have investigated the usefulness of fenofibrate, alone and in combination with other lipid-lowering therapies, in the treatment of hyperlipidemia."( Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Brown, WV, 1989
)
0.82
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."( Drug interactions with fibric acids.
Dujovne, CA; Lozada, A, 1994
)
0.29
" For example, HMG-CoA reductase inhibitors may interact with macrolides, azalides, azole antifungals and cyclosporin."( Drug interactions of lipid-altering drugs.
Bays, HE; Dujovne, CA, 1998
)
0.3
"The purpose of this study was to investigate the effect of low high-density-lipoprotein (HDL) combined with hypertriglyceridemia in coronary artery disease (CAD) patients on prostaglandin I2 (PGI2) biological activity in relation to lipid regulating treatment."( Effect of low HDL combined with hypertriglyceridemia in coronary artery disease patients on PGI2 biological activity in relation to lipid regulating treatment.
Dai, G; Feng, Z; Li, J; Wang, C; Wei, W; Yang, Y; Zhou, B, 1998
)
0.3
" Although the National Cholesterol Education Programme Adult Treatment Panel III guidelines recommend the use of fibrates in combination with statins in patients at very high risk of CHD (e."( Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson, MH, 2006
)
0.33
"Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients."( Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006
)
2.06
"To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout."( Effect of fenofibrate in combination with urate lowering agents in patients with gout.
Lee, CH; Lee, J; Lee, YH, 2006
)
1.04
"In this study, a sensitive and selective method based on liquid chromatography combined with diode array and tandem mass spectrometry detection (LC-DAD-MS/MS) was developed for the simultaneous quantitative determination of fenofibric acid, pravastatin and its main metabolites in human plasma."( An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.
Cahay, B; Klinkenberg, R; Mertens, B; Streel, B, 2008
)
0.35
" A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid."( Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2008
)
0.35
" This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia."( Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2009
)
0.35
" We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia."( Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A, 2010
)
0.83
" The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins."( Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Hilleman, DE; Maciejewski, SR; Mohiuddin, SM; Schima, SM; Williams, MA, 2010
)
0.36
" It has been extensively evaluated both as monotherapy and in combination with atorvastatin, rosuvastatin, and simvastatin in a large number of patients with mixed dyslipidemia for up to 2 years and appears to be a safe and effective option in the management of dyslipidemia."( Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Elisaf, MS; Kei, A; Milionis, HJ; Moutzouri, E, 2010
)
0.36
" In the treatment group, fenofibrate alone and in combination with telmisartan was administered 2 weeks prior to renal ischemia."( Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.
Bhalodia, Y; Jivani, N; Sheth, N; Vaghasiya, J, 2010
)
1.1
"The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA."( Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A, 2011
)
0.59
" The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs."( β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.
Demonte, A; Ferreira, ES; Neves, VA; Silva, MA, 2012
)
0.88
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS."( Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012
)
0.84
"We previously randomised patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group, n = 30)."( Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012
)
0.81
"The purpose of this study was to assess and compare the effect of fenofibrate alone or in combination with pentoxifylline on the measured biochemical parameters, inflammatory pathway and liver stiffness in patients with non-alcoholic fatty liver disease."( Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.
El-Haggar, SM; Mostafa, TM, 2015
)
0.91
" Consequently, the proposed method was applied to the pharmacokinetic interaction study of FBT combined with BBR after oral administration in rats and was proved to be sensitive, specific and reliable to analyze BBR and FBA in biological samples simultaneously."( Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administrati
Li, G; Liu, M; Su, X; Yang, F; Zhao, L; Zhao, M, 2016
)
0.62
"Effects of omega-3 fatty acids (n-3 FA) combined with fenofibrate are not yet investigated, compared with fenofibrate."( Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
Han, SH; Koh, KK; Lee, Y; Oh, PC; Sakuma, I; Shin, EK, 2016
)
0.92
" The purpose of this study is to investigate the effect of per os colchicine administration in combination with fenofibrate and NAC on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits."( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021
)
1.07
"Colchicine administration in combination with fenofibrate or NAC statistically significantly reduced the extent of atherosclerotic lesions in aortic preparations."( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021
)
1.12
"In an experimental rabbit model, it appears that colchicine statistically significantly reduces the development of atherosclerosis of the aorta, especially in combination with NAC."( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021
)
0.86
"To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service."( Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022
)
1.2

Bioavailability

The substantial improvements in bioavailability of fenofibrate from the SLC-based formulations confirm the ability of this formulation strategy to overcome the dissolution and solubility limitations. Colesevelam HCl had no significant effect on fenOfibrate bioavailability when administered either concomitantly with fen Ofibrat.

ExcerptReferenceRelevance
" A lower dispersion of particles size and thereby a better absorption rate leads to a decrease of the daily dose and provides a better control of the amount absorbed."( Micronised fenofibrate.
Guichard, JP; Munoz, A; Reginault, P, 1994
)
0.68
" As a class, these drugs are generally well absorbed from the gastrointestinal tract (immediate-acting fenofibrate being the exception) and display a high degree of binding to albumin."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.51
" Pharmacokinetic parameters of these three compounds were calculated using noncompartmental methods and compared by analyses of variance and bioavailability assessments."( Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
Achari, R; Gustavson, LE; Gutterman, C; Pan, WJ; Rieser, MJ; Wallin, BA; Ye, X, 2000
)
0.54
" Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation."( Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating, GM; Ormrod, D, 2002
)
0.96
"Fenofibrate is well absorbed after oral administration, with peak plasma levels attained in 6 to 8 hours."( Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Najib, J, 2002
)
3.2
" The results suggest that these supramolecular assemblies with high drug loadings and pH-dependent release kinetics can potentially enhance the oral bioavailability of poorly water-soluble drugs."( Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization.
Leroux, JC; Sant, VP; Smith, D, 2004
)
0.32
" Because food increases the bioavailability of fenofibrate, each dose was administered with food to maximize the exposure of fenofibric acid."( Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman, AJ; Burke, J; Hartford, A; He, W; Lasseter, KC; Liu, L; Murphy, G; Paolini, JF; Prueksaritanont, T; Qiu, Y; Valesky, R; Vega, JM; Zhao, JJ, 2004
)
0.8
"Colesevelam HCl had no significant effect on fenofibrate bioavailability when administered either concomitantly with fenofibrate or 4 hours after fenofibrate."( Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
Baker, BA; Jones, MR; Mathew, P, 2004
)
0.85
"The main drawback of the lipid-lowering agent fenofibrate is low bioavailability when taken orally on an empty stomach."( A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Fordyce, D; Guivarc'h, PH; Vachon, MG, 2004
)
1.06
"The aims of this group of studies were to determine the effects of food on the bioavailability of IDD-P fenofibrate and MCF and to compare the bioavailabilities of IDD-P fenofibrate, MF, and MCF under fasting and fed conditions."( A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Fordyce, D; Guivarc'h, PH; Vachon, MG, 2004
)
1.02
" The bioavailabilities of tested treatments were compared using the 90% CIs of ratios of least squares means (RLSMs) of logarithmically transformed AUC(0-infinity) values; 90% CIs within 80% to 125% were considered to indicate equivalent bioavailability (ie, extent of absorption)."( A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Fordyce, D; Guivarc'h, PH; Vachon, MG, 2004
)
0.8
" All of these CIs were within the 80% to 125% range, suggesting equivalent bioavailability of IDD-P fenofibrate independent of food."( A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Fordyce, D; Guivarc'h, PH; Vachon, MG, 2004
)
1.02
"The purpose of the present study was to determine whether pH-sensitive polymeric micelles could improve the oral bioavailability of a poorly water-soluble drug."( Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies.
Leroux, JC; Sant, VP; Smith, D, 2005
)
0.33
"The limited bioavailability of certain fenofibrate formulations necessitates administration with food, raising concerns about efficacy and compliance."( Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005
)
0.88
"The present study was conducted to assess the effect of food on the bioavailability of fenofibric acid from a new tablet formulation containing fenofibrate nanoparticles."( Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.
Dubois, A; Jessent, V; Maillot, C; Sauron, R; Weil, A; Wilkins, M, 2006
)
0.79
"To examine the effects of food on plasma concentration and bioavailability of fenofibrate administered as a sustained-release capsule."( The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.
Choi, SO; Joo Lee, E; Kang, W; Kee Kim, H; Kwon, JT; Kwon, KI; Youn Chung, S; Yun, HY, 2006
)
0.82
" The high-fat breakfast affected the rate of absorption of fenofibrate more than the standard breakfast and fasted conditions."( The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.
Choi, SO; Joo Lee, E; Kang, W; Kee Kim, H; Kwon, JT; Kwon, KI; Youn Chung, S; Yun, HY, 2006
)
0.84
"An increasing number of newly developed drugs show bioavailability problems due to poor water solubility."( Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
Grenier, P; Hanafy, A; Langguth, P; Lenhardt, T; Spahn-Langguth, H; Tubic Grozdanis, M; Vergnault, G, 2007
)
0.62
" The results suggest that cogrinding and spray-drying are powerful techniques for the preparation of rapidly dissolving formulations of fenofibrate, and could potentially lead to improvements in the bioavailability of oral fenofibrate products."( Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations.
Dressman, JB; Kunath, K; Vogt, M, 2008
)
0.85
" Since fenofibrate was first introduced in clinical practice, a major drawback has been its low bioavailability when taken under fasting conditions."( Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
Athyros, VG; Tziomalos, K, 2006
)
2.23
" Oral bioavailability was demonstrated in a Sprague-Dawley rat, while efficacy to reduce plasma triglycerides and plasma glucose was demonstrated in db/db mice."( Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.
Chen, X; Cryan, E; Demarest, KT; Hlasta, DJ; Matthews, JM; Rybczynski, PJ; Strauss, K; Tang, Y; Xu, JZ; Yang, M; Zhou, L, 2007
)
0.34
" The inadequate activity of fenofibrate over the 5 years of the FIELD study might be due to bioavailability problems previously noted with some slow release formulations."( Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer.
Banfi, F; Falcioni, S; Mombelli, G; Sirtori, CR, 2009
)
0.86
" This improvement in lipid levels may have been related to increased bioavailability of the 145-mg formulation."( Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Hilleman, D; Maciejewski, S, 2008
)
0.67
"The main purpose of this study was to evaluate oral bioavailability of the poorly water-soluble drug fenofibrate when liposomes containing a bile salt were used as oral drug delivery systems."( Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.
Chen, J; Chen, Y; Hu, F; Lai, J; Lu, Y; Sun, J; Wu, W, 2009
)
0.81
"In this study, nanosuspension was prepared to improve the dissolution rate and bioavailability of lipophilic fenofibrate."( Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.
Gu, L; Li, X; Wang, Y; Xu, Y, 2009
)
0.92
" Therefore, nanosuspensions may be a suitable delivery system to improve the bioavailability of those drugs with poor water solubility."( Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.
Gu, L; Li, X; Wang, Y; Xu, Y, 2009
)
0.71
"This article aimed to develop fenofibrate solid dispersion with high bioavailability using hot-melt extrusion and compare the difference of Eudragit E100 and polyvinylpyrrolidone-vinyl acetate copolymer S630 (PVP-VA) in dissolution."( In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.
He, H; Tang, X; Yang, R, 2010
)
0.93
"Solid dispersion with carrier of Eudragit E100 or PVP-VA was prepared by hot-melt extrusion and then characterized by differential scanning calorimetry (DSC), X-ray diffraction, in vitro dissolution test, and in vivo bioavailability study."( In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.
He, H; Tang, X; Yang, R, 2010
)
0.64
" When Eudragit E100 1:4 solid dispersion was administrated to beagle dogs, its relative bioavailability to micronization Lipanthyl capsule was 177."( In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.
He, H; Tang, X; Yang, R, 2010
)
0.64
"Hot-melt extrusion is an excellent method to improve the dissolution and therefore the bioavailability of fenofibrate."( In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.
He, H; Tang, X; Yang, R, 2010
)
0.85
" This protection of nano-silibinin might relate to its improved bioavailability compared to normal insoluble silibinin and could act as an anti-oxidative and anti-steatosis agent against ethanol-induced hepatotoxicity."( Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Meng, Q; Ruan, X; Shen, C, 2010
)
0.36
"This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers."( Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Ansquer, JC; Kelly, MT; Pradhan, RS; Sleep, DJ; Zhu, T, 2010
)
0.8
"The purpose of this study was to investigate the dissolution and oral bioavailability of an immediate-release tablet involving wet grinding of a poorly water-soluble drug, fenofibrate."( Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
Chai, G; He, H; Tang, X; Xu, H; Zeng, X; Zhang, L, 2010
)
0.91
" In addition, the oral bioavailability of the wet-milled tablets (test) and Lipanthyl supra-bioavailability tablets (reference) was determined in beagle dogs after a single dose (160 mg fenofibrate) in a randomized crossover, own-control study."( Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
Chai, G; He, H; Tang, X; Xu, H; Zeng, X; Zhang, L, 2010
)
0.9
"These results indicated that the dissolution and the bioavailability of fenofibrate were significantly enhanced by wet-grinding process."( Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
Chai, G; He, H; Tang, X; Xu, H; Zeng, X; Zhang, L, 2010
)
0.95
" Optimised FFB SMEDDS formulations were then selected for in-vivo bioavailability study."( Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
Chen, CH; Chen, ET; Ho, HO; Ke, WT; Sheu, MT; Wei, JD, 2010
)
0.68
" The relative bioavailability of the test (generic) product Lipivim with respect to the reference product was determined in a single dose, randomized, crossover study."( Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.
Leucuta, SE; Muntean, D; Popa, A; Vlase, L, 2010
)
0.61
" The in vitro drug dissolution and in vivo oral bioavailability of this formulation, using fenofibrate as the model drug, were compared with other reference formulations such as a suspension, micronized formulation or self microemulsion drug delivery system (SMEDDS)."( A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
Jia, Z; Lin, P; Wang, J; Wang, X; Xiang, Y; Zhang, Q; Zhang, X, 2011
)
0.8
" They can also block the action of enzymes or receptors used for endogenous metabolism or affect the efficacy and/or bioavailability of a coadministered drug."( Xenobiotic metabolomics: major impact on the metabolome.
Gonzalez, FJ; Idle, JR; Johnson, CH; Patterson, AD, 2012
)
0.38
"The objective of the present study was to formulate a microemulsion system for oral administration to improve the solubility and bioavailability of fenofibrate."( Design of fenofibrate microemulsion for improved bioavailability.
Hu, L; Jia, Y; Niu, F; Wu, H; Yan, C; Yang, X, 2011
)
0.97
"SMEDDS, consisting of Myritol 318 and TPGS combined with Tween 80 at 4:1, was able to enhance the oral bioavailability of FFB."( In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.
Chen, YC; Ho, HO; Ke, WT; Lin, YM; Sheu, MT; Su, YD; Wu, JY, 2011
)
0.58
" By decreasing particle sizes nanosuspensions enhance dissolution rate and bioavailability of the active pharmaceutical ingredient."( Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics.
Geissler, S; Hill, A; Mäder, K; Weigandt, M, 2012
)
0.38
"The objective of this study is to investigate the wet-milled-drug layering process which could significantly improve the dissolution rate and oral bioavailability of fenofibrate pellets."( Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering.
Cai, C; He, H; Luo, Q; Miao, Y; Tang, X; Wang, P; Ying, L, 2012
)
0.83
"These results show that the wet-milled-drug layering technique is a powerful method to improve the dissolution rate and the bioavailability of fenofibrate."( Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering.
Cai, C; He, H; Luo, Q; Miao, Y; Tang, X; Wang, P; Ying, L, 2012
)
0.83
" Fenofibric acid is one of the newly approved forms of fenofibrate with enhanced bioavailability and was recently approved by the Food and Drug Administation (FDA) for the treatment of various types of hyperlipidemia, in conjunction with statins."( Fenofibric acid for hyperlipidemia.
Kaushik, M; Mohiuddin, SM; Saurav, A, 2012
)
0.63
"Considering the poor water solubility and the low oral bioavailability in humans, the complex formation of fenofibrate (FNB) with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in aqueous solution was studied."( Investigation of a fenofibrate-hydroxypropyl-beta-cyclodextrin system prepared by a co-grinding method.
Gu, FG; Han, HB; Meng, GD; Wang, Y; Wu, CZ, 2012
)
0.92
" The bioavailability of compound 70 and its isomer varies between 27 and 29% whereas that of the more polar compound 90a is poor as determined in rat by oral and intraperitoneal administrations."( Flavone-based novel antidiabetic and antidyslipidemic agents.
Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK, 2012
)
0.38
"Lipid-based drug carriers are likely to have influence on bioavailability through enhanced solubilization of the drug in the gastrointestinal tract."( Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
Mohsin, K, 2012
)
0.6
"Nanocrystals exhibit enhanced dissolution rates and can effectively increase the bioavailability of poorly water soluble drug substances."( Development of a new method to assess nanocrystal dissolution based on light scattering.
Anhalt, K; Fricker, G; Geissler, S; Harms, M; Weigandt, M, 2012
)
0.38
" We confirmed that amorphous solid dispersions with large surface areas produced by the TFF process displayed superior dissolution rates and corresponding enhanced bioavailability of the poorly water-soluble drug, FB."( Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing.
Dong, Y; Lang, B; Li, H; O'Donnell, K; Wang, Z; Williams, RO; Wu, C; Zhang, H; Zhang, M, 2012
)
0.64
" The results highlighted the potential of this SC-CO(2) drug loading approach to improve the oral bioavailability of poorly water soluble drugs."( The influence of supercritical carbon dioxide (SC-CO2) processing conditions on drug loading and physicochemical properties.
Ahern, RJ; Crean, AM; Ryan, KB, 2012
)
0.38
"A solid form of self-microemulsifying drug delivery system (Solid SMEDDS) was developed by spray-drying with dextran as the inert solid carrier, to improve the oral bioavailability of a poorly water-soluble drug, fenofibrate."( Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.
Choi, HG; Hiep, TT; Kim, GG; Kim, JO; Lee, DW; Marasini, N; Poudel, BK; Yang, KY; Yong, CS, 2013
)
0.85
" It seems that fenofibrate enhances angiogenesis in hind limb ischemia possibly through increasing of NO bioavailability and can be considered for treatment of diabetic peripheral vascular diseases in future human studies."( Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats.
Khazaei, M; Rashidi, B; Salehi, E, 2012
)
1.17
"The aim of this study was to enhance the bioavailability of fenofibrate, a poorly water-soluble drug, using a melt-adsorption method with supercritical CO(2)."( Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide.
Cha, KH; Cho, KJ; Cho, W; Hwang, SJ; Kim, JS; Kim, MS; Park, HJ; Park, J; Park, JS, 2012
)
0.86
" In vitro dissolution and in vivo bioavailability were also investigated."( Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide.
Cha, KH; Cho, KJ; Cho, W; Hwang, SJ; Kim, JS; Kim, MS; Park, HJ; Park, J; Park, JS, 2012
)
0.62
"The results of this study highlight the usefulness of the melt-adsorption method using supercritical CO(2) for improving the bioavailability of fenofibrate."( Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide.
Cha, KH; Cho, KJ; Cho, W; Hwang, SJ; Kim, JS; Kim, MS; Park, HJ; Park, J; Park, JS, 2012
)
0.82
"375, low solubility (practically insoluble in water) and low oral bioavailability (36%)."( Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Baria, RK; Gattani, SG; Ige, PP, 2013
)
0.74
" Oral bioavailability was also on the order of: heated formulation>intact formulation>crystalline FEN."( Preparation of fenofibrate solid dispersion using electrospray deposition and improvement in oral absorption by instantaneous post-heating of the formulation.
Chauhan, RS; Ishizuka, N; Kataoka, M; Kawakami, K; Masaoka, Y; Sakuma, S; Yamamoto, M; Yamashita, S; Zhang, S, 2013
)
0.74
"5 showed 284% and 145% bioavailability relative to Lipanthyl® and solid dispersion pellets (FB:PEG = 1:3), respectively."( Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating.
Dong, F; Hu, F; Li, S; Lu, Y; Qi, J; Wu, W; Xie, Y, 2013
)
0.39
" Moreover, the oral bioavailability of the drug from mesoporous carbon was higher than that of FFB commercial capsules."( Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability.
Hou, Z; Jiang, T; Niu, X; Sun, C; Sun, J; Wan, L; Wang, S; Wang, T; Zhao, P, 2013
)
0.65
" However, due to its low solubility in water, it has low bioavailability after oral administration."( In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
Cho, YD; Park, YJ, 2014
)
0.62
" Furthermore, in vivo pharmacokinetic study of the optimized formulation showed significant increase in relative oral bioavailability compared to that of the powder suspension."( Application of Box-Behnken design in the preparation and optimization of fenofibrate-loaded self-microemulsifying drug delivery system (SMEDDS).
Cho, HJ; Choi, HG; Kim, JH; Kim, JO; Lee, DW; Marasini, N; Moon, BK; Poudel, BK; Yong, CS, 2014
)
0.63
" The relative bioavailability of the spray-dried formulation was determined to be 89."( Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
He, Z; Li, H; Liu, X; Sun, J; Sun, Y; Zhai, Y; Zuo, B, 2013
)
0.65
" In summary, the present study demonstrated the particle size dependence of bioavailability of fenofibrate loaded LMP in rat model which correlates well with the in vitro drug release performed in the biorelevant medium."( Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Borkar, N; Gan, Y; Holm, R; Mu, H; Müllertz, A; Xia, D; Yang, M, 2014
)
0.85
"In order to investigate the influence of drug physicochemical properties on bioavailability of water insoluble drug nanosuspensions, five drug nanosuspensions were prepared using high pressure homogenization."( Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
Cheng, J; Cun, D; Fang, L; Li, W; Liu, J; Quan, P; Xiang, R; Zhang, Y, 2014
)
0.4
" Oral bioavailability was evaluated in landrace pigs."( Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
Dressman, JB; Faisal, W; Fei, Y; Griffin, BT; Kostewicz, ES; Kuentz, M; O'Driscoll, CM; Reppas, C; Stillhart, C; Vertzoni, M, 2014
)
0.6
" The oral bioavailability of two types of FNT-NCs prepared by antisolvent precipitation in rats increased notably compared to that of the crude powder (5."( Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches.
Dai, W; Meng, Y; Wang, X; Zhang, H; Zhang, Q, 2014
)
0.63
" However, the impact of spray drying on manufacturability, physiochemical stability and bioavailability in relation to conventional drug load processes are yet to be fully investigated."( High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
Chia, LS; Gokhale, R; Hong, S; Irwan, AW; Liu, X; Marsh, K; Ng, WK; Nowak, SA; Shen, S; Tan, DC; Tan, R, 2016
)
0.68
" In addition, the study was designed to investigate the effect of dissolution volume when predicting the oral bioavailability of the formulations."( Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
Abrahamsson, B; Berthelsen, R; Holm, R; Jacobsen, J; Kristensen, J; Müllertz, A; Sjögren, E, 2014
)
0.61
"The aim of this study is to investigate the potential of nanostructured lipid carriers (NLCs) in improving the oral bioavailability of a lipid lowering agent, fenofibrate (FEN)."( Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement.
Choi, HG; Kim, JO; Ramasamy, T; Tran, TH; Truong, DH; Yong, CS, 2014
)
0.87
"Nanopharmaceuticals (NPs) have emerged as an attractive formulation strategy for bioavailability enhancement of poorly soluble drugs."( Continuous and sustainable granulation of nanopharmaceuticals by spray coagulation encapsulation in alginate.
Hadinoto, K; Yang, Y, 2014
)
0.4
" The oral bioavailability of the various formulations was compared in beagle dogs using commercial Lipanthyl® capsules (micronized formulation) as a reference."( The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.
Hu, K; Lu, Y; Qi, J; Tian, Z; Wang, K; Weng, T; Wu, W; Yin, Z, 2014
)
0.63
" Further, oral absorption of FN was significantly enhanced using PLNs with relative bioavailability of 123."( Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation.
Chen, G; Ma, Z; Wu, B; Zhang, T; Zhang, X, 2014
)
0.4
" In the present paper we have looked systematically into the differences between Kolliphor ELP, EL, and RH40 and how they affect the bioavailability of fenofibrate, through pharmacokinetic studies in rats and in vitro lipolysis studies."( Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
Abrahamsson, B; Berthelsen, R; Holm, R; Jacobsen, J; Kristensen, J; Müllertz, A, 2015
)
0.85
" A pharmacokinetic study showed that, although the maximum plasma concentration of the osmotic pump was lower than that of the reference formulation, the relative bioavailability was increased, indicating that the osmotic pump was more efficient than the reference tablets."( Development of an oral push-pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles.
Hao, Y; Liu, Y; Wu, C; Zhao, W; Zhao, Y; Zhao, Z, 2015
)
0.67
"The intention of this research was to prepare and compare various solubility-enhancing nanoparticulated systems in order to select a nanoparticulated formulation with the most improved oral bioavailability of poorly water-soluble fenofibrate."( Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
Choi, HG; Kim, DW; Kim, JO; Oh, YK; Yong, CS; Yousaf, AM, 2015
)
0.88
" All of the formulations significantly improved the aqueous solubility, dissolution rate, and oral bioavailability of fenofibrate compared to the drug powder."( Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
Choi, HG; Kim, DW; Kim, JO; Oh, YK; Yong, CS; Yousaf, AM, 2015
)
0.91
"The aim of this study was to develop a formulation containing fenofibrate and Gelucire(®) 50/13 (Gattefossé, France) in order to improve the oral bioavailability of the drug."( Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation.
Brouwers, A; Evrard, B; Krier, F; Lebrun, P; Pestieau, A; Streel, B, 2015
)
0.89
" The aim of this current paper is to assess the suitability of this HLB-RSM approach to enhance the oral bioavailability of BCS class II compounds using fenofibrate as drug model."( Self-emulsifying drug delivery system developed by the HLB-RSM approach: Characterization by transmission electron microscopy and pharmacokinetic study.
Bahloul, B; Dhotel, H; Lai-Kuen, R; Lassoued, MA; Mignet, N; Seguin, J; Sfar, S, 2015
)
0.62
" Most of these formulations show a higher bioavailability when taken with a high-fat meal."( The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.
Cahay, B; Coffiner, M; De Niet, S; Lebrun, S; Rennie, TW; Streel, B; Tremege, M; Verbeeck, RK, 2015
)
0.69
" The intestinal absorption rate for each drug was acquired by deconvolution, using historical intravenous data as reference, and used with the intestinal surface area and the dose remaining in the lumen to estimate the Peff."( Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E, 2015
)
0.42
"The objective of this study was to develop a novel fenofibric acid-loaded controlled release pellet showing enhanced, or equivalent to, bioavailability compared with two commercially available products containing fenofibrate or choline fenofibrate."( Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
Choi, HG; Jin, SG; Kim, DW; Kim, JO; Kim, KS; Kim, YH; Mustapha, O; Woo, JS; Yong, CS; Yousaf, AM, 2015
)
0.83
" The purpose of this approach is to develop self-microemulsifying drug delivery system (SMEDDS) for oral bioavailability enhancement of fenofibrate."( The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
Dongqin, Q; Man, GE; Minzi, LU; Xiumin, LI; Yinghua, J, 2015
)
0.89
"Novel core-shell dual-mesoporous silica nanoparticles (DMSN) were successfully prepared as a carrier in order to improve the dissolution of fenofibrate and obtain an oral highly bioavailable controlled-release drug delivery system using the osmotic pump technology."( Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
Gao, Y; Hao, Y; Wu, C; Xu, J; Zhao, Y; Zhao, Z, 2016
)
0.84
"This research aimed to develop the omega-3 phospholipids based solid dispersion to improve the oral bioavailability of fenofibrate."( Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability.
Han, HK; Shao, Y; Yang, L, 2015
)
0.87
" There is a clear need for developing bio-enabling formulation approaches to improve oral bioavailability for PWSD, but also to establish a range of predictive in vitro and in silico biopharmaceutics based tools for guiding formulation design and forecasting in vivo effects."( Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
Devine, KJ; Faisal, W; Griffin, BT; Kostewicz, ES; O'Driscoll, CM; O'Shea, JP; Ruane-O'Hora, T, 2015
)
0.65
"Low oral bioavailability can be circumvented by the formulation of the poorly water soluble drug in ordered mesoporous silica (OMS-L-7)."( Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide.
Badens, E; Bouledjouidja, A; Masmoudi, Y; Schueller, L; Van Speybroeck, M, 2016
)
0.78
"The purpose of the present research was to develop a novel electrosprayed nanospherule providing the most optimized aqueous solubility and oral bioavailability for poorly water-soluble fenofibrate."( Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JO; Kim, KS; Mustapha, O; Oh, YK; Yong, CS; Youn, YS; Yousaf, AM, 2016
)
0.84
" Oral bioavailability in rats was also evaluated for the formulation of an optimized nanospherule in comparison with free drug and a conventional fenofibrate-loaded solid dispersion."( Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JO; Kim, KS; Mustapha, O; Oh, YK; Yong, CS; Youn, YS; Yousaf, AM, 2016
)
0.84
"41 μg/mL), an excellent dissolution (~85% in 10 minutes), and an oral bioavailability ~2."( Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JO; Kim, KS; Mustapha, O; Oh, YK; Yong, CS; Youn, YS; Yousaf, AM, 2016
)
0.64
"Mesoporous silica Santa Barbara amorphous-15 (SBA-15), derived from supermolecular assemblies of surfactant Pluronic(®) P123 with well-ordered 2-D hexagonal pores, was investigated as a reservoir to construct a novel solid self-emulsifying matrix for enhancing the oral bioavailability of fenofibrate (FNB)."( Enhancing in vitro dissolution and in vivo bioavailability of fenofibrate by solid self-emulsifying matrix combined with SBA-15 mesoporous silica.
Chen, B; Li, G; Pan, X; Quan, G; Wu, C; Wu, Q; Zhan, Z; Zhang, X; Zhang, Z; Zhou, C, 2016
)
0.85
" An in vivo pharmacokinetic study confirmed that 3DOMG improved the oral bioavailability compared with that of commercial sustained-release capsules."( Preparation of a Novel Form of Gelatin With a Three-Dimensional Ordered Macroporous Structure to Regulate the Release of Poorly Water-Soluble Drugs.
Hao, Y; Ji, P; Jiang, J; Liu, Y; Qiu, Y; Wu, C; Xu, J; Yu, T; Zhao, Y; Zhao, Z, 2016
)
0.43
" Furthermore, the effect of magnesium carbonate, an alkalising agent on the solubility, dissolution and oral bioavailability of fenofibric acid was assessed, a mixture of fenofibric acid and magnesium carbonate being prepared by simple blending at a weight ratio of 2/1."( Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.
Cho, KH; Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JH; Kim, JO; Kim, KS; Li, DX; Woo, JS; Yong, CS, 2016
)
0.43
"This study aimed to prepare the aminoclay-lipid hybrid composite to enhance the drug release and improve the oral bioavailability of poorly water-soluble fenofibrate."( Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
Han, HK; Shao, Y; Yang, L, 2016
)
0.87
"Fenofibrate, a BCS class II compound, has a low bioavailability especially when taken orally on an empty stomach."( Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
Brouwers, A; Evrard, B; Krier, F; Pestieau, A; Streel, B, 2016
)
2.1
"The objective of this study is to explore the influence of polyvinylpyrrolidone (PVP) quantity on the solubility, crystallinity and oral bioavailability of poorly water-soluble fenofibrate in solvent-evaporated microspheres."( Influence of polyvinylpyrrolidone quantity on the solubility, crystallinity and oral bioavailability of fenofibrate in solvent-evaporated microspheres.
Cho, KH; Choi, HG; Kim, DS; Kim, DW; Kim, JO; Yong, CS; Youn, YS; Yousaf, AM, 2016
)
0.84
" The objective of this study was to investigate the factor that can influence the design of successful lipid formulation classification system (LFCS) Type III SNEDDS formulation and improve the oral bioavailability (BA) of fenofibrate."( Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
Ahmad, A; Alamri, R; Alanazi, FK; Hussain, MD; Mohsin, K; Raish, M, 2016
)
0.83
" However, it is not clear if the observed enhanced in vitro dissolution can forecast drug bioavailability in vivo."( In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
Ahern, RJ; Crean, AM; Faisal, W; Griffin, BT; McCarthy, CA; Murphy, C; O'Shea, JP; Ryan, KB, 2017
)
0.46
" In vivo pharmacodynamic study (hyperlipidaemia model) showed SNSS based formulation significantly improved the bioavailability of drug."( Supercritical processed starch nanosponge as a carrier for enhancement of dissolution and pharmacological efficacy of fenofibrate.
Jadhav, NV; Vavia, PR, 2017
)
0.66
" Monoacyl phosphatidylcholine (Lipoid S LPC 80 (LPC)) was incorporated into four different fenofibrate (FF)-loaded long-chain SEDDS to investigate the impact of LPC on the emulsion droplet size, extent of digestion, colloidal structure evolution and drug precipitation during in vitro lipolysis simulating human conditions and drug bioavailability in a rat model."( In vitro and in vivo performance of monoacyl phospholipid-based self-emulsifying drug delivery systems.
Amenitsch, H; Müllertz, A; Rades, T; Siqueira, SDVS; Tran, T, 2017
)
0.68
" After oral administration (20 mg/kg) of JW322, relative bioavailability was approximately 272."( Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate.
Kim, TK, 2017
)
0.66
"Mesoporous silicas (SLC) have demonstrated considerable potential to improve bioavailability of poorly soluble drugs by facilitating rapid dissolution and generating supersaturation."( Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
Dressman, JB; Griffin, BT; Herbert, E; Lubda, D; Nagarsekar, K; O'Driscoll, CM; O'Shea, JP; Saal, C; Wieber, A; Witt, V, 2017
)
0.67
" A positive correlation was identified between bioavailability and dissolution efficiency."( Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
Dressman, JB; Griffin, BT; Herbert, E; Lubda, D; Nagarsekar, K; O'Driscoll, CM; O'Shea, JP; Saal, C; Wieber, A; Witt, V, 2017
)
0.67
"The substantial improvements in bioavailability of fenofibrate from the SLC-based formulations confirm the ability of this formulation strategy to overcome the dissolution and solubility limitations, further raising the prospects of a future commercially available SLC-based formulation."( Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
Dressman, JB; Griffin, BT; Herbert, E; Lubda, D; Nagarsekar, K; O'Driscoll, CM; O'Shea, JP; Saal, C; Wieber, A; Witt, V, 2017
)
0.92
"Development of techniques to enhance bioavailability of drugs having poor water solubility is a big challenge for pharmaceutical industry."( Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation.
Kumar, R; Siril, PF, 2018
)
0.77
"The objective of this study was to enhance physiochemical properties as well as oral bioavailability of the poorly water soluble drug fenofibrate (FB), through preparation of amorphous solid dispersions (ASDs)."( Optimization and evaluation of lyophilized fenofibrate nanoparticles with enhanced oral bioavailability and efficacy.
Ibrahim, AH; Ibrahim, HM; Ismael, HR; Samy, AM, 2018
)
0.95
" Increased calories in the duodenum increased the absorption rate constant of the drug in fed conditions (standard meal = 16."( A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption.
Back, HM; Chae, JW; Chang, MJ; Han, N; Kang, W; Karlsson, MO; Kwon, KI; Pradhan, S; Song, B; Yun, HY; Zheng, J, 2018
)
0.74
"The preparation of an amorphous solid dispersion (ASD) by dissolving a poorly water-soluble active pharmaceutical ingredient (API) in a polymer matrix can improve the bioavailability by orders of magnitude."( Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.
Anantharaman, S; Milsmann, J; Theil, F; van Lishaut, H, 2018
)
0.48
"Lipid based-formulations can enhance the bioavailability of poorly water-soluble lipophilic drugs through enhanced solubilisation of drugs in the gastrointestinal (GI) tract during digestion."( Solubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS.
Boyd, BJ; Hawley, A; Jannin, V; Pouton, C; Vithani, K, 2018
)
0.48
" Over the years, mesoporous materials have been widely used to increase the dissolution rate and oral relative bioavailability of poorly water-soluble drugs."( Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate.
Bai, A; Cao, Y; Hu, L; Liu, X; Liu, Y; Lv, H; Shang, W; Wu, C; Xu, X, 2018
)
0.68
"In order to improve the dissolution rate and increase oral relative bioavailability of the poorly water-soluble drugs, a tin oxide carrier (MSn) with a mesoporous structure was successfully synthesized."( Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate.
Bai, A; Cao, Y; Hu, L; Liu, X; Liu, Y; Lv, H; Shang, W; Wu, C; Xu, X, 2018
)
0.68
" Pharmacokinetic results indicated that MSn significantly increased the oral relative bioavailability of FNB."( Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate.
Bai, A; Cao, Y; Hu, L; Liu, X; Liu, Y; Lv, H; Shang, W; Wu, C; Xu, X, 2018
)
0.68
" At last, in vitro dissolution test and in vivo bioavailability study were also carried out."( Fenofibrate Solid Dispersion Processed by Hot-Melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism.
Niu, B; Pan, X; Quan, G; Wen, T; Wu, C; Wu, Q; Zhou, Y, 2019
)
1.96
" Moreover, pharmacokinetic study in beagle dogs showed that comparing with commercial micronized product Lipanthyl®, the oral bioavailability of FNB solid dispersion was significantly enhanced (2."( Fenofibrate Solid Dispersion Processed by Hot-Melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism.
Niu, B; Pan, X; Quan, G; Wen, T; Wu, C; Wu, Q; Zhou, Y, 2019
)
1.96
"In conclusion, PVP VA64 can be regarded as a promising polymer to enhance the bioavailability of poorly water-soluble drugs such as FNB processed by hot-melt extrusion."( Fenofibrate Solid Dispersion Processed by Hot-Melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism.
Niu, B; Pan, X; Quan, G; Wen, T; Wu, C; Wu, Q; Zhou, Y, 2019
)
1.96
"Supersaturating formulations are widely used to improve the oral bioavailability of poorly soluble drugs."( Calculation of drug-polymer mixing enthalpy as a new screening method of precipitation inhibitors for supersaturating pharmaceutical formulations.
Dressman, J; Kuentz, M; Nair, A; Price, DJ; Saal, C, 2019
)
0.51
"The purpose of this study was to improve solubility and oral bioavailability of fenofibrate via solid dispersion (SD) using a supercritical anti-solvent (SAS) process with amphipathic polymers P407 and TPGS."( Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process.
Ahn, JB; Kim, DH; Lee, SE; Park, JS; Pyo, YC, 2019
)
0.98
"There have been many strategies to increase solubility, dissolution rates, and oral bioavailability of fenofibrate such as micronization, nanonization, solid dispersion, and emulsion so far."( Immediate-released pelletized solid dispersion containing fenofibrate: Formulation, in vitro characterization, and bioequivalence studies in experimental beagle dogs.
Huyen, CPT; Le Thi, H; Le Thien, G; Ngoc, BT; Nguyen, CN; Pham, CV; Thi, TN, 2019
)
0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Fenofibrate is antihyperlipidemic which has low and variable oral bioavailability due to erratic dissolution characteristics."( Preparation of stabilized submicron fenofibrate crystals on niacin as a hydrophilic hydrotropic carrier.
Alshaikh, RA; El Maghraby, GM; Essa, EA, 2020
)
2.28
"There is an increasing attention on solid lipid nanoparticles (SLNs) due to their high biocompatibility and ability to enhance bioavailability for poorly water-soluble drugs."( Preparation, characterization and in vitro cytotoxicity of Fenofibrate and Nabumetone loaded solid lipid nanoparticles.
Dhasmana, D; Garg, N; Kumar, R; Sharma, K; Singh, A; Siril, PF, 2020
)
0.8
" The oral absorption rate in rats increased with particle size reduction."( The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals.
Imono, M; Kadota, K; Miyazaki, S; Tamura, N; Tozuka, Y; Tsutsumimoto, H; Uchiyama, H; Yoshida, S, 2020
)
0.56
"We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses."( Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).
Fan, G; Liu, J; Ma, C; Ren, C; Shang, Y; Wang, Z; Yang, C; Yang, L; Zhang, J, 2020
)
1.1
" But the bioavailability as well as therapeutic efficacy of this drug is limited to its dissolution behaviour."( Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat.
Barman, RK; Ghosh, MK; Habib, A; Khan, RI; Wahed, MII, 2020
)
0.85
"Recently, mesoporous silica (MS) has been used as a material able to maintain amorphous state of active compounds and therefore, enhance the oral bioavailability of BCSII drugs."( Impregnation of mesoporous silica with poor aqueous soluble molecule using pressurized carbon dioxide: Is the solubility in the supercritical and subcritical phase a critical parameter?
Evrard, B; Grignard, B; Jennotte, O; Koch, N; Lechanteur, A, 2020
)
0.56
"Lipid-based drug delivery systems (LbDDS), such as self-nanoemulsifying drug delivery systems (SNEDDS), constitute a prominent formulation approach for enhancing the aqueous solubility and oral bioavailability of poorly water-soluble compounds."( Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) Containing Rice Bran Oil for Enhanced Fenofibrate Oral Delivery: In Vitro Digestion, Ex Vivo Permeability, and In Vivo Bioavailability Studies.
Andreadis, II; Chatzopoulou, P; Fatouros, DG; Karavasili, C; Katsantonis, D; Markopoulou, C; Taitzoglou, IA; Tsantarliotou, MP; Zacharis, CK, 2020
)
0.78
" The aim of this study was to improve the solubility and bioavailability of fenofibrate by formulating it as fenofibrate-loaded nanostructured lipid carriers (FFB-NLCs) and coating it with a biodegradable polymer to allow controlled drug release."( Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy.
Kim, DH; Park, JS; Pyo, YC; Tran, P, 2020
)
1.04
" For both FFB and SQV, drug absorption patterns obtained with the in vitro digestion-in situ perfusion mode, correlated well with in vitro supersaturation data and in vivo drug exposure data from oral bioavailability studies."( Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
Brundel, DHS; Chalmers, DK; Porter, CJH; Pouton, CW; Suys, EJA, 2021
)
0.82
"Top-down wet ball milling (media milling) in zirconia planetary chamber was methodically explored for improving the solubility and bioavailability of fenofibrate by formulating a nanosuspension using polyvinyl alcohol as a stabilizer."( Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective.
Gite, S; Kakade, P; Patravale, V, 2021
)
1.13
" This resulted in a quick onset of action and improved bioavailability as observed from 51."( Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective.
Gite, S; Kakade, P; Patravale, V, 2021
)
0.93
" Drug products using micro- and nanoparticle technology can lower these emissions into the environment by their increased bioavailability to the human patients."( Microparticle formulations alter the toxicity of fenofibrate to the zebrafish Danio rerio embryo.
Böhmer, W; Eilebrecht, E; Fenske, M; Günday-Türeli, N; Heng, PWS; Hering, I; Modh, H; Parnham, MJ; Schäfers, C; Türeli, AE; Wacker, MG; Weiler, M, 2021
)
0.88
"Amorphous solid dispersions (ASDs) of a poorly water-soluble active pharmaceutical ingredient (API) in a polymer matrix can enhance the water solubility and therefore generally improve the bioavailability of the API."( Crystallization Risk Assessment of Amorphous Solid Dispersions by Physical Shelf-Life Modeling: A Practical Approach.
Gessner, D; Lehmkemper, K; Li, Y; Liu, B; Theil, F; van Lishaut, H, 2021
)
0.62
" The use of the CAOM in the SMEDDS resulted in an unprecedented enhancement in fenofibrate bioavailability, which exceeded the bioavailability values obtained using SMEDDSs based on corn oil, a conventional triglyceride oil, or Labrasol, an enhancer of intestinal permeation."( Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations.
Abbasi, S; Harashima, H; Higashino, H; Kataoka, M; Minami, K; Sato, Y; Yamashita, S, 2021
)
0.85
"This study aimed to evaluate the effect of solid self-nanoemulsifying drug delivery system (S-SNEDDS) formation on the bioavailability of fenofibric acid."( Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects.
Mudhakir, D; Pamudji, JS; Suhery, WN; Sumirtapura, YC, 2022
)
0.72
" Bioavailability study was conducted in 12 Indonesian healthy male subjects after a single-dose administration of each formulation with three-way crossover design."( Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects.
Mudhakir, D; Pamudji, JS; Suhery, WN; Sumirtapura, YC, 2022
)
0.72
"S-SNEDDS increased the dissolution rate in acid medium and absorption rate of fenofibric acid but did not increase the extent of fenofibric acid absorption."( Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects.
Mudhakir, D; Pamudji, JS; Suhery, WN; Sumirtapura, YC, 2022
)
0.72
"As numerous new drug candidates are poorly water soluble, enabling formulations are needed to increase their bioavailability for oral administration."( Insight into the mechanism behind oral bioavailability-enhancement by nanosuspensions through combined dissolution/permeation studies.
Bauer-Brandl, A; Brandl, M; Eriksen, JB; Holsæter, AM; Lynnerup, JT, 2023
)
0.91
"Amorphous solid dispersions (ASD) represent a viable formulation strategy to improve dissolution and bioavailability of poorly soluble drugs."( Hydrogenated phospholipid, a promising excipient in amorphous solid dispersions of fenofibrate for oral delivery: Preparation and in-vitro biopharmaceutical characterization.
Bauer-Brandl, A; Brandl, M; Czajkowski, M; Jacobsen, AC; Skupin-Mrugalska, P, 2023
)
1.14

Dosage Studied

The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. To evaluate untargeted metabolic profiling as a tool for gaining insight into the underlying pharmacology and hepatotoxicology, Fischer 344 male rats were dosed with 300 mg/kg/day of fenfibrate for 14 days.

ExcerptRelevanceReference
" At the recommended dosage of 200 to 400 mg daily, it produces substantial reductions in plasma triglyceride levels in hypertriglyceridaemic patients and in plasma total cholesterol levels in hypercholesterolaemic patients."( Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Balfour, JA; Heel, RC; McTavish, D, 1990
)
1.72
"Lean Zucker rats were dosed orally for 1 week with fenofibrate (100 mg/kg/day)."( Short term treatment by fenofibrate enhances oxidative activities towards long-chain fatty acids in the liver of lean Zucker rats.
Bezard, J; Boichot, J; Clouet, P; Henninger, C; Niot, I, 1990
)
0.84
" Afterwards, they were treated with fenofibrate (Katalip) in a dosage of 100 mg, 2 capsules in the morning and 1 in the evening."( [The effect of fenofibrate in various types of hyperlipoproteinemias].
Sucić, M, 1989
)
0.9
"2-fold) but not clofibrate or bezafibrate when dosed PO at 50 mg/kg for 2 weeks in cholesterol-fed rats."( Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Krause, BR; Newton, RS, 1986
)
0.27
" At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate."( Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.
Balestreri, R; Bertolini, S; Carozzi, A; Cotta Ramusino, AM; Daga, A; Degl'Innocenti, ML; Elicio, N; Fusi, MG, 1988
)
0.74
" At the end of this period, P was continued at the same dosage but F (300 mg daily) was added and both drugs were given simultaneously for a further eight-day period (period P + F)."( Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Desager, JP; Harvengt, C; Heller, FR, 1988
)
0.47
"Obese Zucker rats were dosed orally for one week with fenofibrate (100 mg/kg)."( Effects of fenofibrate treatment on fatty acid oxidation in liver mitochondria of obese Zucker rats.
Bezard, J; Cao Danh, H; Clouet, P; Henninger, C; Pascal, M, 1987
)
0.91
" The study, followed-up as an open trial using higher doses (100 or 200 mg/day ciprofibrate, 400 mg/day fenofibrate) tried to demonstrate clearly the benefit of therapy after 9 months with the 2 drugs and to establish the dose-response effects."( Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985
)
0.73
" Compared with the control animals, activity of cyanide-insensitive fatty acyl-CoA (FA-CoA) oxidizing system was significantly increased by fenofibrate at the high dosage, carnitine acetyltransferase activity was markedly increased by both drugs at the high dosage and catalase activity remained unmodified."( Effect of fenofibrate and LF 2151 on hepatic peroxisomes in hamsters.
Harvengt, C; Heller, F; Pourbaix, S, 1984
)
0.87
" The drug was further evaluated in a study comprising 56 patients, which combined a dose-response trial with a subsequent comparison between the optimal fenofibrate dose and a clofibrate dose of 2 g/day."( Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
Orö, L; Rössner, S,
)
1.77
" Under the same experimental conditions clofibrate presents a poor dose-response correlation on plasma lipids and generally appears at least 10 times less active than LR 19731 on cholesterol but more effective on liver weight."( Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731).
Fregnan, GB; Frigerio, L; Porta, R, 1981
)
0.26
" Micronized fenofibrate, a new formulation chemically identical to the parent compound, has improved pharmacokinetic parameters which increase absorption, provide more stable plasma levels, and thus dosage can be decreased."( The fibrates in clinical practice: focus on micronised fenofibrate.
Shepherd, J, 1994
)
0.91
" Chow-fed rats were orally gavaged daily with a dosing vehicle alone or with 100 mg/kg of each of the fibrates for 1 week and in addition with gemfibrozil for 2 weeks."( Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME, 1995
)
0.29
" Micronised fenofibrate has improved absorption characteristics compared with the standard preparation, allowing a lower daily dosage and once-daily administration."( Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins, JC; Faulds, D, 1997
)
1.07
" The dose-response curve was bell-shaped for serum lipids changes, whereas no clear dose-response relationship for blood glucose level modifications could be established."( Effects of acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in hyperlipidemic albino rats.
Cuparencu, B; Horák, A; Horák, J,
)
0.13
" The need for dosage titration of the micronized preparation from 67 mg/d upward to a final dose of 200 mg/d is also not supported by peer-reviewed literature (except in the case of renal impairment)."( Micronized fenofibrate: a new fibric acid hypolipidemic agent.
Guay, DR, 1999
)
0.69
" Single oral dosing with the other formulation occurred after a washout period of at least 8 days."( Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers.
Houin, G; Sonet, B; Streel, B; Vanderbist, F, 2002
)
0.56
" It is concluded that the increase in creatininemia induced by fenofibrate in renal patients does not reflect an impairment of renal function, nor an alteration of tubular creatinine secretion, and is not falsely increased by a dosage interference."( Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
Achard, JM; El Esper, N; Fournier, A; Hottelart, C; Rose, F, 2002
)
2
" Patients receiving concomitant statin therapy before crossover continued the statin at the same dosage after crossover."( Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002
)
0.6
" During the course of anticoagulation, both patients were prescribed fenofibrate and experienced threefold and twofold increases in international normalized ratio (INR), respectively, requiring total weekly warfarin dosage reductions of 30-40%."( Fenofibrate potentiates warfarin effects.
Kim, KY; Mancano, MA, 2003
)
2
"We suggest serial monitoring of INR and consider an empiric 20% reduction in warfarin dosage when fenofibrate is initiated, with the possibility for a greater warfarin dosage reduction based on INR results."( Fenofibrate potentiates warfarin effects.
Kim, KY; Mancano, MA, 2003
)
1.98
" Healthy male volunteers received one of the following treatment regimens in each period: rosuvastatin 10 mg orally once daily; fenofibrate 67 mg orally TID; and rosuvastatin + fenofibrate dosed as above."( An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Dane, AL; Martin, PD; Schneck, DW; Warwick, MJ, 2003
)
0.74
" The two PPAR-alpha activators, fenofibrate and Wy-14643, were dosed at different concentrations in high-fat fed Sprague-Dawley rats, and the transcriptional responses were examined in liver using cDNA microarrays."( Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.
Fleckner, J; Frederiksen, KS; Sauerberg, P; Wassermann, K; Wulf, EM, 2003
)
0.6
" This became more prominent as the dosing period progressed and reached an 8-fold increase in the 400 mg/kg group and 11-fold increase in the 800 mg/kg group compared with the data before dosing on Day 14."( Urinary excretion of oxidative metabolites of bilirubin in fenofibrate-treated rats.
Iwatsuka, H; Kobayashi, A; Miyakawa, Y; Sugai, S; Takahashi, T; Yamaguchi, T, 2003
)
0.56
" In treatment B, subjects received a 160-mg micronized fenofibrate capsule in the morning for 7 days, followed by a 160-mg micronized fenofibrate capsule dosed together with an 80-mg simvastatin tablet on days 8 to 14."( Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman, AJ; Burke, J; Hartford, A; He, W; Lasseter, KC; Liu, L; Murphy, G; Paolini, JF; Prueksaritanont, T; Qiu, Y; Valesky, R; Vega, JM; Zhao, JJ, 2004
)
0.8
" However, based on the established safety profile and flat dose-response of ezetimibe, this effect is not considered to be clinically significant."( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004
)
0.57
"In healthy adult volunteers, IDD-P fenofibrate had an equivalent extent of absorption under fed or fasting conditions, suggesting that dosage regimens could include administration of the product without food."( A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Fordyce, D; Guivarc'h, PH; Vachon, MG, 2004
)
1.08
" Treatment with the daily dosage of fenofibrate given as a bolus did not produce a conditioned flavor aversion."( Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
Friedman, MI; Ji, H; Outterbridge, LV, 2005
)
0.84
" Blood samples were collected for 24 hours after dosing on days 5, 6, and 15."( The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.
Achari, R; Chira, TO; Esslinger, HU; Gustavson, LE; Koehne-Voss, S; Schweitzer, SM; Yannicelli, HD, 2005
)
0.61
" Rats were dosed orally for 16 days with bladder carcinogenic (ragaglitazar) as well as non-bladder carcinogenic (fenofibrate and rosiglitazone) PPAR agonists and protein changes were assayed in the urinary bladder urothelium by Western blotting."( Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.
Egerod, FL; Iversen, L; Nielsen, HS; Oleksiewicz, MB; Storgaard, T; Thorup, I,
)
0.34
" Statistically significant increases in mean fluorescence intensity were observed from animals dosed at 30, 150, and 400 mg/kg/day compared to control."( Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys.
Cariello, NF; Colton, HM; Creech, DR; Falls, JG; Kwanyuen, P; Witherspoon, SM,
)
0.13
" Blood samples were collected for up to 24 hours after dosing on study day 1 and up to 120 hours after dosing on study day 10 for determination of plasma concentrations of fenofibric acid, unconjugated (free) ezetimibe, and total (conjugated and unconjugated) ezetimibe using validated high-performance liquid chromatography methods with mass-spectrometric detection."( Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD, 2006
)
0.57
" The dosage of 1-methyl-4-phenyl pyridinium (MPP+) in the striatum by high-performance liquid chromatography indicated that fenofibrate did not affect MPTP metabolism."( Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF, 2007
)
0.78
" Repeat-dose nonclinical safety studies of LY465608 revealed abnormities in mitochondrial morphology and evidence of single-cell necrosis following 30 days of dosing exclusively in dogs, but not in rats."( Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.
Baker, TK; Calley, JN; Gao, H; Guo, Y; Halstead, BW; Huffman, M; Irizarry, AR; Jolly, RA; Li, S; Qian, HR; Ryan, TP; Searfoss, GH; Stevens, JL; Stutz, JP; West, A, 2007
)
0.34
" In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes."( Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007
)
0.86
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
"Two simple and accurate methods to determine atorvastatin calcium (ATO) and fenofibrate (FEN) in combined dosage forms were developed using second-derivative spectrophotometry and reversed-phase liquid chromatography (LC)."( Estimation of atorvastatin calcium and fenofibrate in tablets by derivative spectrophotometry and liquid chromatography.
Bhatt, HS; Bhatt, KK; Nakarani, NV; Patel, RD,
)
0.63
" Fifty-six patients were randomized to receive optimal dosage of atorvastatin (n = 27) or 200 mg/d micronized fenofibrate (n = 29) for 24 weeks."( Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G, 2007
)
0.83
", 402 mg/dL), the fenofibrate dosage was increased to 145 mg daily."( Elevated serum creatinine levels associated with fenofibrate therapy.
Anderson, J; Griego, J; McQuade, CR; Pai, AB, 2008
)
0.93
" An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%."( Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008
)
0.35
"To compare changes in lipid levels (total cholesterol [total-C], low-density lipoprotein cholesterol [LDL-C], triglycerides [TG], and high-density lipoprotein cholesterol [HDL-C]) for patients who switched from standard fenofibrate 160 mg (requiring dosing with food) to fenofibrate 145 mg with no food effect (NFE)."( Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
Davidson, MH; Jones, PH, 2008
)
0.78
"More patients treated in an outpatient clinical practice had better lipid results when prescribed fenofibrate 145 mg NFE than those prescribed standard fenofibrate 160 mg, suggesting that a less restrictive dosing regimen improves lipid outcomes."( Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
Davidson, MH; Jones, PH, 2008
)
0.81
"The usefulness of a dissolution/permeation (D/P) system to predict the in vivo performance of solid dosage forms containing the poorly soluble drug, fenofibrate, was studied."( IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
Buch, P; Kataoka, M; Langguth, P; Yamashita, S, 2009
)
0.84
" Blood samples were collected prior to dosing on multiple days and up to 120 hours after day 10 dosing for the measurements of fenofibric acid and rosuvastatin plasma concentrations."( ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Awni, WM; Chira, TO; Hosmane, B; Kelly, MT; Pradhan, RS; Sleep, DJ; Stolzenbach, JC; Wan, K; Zhu, T, 2009
)
0.35
" Animals were fed a fat-enriched (54% kcal fat) diet for 6 weeks, 2 weeks high of fat-exposure alone followed by a 4-week dosing period."( Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D, 2009
)
0.35
" To evaluate untargeted metabolic profiling as a tool for gaining insight into the underlying pharmacology and hepatotoxicology, Fischer 344 male rats were dosed with 300 mg/kg/day of fenofibrate for 14 days and the urine and plasma were analyzed on days 2 and 14."( Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats.
Beebe, KD; Guo, L; Masutomi, N; Milburn, MV; Mitchell, M; Ohta, T; Ryals, JA; Sakairi, T; Tsutsui, N, 2009
)
0.79
" Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric acid 135 mg/day or the corresponding statin dosage in the three phase III trials in patients with mixed dyslipidemia."( Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Keating, GM; Yang, LP, 2009
)
0.35
" In contrast, Egr-1 was induced in the nuclei of bladder, as well as kidney pelvis, urothelia within one day (2 doses) of oral dosing of rats with a combination of 8 mg/kg rosiglitazone and 200 mg/kg fenofibrate (specific PPAR gamma and PPAR alpha agonists, respectively)."( PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.
Bartels, A; Brünner, N; Egerod, FL; Hinley, J; Oleksiewicz, MB; Southgate, J; Svendsen, JE, 2009
)
0.54
" Visual analog scale (VAS), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and prednisolone (PSL) dosage were also recorded immediately before and after the study."( A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.
Goto, M, 2010
)
0.59
" The dose-response for one or more key event(s) linked to the MOA for carcinogenicity allows a point of departure (POD) to be selected from the most sensitive effect dose or no-effect dose."( Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
Baker, TK; Bercu, JP; Flagella, KM; Jolly, RA; Romero, P; Stevens, JL, 2010
)
0.36
"The healthy male Wistar rats fed high fat diet were treated with fenofibrate (80 mg/kg per day) alone, allicin (60 mg/kg per day) alone and a lower dosage of combined therapy (allicin 20 mg/kg per day and fenofibrate 30 mg/kg per day) respectively for 8 weeks."( The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats.
Li, W; Qiao, X; Qin, S; Song, G; Wang, D; Zuo, C, 2010
)
0.85
" In addition, the lower dosage of combined therapy significantly ameliorated severe fatty degeneration of liver cells occurred in the high fat diet fed rat although the single fenofibrate treatment showed spotty necrosis of liver cells and bile duct expansion."( The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats.
Li, W; Qiao, X; Qin, S; Song, G; Wang, D; Zuo, C, 2010
)
0.81
" After establishing a dose-response curve for each drug, the drugs were orally administered for 3 weeks either alone or in combination."( Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY, 2011
)
0.6
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Study 2 followed a similar dosing scheme and differed only in that volunteers received their single dose after being fed a standard meal (575 calories, of which 36% were contributed by fat)."( Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Davis, MW; Digiacinto, J; Godfrey, AR, 2011
)
0.6
" After being fed a high-fat diet (HFD) for two weeks, rats were dosed orally with kaempferol (75, 150, or 300 mg/kg) or fenofibrate (100 mg/kg) once daily for eight weeks."( Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Chang, CJ; Chang, YS; Liou, SS; Liu, IM; Tzeng, TF, 2011
)
0.58
" Fifty patients in each group were given placebo, omega-3 fatty acids 2 g (most commonly used dosage in Korean patients), or fenofibrate 160 mg, respectively daily for 2 months."( Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC, 2012
)
0.83
" Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally."( Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012
)
0.94
"In this study, the potential of wet granulation of ordered mesoporous silica (OMS) material was evaluated to assess the risk of premature drug release during processing and to improve the bulk powder flow properties and compactibility for the development of an immediate release oral dosage form."( Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen.
Backhuijs, F; Martens, JA; Van den Mooter, G; Vialpando, M, 2012
)
0.58
" Of particular interest is the finding that by adding polymers with differing release characteristics to the drug-carrier mixture, the dissolution performance of hot-melt extruded solid dosage forms can be readily adapted to meet specific requirements."( Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion.
Fischbach, M; Kalivoda, A; Kleinebudde, P, 2012
)
0.61
" A comprehensive, 12-concentration dose-response analysis using a cell-based assay showed aleglitazar to be highly potent, with EC(50) values of 5 nM and 9 nM for PPARα and PPARγ, respectively."( Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB, 2012
)
0.38
"Here we evaluate poly(2-ethyl-2-oxazoline)s (PEtOx) as a matrix excipient for the production of oral solid dosage forms by hot melt extrusion (HME) followed by injection molding (IM)."( Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding.
Claeys, B; De Geest, BG; Hoogenboom, R; Remon, JP; Vervaeck, A; Vervaet, C, 2012
)
0.38
"To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS."( Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V, 2012
)
0.84
" statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.39
" The statement outlines a bexarotene dosing schedule and monitoring protocol."( U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013
)
0.39
"The objective of this study was to prepare amorphous fenofibrate (FB) solid dispersions using thin film freezing (TFF) and to incorporate the solid dispersions into pharmaceutically acceptable dosage forms."( Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing.
Dong, Y; Lang, B; Li, H; O'Donnell, K; Wang, Z; Williams, RO; Wu, C; Zhang, H; Zhang, M, 2012
)
0.89
" Thus, these results suggest that solid SMEDDS could be used as an effective oral solid dosage form to improve dissolution and oral bioavailability of fenofibrate."( Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.
Choi, HG; Hiep, TT; Kim, GG; Kim, JO; Lee, DW; Marasini, N; Poudel, BK; Yang, KY; Yong, CS, 2013
)
0.86
" In order to better understand their potential advantages over solid oral dosage forms, we studied the solubility and dissolution/precipitation characteristics of three self-microemulsifying drug delivery system (SMEDDS) formulations and one suspension of micronized fenofibrate in lipid excipients, for which pharmacokinetic studies had already been reported in the open literature."( Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Dressman, JB; Fei, Y; Kostewicz, ES; Sheu, MT, 2013
)
0.82
" The additive inhibitory effect on cell proliferation by budesonide and fenofibrate combination suggests that the same or greater therapeutic effect could be achieved with reduced dosage and side effects when the two compounds are applied simultaneously."( Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors.
Junco, JJ; Klug-De Santiago, HL; Kowalczyk, P; Liang, H; Malik, G; Slaga, TJ; Wei, SJ, 2014
)
0.63
" The pharmacokinetic characteristics were studied in rats after oral administration of fenofibrate nanosuspension or suspension at the dosage of 27 mg/kg."( Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.
Chen, B; Chen, W; Huang, Q; Li, XM; Liu, R; Wang, Y; Wei, P; Xu, Y, 2014
)
0.93
" In this study, beagle dogs were orally dosed with fenofibrate mixed with feeds."( Metabolism of fenofibrate in beagle dogs: new metabolites identified and metabolic pathways revealed.
Chen, L; Dai, R; Liu, A; Luo, W; Yang, J, 2013
)
1
"Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors."( A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014
)
0.4
" At a daily dosage of 400 mg/kg, fenofibrate treatment causes reduction of liver NAD(+)/NADH ratio, induces hyper-acetylation of peroxisomal bifunctional enzyme (ECHD) and acyl-CoA oxidase 1 (ACOX1), and induces excessive accumulation of long chain fatty acids (LCFA) and very long chain fatty acids (VLCFA)."( Uridine prevents fenofibrate-induced fatty liver.
Le, TT; Pizzorno, G; Urasaki, Y, 2014
)
1.02
" The geometric mean AUC0-24h ratio of simvastatin acid for the two combined dosing regimens (B/C) and 90% confidence interval were 111% (102-121)."( Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?
Ansquer, JC; Aubonnet, P; Beckmann, K; Driessen, S; Lehnick, D; Mihara, K; Olbrich, M; Piskol, G; van Amsterdam, P; van Assche, H; Winsemius, A, 2014
)
0.65
" Replicate dosing was conducted for the reference formulation to determine its intrasubject variability."( Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.
Chachad, SS; Gole, M; Malhotra, G; Naidu, R, 2014
)
0.67
" Their oral solid dosage form preparation requires them to undergo granulation before they can be processed into tablets."( Continuous and sustainable granulation of nanopharmaceuticals by spray coagulation encapsulation in alginate.
Hadinoto, K; Yang, Y, 2014
)
0.4
"Floating dosage forms with prolonged gastric residence time have garnered much interest in the field of oral delivery."( Modulating drug release from gastric-floating microcapsules through spray-coating layers.
Lee, WL; Loo, SC; Tan, CN; Tan, JW, 2014
)
0.4
"The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies."( The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.
Cahay, B; Coffiner, M; De Niet, S; Lebrun, S; Rennie, TW; Streel, B; Tremege, M; Verbeeck, RK, 2015
)
0.94
"Although higher dosing or other proliferator-activated receptor-alpha agonists may show efficacy, this study indicates that fenofibrate does not aid ability to stop smoking during a brief practice quit period in dependent smokers high in current quit interest."( Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.
Chengappa, KN; Conklin, CA; Fromuth, M; Hope, C; Karelitz, JL; Lerman, C; Michael, VC; Perkins, KA, 2016
)
0.96
"Mesoporous silica-based dosage forms offer the potential for improving the absorption of poorly soluble drugs after oral administration."( Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
Birk, G; Dressman, JB; Herbert, E; Lubda, D; Saal, C; Wieber, A, 2016
)
0.65
" Interestingly, the present Ns could be converted to solid dosage form using fluid-bed coating technology, maintaining a nanoscale size."( Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
Fan, L; He, W; Jin, Z; Lv, Y; Qin, C; Wang, Y; Yang, K; Yin, L; Zhu, S, 2015
)
0.42
" Every-4-weeks dosing of alirocumab may be appropriate for some patients in absence of background statin but is not yet approved."( Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK, 2016
)
0.43
" Two capsule dosage forms (containing 33."( In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs.
Bugarski, B; Bukara, K; Daems, T; Eelen, S; Kiekens, F; Martens, JA; Rosier, J; Schueller, L; Van den Mooter, G; Verheyden, L, 2016
)
0.74
" Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone."( Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF, 2016
)
0.61
" This first use of a precisely controlled solvent free inkjet printing to produce drug loaded solid dosage forms is demonstrated using a naturally derived FDA approved material (beeswax) as the drug carrier and fenofibrate as the drug."( 3D inkjet printing of tablets exploiting bespoke complex geometries for controlled and tuneable drug release.
Adedeji, A; Alexander, MR; Ashcroft, I; Gellert, PR; Kyobula, M; Roberts, CJ; Saleh, E; Wildman, R, 2017
)
0.64
"Solid self-emulsifying drug delivery system (SSEDDS), which incorporates liquid SEDDS into a solid dosage form, has been recently introduced to improve the oral bioavail-ability of poorly water-soluble drugs."( Supersaturable solid self-microemulsifying drug delivery system: precipitation inhibition and bioavailability enhancement.
Niu, B; Pan, X; Quan, G; Singh, V; Wu, C; Wu, CY; Zhou, Y, 2017
)
0.46
" Commonly, the impact of crystalline API on the drug release of the dosage form is studied with samples containing spiked crystallinity."( Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.
Anantharaman, S; Milsmann, J; Theil, F; van Lishaut, H, 2018
)
0.48
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)."( New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason, R, 2019
)
0.51
" However, existing techniques require additional processing into a final dosage form, which strongly influences drug delivery and clinical performance."( Photopolymerized Micelle-Laden Hydrogels Can Simultaneously Form and Encapsulate Nanocrystals to Improve Drug Substance Solubility and Expedite Drug Product Design.
Doyle, PS; Godfrin, PD; Lee, H; Lee, JH, 2019
)
0.51
"Oral administration of a solid dosage form requires drug dissolution in the gastrointestinal tract before absorption."( Topography of Simulated Intestinal Equilibrium Solubility.
Dunn, C; Halbert, GW; Khadra, I; Perrier, J; Wilson, CG, 2019
)
0.51
"The use of three-dimensional printing (3DP) in the development of pharmaceutical dosage forms is growing rapidly."( A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics.
Basit, AW; Boyd, BJ; Gaisford, S; Goyanes, A; Jannin, V; Vithani, K, 2019
)
0.51
" The digestion process was affected by the initial geometry of the dosage form by virtue of the kinetics of dispersion of the dosage forms into the digestion medium."( A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics.
Basit, AW; Boyd, BJ; Gaisford, S; Goyanes, A; Jannin, V; Vithani, K, 2019
)
0.51
"This proof of concept study has demonstrated the potential of 3DP for the development of customised S-SMEDDS formulations without the need for an additional carrier or additive and with optimisation could elaborate a new class of dosage forms based on 3D printed lipids."( A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics.
Basit, AW; Boyd, BJ; Gaisford, S; Goyanes, A; Jannin, V; Vithani, K, 2019
)
0.51
" Mice were dosed fenofibrate 25 mg/kg twice every day for 10 days to investigate the therapeutic action of fenofibrate on chronic cholestatic liver injury."( Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling.
Dai, M; Liu, A; Luo, Y; Xu, G; Xu, L; Yang, J; Zhang, H, 2020
)
1.13
" SNEDDSs for which pharmacokinetic data after oral dosing to rats was available in the literature were prepared, and the ability of the SNEDDSs to maintain fenofibrate solubilized during in vitro lipolysis was determined, followed by the assessment of drug permeation across the mucus-PVPA barriers."( Predicting Oral Absorption of fenofibrate in Lipid-Based Drug Delivery Systems by Combining In Vitro Lipolysis with the Mucus-PVPA Permeability Model.
Berthelsen, R; Falavigna, M; Flaten, GE; Klitgaard, M; Müllertz, A, 2021
)
1.11
" In this study, wild-type (WT) and Pparα-null (KO) mice were dosed alpha-naphthylisothiocyanate (ANIT) diet to induce chronic cholestasis."( Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate.
Dai, M; Li, S; Liu, A; Lu, Z; Luo, J; Luo, Y; Qiu, J; Yang, J; Zheng, X, 2021
)
2.06
" According to literature study reports several analytical techniques have been used for determination of FEN alone or in the combined dosage forms."( An Investigative Review for Pharmaceutical Analysis of Fenofibrate.
Asati, V; Dhiman, S; Gupta, GD; Saha, M, 2023
)
1.16
" Meanwhile, in vivo dosing of fenofibrate ameliorated the downregulated amplitudes of ERG c-wave in HFD-fed mice and suppressed the HFD-induced oxidative injury and inflammatory response in RPE tissues."( Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling.
Feng, Y; Li, S; Li, W; Liu, X; Tzekov, R; Wang, X; Wu, Y; Xu, Y; Yang, J; Yu, C, 2023
)
2.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
Sir2 inhibitorAn EC 3.5.1.98 (histone deacetylase) inhibitor that interferes with the action of Sir2.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
benzochromenoneA benzochromene in which the heterotricyclic ring system is substituted by an oxo group.
delta-lactoneA lactone having a six-membered lactone ring.
naphtho-alpha-pyroneAny naphthopyran whose skeleton consists of a naphathalene ring system ortho-fused to an alpha-pyrone.
chlorobenzophenoneA member of the class of benzophenones that is any substituted benzophenone in which at least one of the substituents is a chlorine.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
isopropyl esterAny carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (138)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
regulator of G-protein signaling 4Homo sapiens (human)Potency6.70160.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency29.88160.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency41.60604.466818.391635.4813AID1467; AID2107
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.07940.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.94330.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency39.81070.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency56.23410.354828.065989.1251AID504847
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID883
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency20.95090.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency14.12545.623417.292931.6228AID2323
LuciferasePhotinus pyralis (common eastern firefly)Potency31.07710.007215.758889.3584AID1224835; AID588342
endonuclease IVEscherichia coliPotency15.84890.707912.432431.6228AID1708
phosphopantetheinyl transferaseBacillus subtilisPotency11.22020.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency45.35350.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency47.39350.031637.5844354.8130AID504865; AID743255
TDP1 proteinHomo sapiens (human)Potency23.41710.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency21.63100.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency4.46680.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency42.39190.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.21910.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.80650.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency19.18030.000417.946075.1148AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency8.31360.001310.157742.8575AID1259252; AID1259253
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency74.80630.003041.611522,387.1992AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.18640.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.48410.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency48.96620.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency36.97210.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.80380.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency2.45450.01238.964839.8107AID1645842
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency44.66840.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency39.71260.001024.504861.6448AID588534; AID743212; AID743215; AID743227
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.49380.023723.228263.5986AID743222
arylsulfatase AHomo sapiens (human)Potency0.15101.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency24.13200.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency57.71100.000723.06741,258.9301AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.58960.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency48.21810.001628.015177.1139AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
serine-protein kinase ATM isoform aHomo sapiens (human)Potency44.66840.707925.111941.2351AID485349
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.26630.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency5.01190.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency53.88200.006026.168889.1251AID488953; AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency11.51890.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency52.64300.042027.378961.6448AID743210; AID743228
mitogen-activated protein kinase 1Homo sapiens (human)Potency32.46480.039816.784239.8107AID1454; AID995
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency6.30960.65619.452025.1189AID927
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency13.09180.00378.618923.2809AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency52.24410.000627.21521,122.0200AID651741; AID720636; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency23.35070.00798.23321,122.0200AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency21.95110.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency8.28520.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency36.94840.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency23.35070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.06310.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency15.84890.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency2.45450.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.45450.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.01190.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency6.30961.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.45450.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.45450.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency47.75480.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)75.00000.00040.619610.0000AID331898; AID331899
Histone deacetylase 3Homo sapiens (human)Ki75.00000.00020.42378.1900AID331899
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CIC50 (µMol)67.00008.80008.80008.8000AID204971; AID729882
Histone deacetylase 4Homo sapiens (human)IC50 (µMol)75.00000.00061.052610.0000AID331898
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)75.00000.00010.55439.9000AID331898
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)112.90000.50003.848110.0000AID460416
Histone deacetylase 7Homo sapiens (human)IC50 (µMol)75.00000.00071.02609.9000AID331898
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)75.00000.00010.72219.9700AID331898
Polyamine deacetylase HDAC10Homo sapiens (human)IC50 (µMol)75.00000.00050.72459.9000AID331898
Histone deacetylase 11 Homo sapiens (human)IC50 (µMol)75.00000.00030.92989.9000AID331898
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)IC50 (µMol)298.10000.00601.62509.0000AID455742; AID460415
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)75.00000.00070.99479.9000AID331898
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)IC50 (µMol)100.00000.10003.38006.6000AID1194531
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)75.00000.00000.53769.9000AID331898; AID331900
Histone deacetylase 6Homo sapiens (human)Ki75.00000.00010.41568.1900AID331900
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)75.00000.00050.94139.9000AID331898
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)75.00000.00070.961010.0000AID331898
Histone deacetylase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)10.00000.00060.16880.9400AID414980
Nuclear receptor corepressor 2Homo sapiens (human)IC50 (µMol)75.00000.00170.59528.0000AID331899
Nuclear receptor corepressor 2Homo sapiens (human)Ki75.00000.00030.33253.2000AID331899
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)2.37100.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki1.24200.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)23.86670.11007.190310.0000AID1443980; AID1443986; AID1473738
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki0.11180.01501.24876.9200AID1800412; AID407366; AID407369
Fatty acid-binding protein, liverHomo sapiens (human)Ki0.04330.01501.47708.1700AID1800412
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)21.40800.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki21.23100.00322.28879.3160AID625207
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)5.70100.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki3.22200.00000.930610.0000AID625196
Fatty acid-binding protein, intestinalHomo sapiens (human)Ki6.10000.30005.48149.4000AID1801103
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)123.94500.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki92.95900.00302.30986.0450AID625206
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.70100.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki3.22200.00010.949010.0000AID625196
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)15.55100.00000.933210.0000AID625193
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)21.40800.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki21.23100.00031.465610.0000AID625207
CruzipainTrypanosoma cruziIC50 (µMol)280.50000.00022.04508.0000AID484274; AID484275
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)2.11800.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.60500.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)2.37100.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki1.24200.00010.954910.0000AID625218
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)137.53300.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki46.70900.00000.602010.0000AID625254
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)IC50 (µMol)5.00000.00501.205110.0000AID421047
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.70100.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki3.22200.00000.965010.0000AID625196
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)8.63300.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki6.85900.00021.11158.0280AID625256
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)IC50 (µMol)1.00000.00050.82696.3100AID421048
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)5.10000.00401.966610.0000AID1873192
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)EC50 (µMol)30.00000.00200.47533.2000AID240312
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Kd0.13780.01801.78799.6000AID427199; AID427200; AID427203; AID427205; AID427206; AID427207; AID427208; AID427209; AID427210; AID427211; AID427212; AID427213; AID427214; AID427215; AID427216
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)EC50 (µMol)250.00000.00001.262610.0000AID141913
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)250.00000.00000.764610.0000AID141913
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)EC50 (µMol)250.00000.00000.990510.0000AID141913
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)EC50 (µMol)250.00000.00001.052810.0000AID141913
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)EC50 (µMol)250.00000.00001.160510.0000AID141913
Fatty acid-binding protein, intestinalHomo sapiens (human)Kd4.41000.36003.31757.2000AID1801104
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)18.00000.00021.397110.0000AID141903
Peroxisome proliferator-activated receptor alphaRattus norvegicus (Norway rat)EC50 (µMol)29.50000.16600.86772.2600AID156451; AID311946
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)157.76170.00000.992210.0000AID1546883; AID156934; AID240313; AID317698; AID421049; AID91246
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)250.00000.00031.654210.0000AID141913
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)29.43500.00061.607410.0000AID1377502; AID1546882; AID155981; AID156133; AID156138; AID1588892; AID240312; AID391552; AID421050; AID439370; AID736344; AID91237
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Kd0.16000.16000.16000.1600AID427214
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CInhibition0.66000.15000.67600.9400AID204972
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CMGC0.49000.49000.67000.8500AID204974
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (644)

Processvia Protein(s)Taxonomy
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
chromatin remodelingHistone deacetylase 4Homo sapiens (human)
protein deacetylationHistone deacetylase 4Homo sapiens (human)
inflammatory responseHistone deacetylase 4Homo sapiens (human)
nervous system developmentHistone deacetylase 4Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 4Homo sapiens (human)
response to denervation involved in regulation of muscle adaptationHistone deacetylase 4Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone deacetylase 4Homo sapiens (human)
protein sumoylationHistone deacetylase 4Homo sapiens (human)
B cell differentiationHistone deacetylase 4Homo sapiens (human)
positive regulation of protein sumoylationHistone deacetylase 4Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 4Homo sapiens (human)
B cell activationHistone deacetylase 4Homo sapiens (human)
regulation of protein bindingHistone deacetylase 4Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 4Homo sapiens (human)
negative regulation of glycolytic processHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
type I interferon-mediated signaling pathwayHistone deacetylase 4Homo sapiens (human)
response to interleukin-1Histone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 7Homo sapiens (human)
vasculogenesisHistone deacetylase 7Homo sapiens (human)
chromatin remodelingHistone deacetylase 7Homo sapiens (human)
protein deacetylationHistone deacetylase 7Homo sapiens (human)
cell-cell junction assemblyHistone deacetylase 7Homo sapiens (human)
protein sumoylationHistone deacetylase 7Homo sapiens (human)
negative regulation of interleukin-2 productionHistone deacetylase 7Homo sapiens (human)
negative regulation of osteoblast differentiationHistone deacetylase 7Homo sapiens (human)
regulation of mRNA processingHistone deacetylase 7Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 7Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionHistone deacetylase 7Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolyamine deacetylase HDAC10Homo sapiens (human)
DNA repairPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationPolyamine deacetylase HDAC10Homo sapiens (human)
regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
macroautophagyPolyamine deacetylase HDAC10Homo sapiens (human)
positive regulation of mismatch repairPolyamine deacetylase HDAC10Homo sapiens (human)
homologous recombinationPolyamine deacetylase HDAC10Homo sapiens (human)
negative regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
polyamine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
spermidine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
epigenetic regulation of gene expressionPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationHistone deacetylase 11 Homo sapiens (human)
oligodendrocyte developmentHistone deacetylase 11 Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 11 Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor corepressor 2Homo sapiens (human)
lactationNuclear receptor corepressor 2Homo sapiens (human)
response to organonitrogen compoundNuclear receptor corepressor 2Homo sapiens (human)
regulation of cellular ketone metabolic processNuclear receptor corepressor 2Homo sapiens (human)
cerebellum developmentNuclear receptor corepressor 2Homo sapiens (human)
response to estradiolNuclear receptor corepressor 2Homo sapiens (human)
estrous cycleNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of miRNA transcriptionNuclear receptor corepressor 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
positive regulation of fatty acid beta-oxidationFatty acid-binding protein, liverHomo sapiens (human)
response to vitamin B3Fatty acid-binding protein, liverHomo sapiens (human)
negative regulation of apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
intestinal absorptionFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hydrogen peroxideFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hypoxiaFatty acid-binding protein, liverHomo sapiens (human)
cellular oxidant detoxificationFatty acid-binding protein, liverHomo sapiens (human)
fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
fatty acid metabolic processFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
intestinal lipid absorptionFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (209)

Processvia Protein(s)Taxonomy
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 4Homo sapiens (human)
histone bindingHistone deacetylase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase activityHistone deacetylase 4Homo sapiens (human)
protein bindingHistone deacetylase 4Homo sapiens (human)
zinc ion bindingHistone deacetylase 4Homo sapiens (human)
SUMO transferase activityHistone deacetylase 4Homo sapiens (human)
potassium ion bindingHistone deacetylase 4Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 4Homo sapiens (human)
identical protein bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 4Homo sapiens (human)
molecular adaptor activityHistone deacetylase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingHistone deacetylase 7Homo sapiens (human)
transcription corepressor activityHistone deacetylase 7Homo sapiens (human)
histone deacetylase activityHistone deacetylase 7Homo sapiens (human)
protein kinase C bindingHistone deacetylase 7Homo sapiens (human)
protein bindingHistone deacetylase 7Homo sapiens (human)
SUMO transferase activityHistone deacetylase 7Homo sapiens (human)
protein kinase bindingHistone deacetylase 7Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 7Homo sapiens (human)
metal ion bindingHistone deacetylase 7Homo sapiens (human)
14-3-3 protein bindingHistone deacetylase 7Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 7Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
protein bindingPolyamine deacetylase HDAC10Homo sapiens (human)
zinc ion bindingPolyamine deacetylase HDAC10Homo sapiens (human)
deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
enzyme bindingPolyamine deacetylase HDAC10Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase bindingPolyamine deacetylase HDAC10Homo sapiens (human)
acetylputrescine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
acetylspermidine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityHistone deacetylase 11 Homo sapiens (human)
protein bindingHistone deacetylase 11 Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 11 Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA bindingNuclear receptor corepressor 2Homo sapiens (human)
chromatin bindingNuclear receptor corepressor 2Homo sapiens (human)
transcription corepressor activityNuclear receptor corepressor 2Homo sapiens (human)
Notch bindingNuclear receptor corepressor 2Homo sapiens (human)
protein bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
histone deacetylase bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
chromatin bindingFatty acid-binding protein, liverHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, liverHomo sapiens (human)
protein bindingFatty acid-binding protein, liverHomo sapiens (human)
phospholipid bindingFatty acid-binding protein, liverHomo sapiens (human)
antioxidant activityFatty acid-binding protein, liverHomo sapiens (human)
bile acid bindingFatty acid-binding protein, liverHomo sapiens (human)
oleic acid bindingFatty acid-binding protein, liverHomo sapiens (human)
heterocyclic compound bindingFatty acid-binding protein, liverHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, liverHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
protein bindingFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (119)

Processvia Protein(s)Taxonomy
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 4Homo sapiens (human)
cytoplasmHistone deacetylase 4Homo sapiens (human)
cytosolHistone deacetylase 4Homo sapiens (human)
nuclear speckHistone deacetylase 4Homo sapiens (human)
histone deacetylase complexHistone deacetylase 4Homo sapiens (human)
chromatinHistone deacetylase 4Homo sapiens (human)
transcription repressor complexHistone deacetylase 4Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusHistone deacetylase 7Homo sapiens (human)
nucleoplasmHistone deacetylase 7Homo sapiens (human)
cytoplasmHistone deacetylase 7Homo sapiens (human)
cytosolHistone deacetylase 7Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleusPolyamine deacetylase HDAC10Homo sapiens (human)
nucleoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytosolPolyamine deacetylase HDAC10Homo sapiens (human)
intracellular membrane-bounded organellePolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase complexPolyamine deacetylase HDAC10Homo sapiens (human)
nucleusHistone deacetylase 11 Homo sapiens (human)
plasma membraneHistone deacetylase 11 Homo sapiens (human)
histone deacetylase complexHistone deacetylase 11 Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
nucleusNuclear receptor corepressor 2Homo sapiens (human)
nucleoplasmNuclear receptor corepressor 2Homo sapiens (human)
membraneNuclear receptor corepressor 2Homo sapiens (human)
nuclear matrixNuclear receptor corepressor 2Homo sapiens (human)
nuclear bodyNuclear receptor corepressor 2Homo sapiens (human)
chromatinNuclear receptor corepressor 2Homo sapiens (human)
transcription repressor complexNuclear receptor corepressor 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleoplasmFatty acid-binding protein, liverHomo sapiens (human)
peroxisomal matrixFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
apical cortexFatty acid-binding protein, liverHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, liverHomo sapiens (human)
protein-containing complexFatty acid-binding protein, liverHomo sapiens (human)
nucleusFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
microvillusFatty acid-binding protein, intestinalHomo sapiens (human)
apical cortexFatty acid-binding protein, intestinalHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
nucleusFatty acid-binding protein, intestinalHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (610)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1194532Inhibition of SIRT5 (unknown origin) at 30 uM using (DABCYL)ISGASE(SuK)DIVHSE(EDANS)G peptide substrate incubated for 1 hrs followed by 1 hr incubation with trypsin and nicotinamide by FRET-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID204974Tested for Sirtuin 2 inhibitory activity and was reported as minimum growth-stimulating concentration in Saccharomyces cerevisiae2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID460420Reduction of PABPN1 expression in transgenic Caenorhabditis elegans coexpressing nuclear GFP and PABPN1-A13 by Q-RT-PCR2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID460415Inhibition of human recombinant SIRT1 by Flour de Lys assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1371031Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 24 hrs by measuring incorporation of [3H]-hypoxanthine by liquid scintillation counting method2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID331899Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC3/NcoR2 by fluorescence polarization assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID204972In vitro inhibition of sirtuin 2 was evaluated using yeast whole cell lysates at 75 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID602647Induction of granulocytic differentiation in human U937 cells assessed as change in CD11c expression at 50 uM incubated for 30 mins by FACS assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile.
AID460418Protection against mutant PABPN1-induced toxicity in transgenic Caenorhabditis elegans coexpressing nuclear GFP and PABPN1-A13 assessed as inhibition of deffective worm motility2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID455741Inhibition of yeast Hst2 by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID460417Protection against mutant PABPN1-induced toxicity in transgenic Caenorhabditis elegans coexpressing nuclear GFP and PABPN1-A13 assessed as inhibition of nuclear collapse2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID455742Inhibition of human full length SIRT1 expressed in DE3 cells by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID235797Selectivity index was reported as the ratio of the MGC to IC50 value2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID331900Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from human HDAC6 by fluorescence polarization assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID460416Inhibition of human recombinant SIRT2 by Flour de Lys assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1371029Inhibition of Plasmodium falciparum Sir2A2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID460426Effect on nuclear integrity in transgenic Caenorhabditis elegans coexpressing nuclear GFP and normal PABPN1-A102010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID414980Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID19538Half-life period was determined2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID1194531Inhibition of human SIRT5 assessed as reduction in desuccinylase activity using KQTAR(SuK)STGGKA substrate2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID1202497Inhibition of SIRT6 (unknown origin) at 300 uM using (DABCYL)ISGASE(MyK)DIVHSE(EDANS)G substrate in presence of NAD followed by 1 hr incubation with trypsin by FRET assay2015European journal of medicinal chemistry, , Volume: 96A FRET-based assay for screening SIRT6 modulators.
AID204971In vitro inhibition of sirtuin 2 was evaluated using yeast whole cell lysates2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID729882Inhibition of yeast Sir 2 protein2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Spiro heterocycles as potential inhibitors of SIRT1: Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines.
AID414981Antimalarial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID331898Displacement of fluorescent 5-(3-(3-(4-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)thioureido)-2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid from HDAC in human HeLa nuclear cell extract by fluorescence p2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1799021pfHDAC-1 Enzyme Assay from Article 10.1021/jm801654y: \\Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.\\2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346060Human sirtuin 1 (3.5.1.- Histone deacetylases (HDACs))2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID776248Antidyslipidemic activity in Charles foster rat assessed as increase in triton WR-1339-reduced post heparin lipolytic activity level in plasma at 100 mg/kg, po after 18 hrs by spectrophotometric analysis relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID701616Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as increase in HDL-cholesterol level at 100 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID91237Agonist activity for Human PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID410244Antihyperglycemic activity in diabetic C57BL/KsJ-db/db mouse model assessed as increase in high-density lipoprotein cholesterol at 50 mg/kg, po for 10 days relative to control2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID1139726Hypolipidemic activity in triton WR-1339 Wistar rat assessed as increase in protection at 250 mg/kg, po for 7 days2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID662724Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in plasma HDL-total cholesterol level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID277154Decrease in plasma TG level in human Apo-A-I transgenic C57BL/6 mouse at 50 mg/kg2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID662729Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in liver phospholipid level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID231070Percent change in high density lipoprotein cholesterol in hypercholesterolemic rats1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID115859Compound was evaluated in human apoA-I transgenic mice for maximal percent increase in HDL-cholesterol2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1762001Upregulation of PPAR-alpha expression in mouse model of HFD-induced hyperlipidemia at 13 mg/kg, IG by Western blot analysis2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID490633Toxicity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as increase of locomotor activity at 250 mg/kg, po for 7 days measured for 5 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID1905840Reduction of lipid accumulation in oleic acid-induced steatosis in human HepaRG cells at 250 uM treated for 24 hrs by Oil Red O staining based microscopy2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID701592Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as increase in lipoprotein lipase level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID551420Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat assessed as blood VLDL level at 250 mg/kg, po after 7 days (Rvb = 27 +/- 0.3183 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID1529855In vivo anti-inflammatory activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in IL-6 level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1266113Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth at 50 uM after 48 to 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID114822Compound was evaluated in human apoA-I transgenic mice for its ability to alter serum triglyceride level2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
AID701595Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in glycerol level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1742271Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in lipid level in liver at 100 mg/kg, po measured after 24 hrs by Oil Red O staining based assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID432541Antidyslipidemic activity in high fat diet fed dyslipidemic golden Syrian hamster model assessed as change in plasma cholesterol level at 108 mg/kg, po administered once daily from day 4 to day 10 measured on day 10 after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
AID1610325Hepatoprotective activity in Met-induced hyperlipidemia rat model assessed as decrease in serum AST level at 9 mg/kg, po administered with compound for last 30 days during feeding of 0.2% Met solution for 60 days2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID277155Decrease in plasma VLDL level in human Apo-A-I transgenic C57BL/6 mouse at 50 mg/kg2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1742319In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in SREBP1-C expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID701828Antihyperlipidemic activity in Triton-induced dyslipidemic Wistar rat model assessed as reduction in phospholipid level at 100 mg/kg, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1873192Inhibition of ABCG2 (unknown origin) expressed in human HEK293-A cells membrane vesicles assessed inhibition of ABCG2-mediated urate transport activity by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID701612Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in cholesterol level at 25 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID421166Toxicity in Sprague-Dawley rat assessed as increase bilirubin levels at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID318261Hypolipidemic effect on diabetic KKAy mouse model assessed as reduction of VLDL cholesterol level at 300 mg/kg, po QD for 4 days2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID1742329In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARgamma expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1610333Upregulation of PPAR-alpha protein expression in liver of Met-induced hyperlipidemia rat model at 9 mg/kg, po administered with compound for last 30 days during feeding of 0.2% Met solution for 60 days2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID173234Percent change in triglyceride concentration in serum from hypercholesterolemic rats at dose 100 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID1139723Hypolipidemic activity in triton WR-1339 Wistar rat assessed as low-density lipoprotein at 250 mg/kg, po for 7 days (Rvb = 154 +/- 1.82 mg/dl)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID305962Decrease in plasma FFA levels in dyslipidemic hamster model at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID690921Drug metabolism in Sprague-Dawley rat assessed as fenofibric acid level in plasma at 100 mg/kg, po after 4 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of highly water-soluble fibrate derivatives via BGLation.
AID701830Antihyperlipidemic activity in Triton-induced dyslipidemic Wistar rat model assessed as reduction in triglyceride level at 100 mg/kg, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1742326In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARalpha expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID141909Agonist activity for murine PPAR delta receptor in transcriptional activation assay at 100 uM; IA means inactive2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID768601Agonist activity at LXRbeta in mouse RAW264.7 cells assessed as induction of ABCA1 promoter activation at 1 uM after 24 hrs by Dual-Glo luciferase reporter gene assay relative to vehicle-treated control2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation.
AID1743612Antihyperlipidemic activity in Triton WR1339-treated C57BL6 mouse assessed as reduction in total cholestrol level at 100 mg/kg, ig measured after 8 days2020European journal of medicinal chemistry, Nov-15, Volume: 206Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
AID1143913Antidyslipidemic activity in triton-induced hyperlipidemic Charles Foster rat assessed as reduction in triglyceride in plasma at 100 mg/kg, po relative to control2014European journal of medicinal chemistry, Jun-23, Volume: 81Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
AID662733Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in [I125]-LDL catabolism in plasma membrane of liver at 100 mg/kg/day, po administered for 4 weeks2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID597541Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as change in serum HDL-cholesterol at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID1588916Antihyperglycemic activity in fructose-challenged Sprague-Dawley rat assessed as increase in liver ACOX1 mRNA expression at 30 mg/kg, po administered once daily via gavage for 2 weeks measured after 5 hrs fasting by SYBR green dye-based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID410246Antihyperglycemic activity in diabetic C57BL/KsJ-db/db mouse model assessed as decrease in very low-density lipoprotein cholesterol at 50 mg/kg, po for 10 days relative to control2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID1529846Antihyperlipidemic activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in serum triglyceride level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID772437Ratio of LDL level in serum to HDL level in serum in Triton-X-100-induced hyperlipidemia Wistar albino rat model at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427200Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 5 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID484393Colloidal aggregation in fed state simulated intestinal fluid at 450 uM by dynamic light scattering-based beads autocorrelation assay in presence of 1.8% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID701597Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in cholesterol level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID701615Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in body weight at 100 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID91242Agonist activity for Human PPAR delta receptor in transcriptional activation assay at 100 uM; IA means inactive2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID662718Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma VLDL-triglyceride level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID155981In vitro effective concentration for agonist activity on dog Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID592751Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 42) level at 200 uM after 24 hrs by ELISA relative to control2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1313528Increase in HDL cholesterol level in transgenic mouse expressing human ApoA1 at 100 mg/kg administered qd through oral gavage measured after 10 days relative to vehicle control2016ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.
AID1873501Antidiabetic activity in nicotinamide and streptozotocin induced hyperglycemic mouse model assessed as reduction in triglyceride level at 100 mg/kg, IG administered as single dose and measured on day 1 (Rvb = 88 +/- 6 mg/dl)2022Bioorganic & medicinal chemistry letters, 08-15, Volume: 70Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID597544Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as reduction in glycerol level at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID712723Induction of PPARalpha-mediated upregulation of Acadm mRNA expression in liver of high fat diet fed-induced obesity and insulin resistance C57Bl/6J mouse model at 100 mg/kg/day, po administered once daily for 2 weeks by real time qPCR analysis2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID662722Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma LDL-triglyceride level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1529857Hepatoprotective activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in ALT level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1742316In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in ACC phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID194689Activity to induce the elevation of alpha/beta cholesterol ratio in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID280011Reduction of LDL level in fat fed hyperlipidemic Golden Syrian hamster at 100 mg/kg, po after 14 days2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID317699Inhibition of triglyceride level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID1761985Hypolipidemic activity in mouse model of HFD-induced hyperlipidemia assessed as reduction in serum LDL-C level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID427208Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 30 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID503333Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID427206Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 37 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID249590Percentage change in the serum triglyceride upon administration of compound (100 mpk) in dogs2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID305956Increase in plasma HDL-C levels in dyslipidemic hamster model at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID421124Antidiabetic activity in Syrian golden hamster assessed as reduction in cholesterol level at 100 mg/kg, po once daily for 9 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1743613Antihyperlipidemic activity in Triton WR1339-treated C57BL6 mouse assessed as reduction in LDL-C level at 100 mg/kg, ig measured after 8 days2020European journal of medicinal chemistry, Nov-15, Volume: 206Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
AID84315In vivo percent change in serum cholesterol in hamsters at 100 mg/kg2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
AID1139725Hypolipidemic activity in triton WR-1339 Wistar rat assessed as atherogenic index at 250 mg/kg, po for 7 days (Rvb = 10.18 no unit)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1347925Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as increase in ABCG8 mRNA expression in eWAT at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID736344Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID503325Activation of c-Jun expressed in HEK293 cells assessed as induction of protein interaction with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID59462In vivo percent change in serum cholesterol in dogs at 50 mg/kg2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
AID1743611Antihyperlipidemic activity in Triton WR1339-treated C57BL6 mouse assessed as reduction in serum triglyceride level at 100 mg/kg, ig measured after 8 days2020European journal of medicinal chemistry, Nov-15, Volume: 206Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
AID173045Percent change in low density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 100 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID184860Minimum effective dose (MED) is the dose (mg/kg)that cause significant reduction in serum cholesterol of 30% compared to concurrent controls.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
AID701583Reduction in body weight in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model at 30 mg/kg/day, po for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1529854In vivo anti-inflammatory activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in TNF-alpha level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID84139In vivo triglyceride in hamsters at 100 mg/kg2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
AID156133In vitro activation of human peroxisome proliferator activated receptor alpha2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
AID592842Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 42) level at 200 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1347872Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as decrease in CYP7A1 mRNA expression in liver at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID613812Aqueous solubility of the compound in 0.1 M boric acid buffer at pH 9.0 after 4 hrs by HPLC method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID421154Toxicity in Sprague-Dawley rat assessed as increase in brown adipose tissue weight at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1742260Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum total cholesterol level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID776252Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced total cholesterol level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID244649Effect on cholesterol lowering in male Beagle dog at an oral dose of 50 mkd for 10 days2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID421148AUC in Sprague-Dawley rat at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID503308Antiproliferative activity against human PC3 cells at 30 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID170870Percent increase in liver weight in rats when a 50 mg/Kg dose was administered1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID597571Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as increase in lipoprotein lipase activity at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID503335Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1474129Ratio of drug concentration at steady state in human at 43 to 130 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1588912Antihyperglycemic activity in fructose-challenged Sprague-Dawley rat assessed as increase in liver ACADM mRNA expression at 30 mg/kg, po administered once daily via gavage for 2 weeks measured after 5 hrs fasting by SYBR green dye-based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID551418Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat assessed as blood cholesterol level at 250 mg/kg, po after 7 days (Rvb = 121.5 +/- 1.335 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID156451In vitro effective concentration for agonist activity on rat Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID253021Effect (100 mpk) on serum triglyceride in hamster2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID420698Increase of plasma HDL cholesterol level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID1636420Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 194 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID701807Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in cholesterol level at 100 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1761991Antioxidant activity in mouse model of HFD-induced hyperlipidemia assessed as decrease in MDA level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID372090Toxicity in Sprague-Dawley rat assessed as brown adipose tissue weight at 300 mg/kg dosed daily for 2 weeks2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
AID701593Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as increase in HDL-cholesterol level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID484377Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1.8% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1139724Hypolipidemic activity in triton WR-1339 Wistar rat assessed as very low-density lipoprotein at 250 mg/kg, po for 7 days (Rvb = 38 +/- 1.80 mg/dl)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID173218Percent change in total cholesterol concentration in serum from hypercholesterolemic rats at dose 100 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID114820Compound was evaluated in human apoA-I transgenic mice for its ability to alter HDL-cholesterol levels2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
AID662727Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in plasma HDL-apoprotein level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID592843Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 42)/(1 to 40) ratio at 200 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID244643Effect on cholesterol lowering in male Beagle dog at an oral dose of 50 mkd for 7 days2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID251186In vivo efficacy at 100 mpk against Hamster for cholesterol lowering effect after oral dosing; Number of animals= 9 (vehicle 0.5% methylcellulose)2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.
AID701806Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in LDL-cholesterol level at 100 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1742315In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in ACC phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1347924Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as increase in ABCA1 mRNA expression in eWAT at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID551422Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat assessed as blood HDL level at 250 mg/kg, po after 7 days (Rvb = 19 +/- 0.5774 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID1610327Hepatoprotective activity in Met-induced hyperlipidemia rat model assessed as decrease in red lipid droplets in hepatocytes at 9 mg/kg, po administered with compound for last 30 days during feeding of 0.2% Met solution for 60 days by oil red O-staining ba2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID476404Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as Reduction of plasma LDLC level at 100 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
AID613808Aqueous solubility of the compound in 0.2 M hydrochloric acid buffer at pH 1.0 after 4 hrs by HPLC method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1742320In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in SREBP1-C expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID701614Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in triglyceride level at 25 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID484276Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1588910Antihyperglycemic activity in fructose-challenged Sprague-Dawley rat assessed as reduction in serum triglyceride level at 30 mg/kg, po administered once daily via gavage for 2 weeks measured after 5 hrs fasting2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID1761990Antioxidant activity in mouse model of HFD-induced hyperlipidemia assessed as increase in GSH-PX level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID209337Screening was performed to determine its plasma triglyceride lowering activity on administration of 10 mg/kg/day on inbreed colony of Swiss Albino Mice; No significant reduction2002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthetic studies of cis-4-Amino-L-proline derivatives as novel lipid lowering agents.
AID427207Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 30 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID772435Hepatotoxicity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as SGOT level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID1269189Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as LDL level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 22.42 +/- 0.41 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID701611Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in LDL-cholesterol level at 25 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID420697Reduction of plasma triglyceride level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID1529847Antihyperlipidemic activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in total cholesterol level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID410243Antihyperglycemic activity in diabetic C57BL/KsJ-db/db mouse model assessed as decrease in total cholesterol at 50 mg/kg, po for 10 days relative to control2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID1742322In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in FAS expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636364Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 36.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID156778In vitro Fold activation relative to maximum activation obtained with carbacyclin (~ 250-fold corresponded to 100%) for human peroxisome proliferator activated receptor delta2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID503301Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID111201Plasma triglyceride lowering activity in swiss albino mice was determined after 30 mg/kg compound administered for 6 days2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents.
AID1588892Transactivation of human GAL4-fused PPARalpha LBD expressed in human HepG2 cells after 24 hrs by renilla luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID551423Antihyperglycemic activity in high fat diet-induced hyperglycemic Sprague-Dawley rat assessed as blood glucose level at 250 mg/kg, po after 7 days (Rvb = 106.3 +/- 0.6666 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID1742285Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as epididymis white adipose tissue index at 100 mg/kg, po measured after 24 hrs (Rvb = 23.43 +/- 3.10 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID613809Aqueous solubility of the compound in 0.1 M citric acid buffer at pH 3.0 after 4 hrs by HPLC method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID427214Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 15 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID427205Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 37 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID484383Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 10 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID701596Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in LDL-cholesterol level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID503334Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1143914Antidyslipidemic activity in triton-induced hyperlipidemic Charles Foster rat assessed as plasma post heparin lipolytic activity at 100 mg/kg, po relative to control2014European journal of medicinal chemistry, Jun-23, Volume: 81Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
AID490632Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of body circumference at 250 mg/kg, po for 7 days2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID249603Percentage change of triglycerides in obese female Zucker rats after 2 weeks of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID1143912Antidyslipidemic activity in triton-induced hyperlipidemic Charles Foster rat assessed as reduction in phospholipid in plasma at 100 mg/kg, po relative to control2014European journal of medicinal chemistry, Jun-23, Volume: 81Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
AID1742313In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AMPKalpha phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID662712Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in serum total cholesterol level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1742282Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as kidney index at 100 mg/kg, po measured after 24 hrs (Rvb = 11.20 +/- 0.58 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID308337Decrease in triglyceride level in Sprague-Dawley rat at 100 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
AID421048Inhibition of human PPARalpha receptor by scintillation proximity assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID308339Increase in liver weight in Sprague-Dawley rat at 100 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
AID662716Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma VLDL-total cholesterol level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID249593Percentage change in the serum cholesterol upon administration of compound (100 mpk) in hamster2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID701832Antidiabetic activity in sucrose challenged streptozotocin-induced diabetic Sprague-Dawley rat model assessed as reduction in glucose levels at 100 mg/kg, po measured after 5 hrs2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID662728Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in liver total cholesterol level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1610315Hypolipidemic activity in Triton WR1339-induced hyperlipidemia mouse model assessed as decrease in serum TC level at 13 mg/kg, ig administered for one week and administered with Triton WR 1339 on day 6 and measured after 24 hrs2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID427215Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 10 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID427201Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1742318In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in CPT-1A phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1143921Antidyslipidemic activity in triton-induced hyperlipidemic Charles Foster rat assessed as increase in total lipolytic activity of lipoprotein lipase at 100 mg/kg, po relative to control2014European journal of medicinal chemistry, Jun-23, Volume: 81Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
AID476397Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase of plasma HDLC level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
AID317700Inhibition of cholesterol level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID240313Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID261952Decrease in cholesterol level in Golden Syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Design and synthesis of potent and subtype-selective PPARalpha agonists.
AID776249Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced triglyceride level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID1873500Antidiabetic activity in nicotinamide and streptozotocin induced hyperglycemic mouse model assessed as reduction in triglyceride level at 100 mg/kg, IG administered as single dose and measured on day 0 (Rvb = 92 +/- 10 mg/dl)2022Bioorganic & medicinal chemistry letters, 08-15, Volume: 70Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation.
AID1347873Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as decrease in CETP mRNA expression in liver at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID662730Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in liver triglyceride level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID305950Decrease in plasma triglyceride levels in dyslipidemic hamster model at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID427213Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 15 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID157110In vitro fold activation of human PPAR gamma relative to maximum activation with Fenofibric acid2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
AID277156Decrease in LDL cholesterol level in human Apo-A-I transgenic C57BL/6 mouse at 50 mg/kg2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID238856Binding affinity for human peroxisome proliferator activated receptor alpha2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1377504Agonist activity at GAL4-fused PPARalpha LBD (unknown origin) expressed in HEK293 cells assessed as receptor transactivation at 10 uM after 18 hrs by dual luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-29, Volume: 138A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies.
AID249611Percentage change of HDL cholesterol levels in obese female Zucker rats after 2 weeks of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID772436Hepatotoxicity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as SGPT level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID701829Antihyperlipidemic activity in Triton-induced dyslipidemic Wistar rat model assessed as reduction in cholesterol level at 100 mg/kg, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID421138Antidiabetic activity in Beagle dog assessed as reduction in total cholesterol level at 50 mg/kg, po once daily for 14 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID317703Inhibition of glycerol level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID421049Agonist activity at human PPARgamma receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1742284Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as perirenal white adipose tissue index at 100 mg/kg, po measured after 24 hrs (Rvb = 18.14 +/- 1.44 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID372092AUC in Sprague-Dawley rat at 300 mg/kg dosed daily for 2 weeks2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
AID1610316Hypolipidemic activity in Triton WR1339-induced hyperlipidemia mouse model assessed as decrease in serum MDA level at 13 mg/kg, ig administered for one week and administered with Triton WR 1339 on day 6 and measured after 24 hrs2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID427204Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 42 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID772443Antihyperlipidemic activity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as reduction of total cholesterol level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID410242Antihyperglycemic activity in diabetic C57BL/KsJ-db/db mouse model assessed as decrease in plasma triglyceride level at 50 mg/kg, po for 10 days relative to control2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID421151Toxicity in Sprague-Dawley rat assessed as increase in heart weight at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1742323In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in mTOR phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID484378Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 450 uM by dynamic light scattering assay in presence of 1% DMSO2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID1313523Decrease in triglyceride level in transgenic mouse expressing human ApoA1 at 100 mg/kg administered qd through oral gavage measured after 10 days relative to vehicle control2016ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.
AID305959Decrease in plasma glycerol levels in dyslipidemic hamster model at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID1742269Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in fatty liver phenotype at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1529851Antioxidant activity in high fat diet-induced hyperlipidemic mouse model assessed as increase in SOD level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID249595Percentage change in the serum triglyceride upon administration of compound (100 mpk) in hamster2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID662726Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in plasma HDL-triglyceride level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID490631Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of body weight at 250 mg/kg, po for 7 days2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID1742321In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in FAS expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1762003Hypolipidemic activity in mouse model of HFD-induced hyperlipidemia assessed as increase in serum HDL-C level at 13 mg/kg, IG relative to control2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID432544Antidyslipidemic activity in high fat diet fed dyslipidemic golden Syrian hamster model assessed as change in plasma HDL to cholesterol ratio at 108 mg/kg, po administered once daily from day 4 to day 10 measured on day 10 after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID141903Agonist activity for murine PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID662725Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in plasma HDL-phospholipid level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID503341Inhibition of Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID311946Agonist activity at rat PPARalpha in rat H4IIE cells assessed as gene induction2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1742311In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AKT phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID476400Antidyslipidemic activity in syrian golden hamster high fat diet model assessed as reduction of plasma triglyceride level at 100 mg/kg, po qd for 21 days measured after 18 hrs fasting and 24 hrs last dose by FPLC method2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
AID1139720Hypolipidemic activity in triton WR-1339 Wistar rat assessed as total cholesterol at 250 mg/kg, po for 7 days (Rvb = 209 +/- 1.45 mg/dl)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID597587Antidiabetic activity against high fructose high fat diet fed syrian golden hamster assessed as change in serum insulin level at 30 mg/kg, po for 7 days by ELISA relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID1742314In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AMPKalpha phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1529843Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic mouse model assessed as decrease in total cholesterol level at 13 mg/kg, po for 7 days and co-treated with Triton WR-1339 on day 62018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID712728Increase in liver weight in high fat diet fed-induced obesity and insulin resistance C57Bl/6J mouse model at 100 mg/kg/day, po administered once daily for 2 weeks2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID238857Binding affinity for human peroxisome proliferator activated receptor gamma2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID318258Hypoglycemic effect on diabetic KKAy mouse model assessed as reduction of plasma glucose level at 300 mg/kg, po QD for 4 days2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID476390Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as increase in serum ApoA1 protein level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID391552Agonist activity at PPARalpha2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
AID662723Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma LDL-apoprotein level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1742267Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum IL6 level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1474127AUC in human at 43 to 130 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID251187In vivo efficacy at 100 mpk against Hamster for triglceride lowering effect after oral dosing; Number of animals= 9 (vehicle 0.5% methylcellulose)2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.
AID662720Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma LDL-total cholesterol level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID597586Antidiabetic activity against high fructose high fat diet fed syrian golden hamster assessed as change in fasting blood glucose level at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID277157Increase in HDL cholesterol level in human Apo-A-I transgenic C57BL/6 mouse at 50 mg/kg2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID432543Antidyslipidemic activity in high fat diet fed dyslipidemic golden Syrian hamster model assessed as change in plasma glycerol level at 108 mg/kg, po administered once daily from day 4 to day 10 measured on day 10 after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
AID194703Activity to induce the elevation of triglycerides in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID613811Aqueous solubility of the compound in 0.2 M phosphate buffer at pH 7.4 after 4 hrs by HPLC method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID1761997Hepatoprotective activity against mouse model of HFD-induced hyperlipidemia assessed as decrease in ALT level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID1905835Agonist activity at PPAR in oleic acid-induced steatosis in human HepaRG cells assessed as increase in PDK4 mRNA levels at 250 uM treated for 2 weeks with media replenishment along with compound and inducer for every 2 days by RT-qPCR analysis2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID240312Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1546883Agonist activity at PPARgamma (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID421050Agonist activity at human PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID662721Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma LDL-phospholipid level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID194558Activity to induce the elevation of HDL(High Density Lipoproteins)-Cholesterol in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID551421Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat assessed as blood LDL level at 250 mg/kg, po after 7 days (Rvb = 75.5 +/- 1.24 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID613810Aqueous solubility of the compound in 0.1 M phosphate buffer at pH 5.2 after 4 hrs by HPLC method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID249587Percentage change in the serum cholesterol upon administration of compound (20 mpk) in dogs2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID1347869Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as increase in LCAT mRNA expression in liver at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID1873503Antidiabetic activity in nicotinamide and streptozotocin induced hyperglycemic mouse model assessed as reduction in triglyceride level at 100 mg/kg, IG administered as single dose and measured on day 5 (Rvb = 93 +/- 10 mg/dl)2022Bioorganic & medicinal chemistry letters, 08-15, Volume: 70Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation.
AID439377Cytotoxicity against HEK293 cells assessed as decrease in viable cells at 50 uM after 48 hrs by aqueous one solution cell proliferation assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID421145Cmax in Beagle dog at 50 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID490637Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of blood cholesterol level at 250 mg/kg, po for 7 days (Rvb = 128.8 +/- 1.20 mg/dl)2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID372088Toxicity in Sprague-Dawley rat assessed as liver weight at 300 mg/kg dosed daily for 2 weeks2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
AID1347870Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as increase in SCARB1 mRNA expression in liver at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID597570Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as reduction in NEFA level at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID776250Antidyslipidemic activity in Charles foster rat assessed as decrease in triton WR-1339-induced phospholipid level in plasma at 100 mg/kg, po after 18 hrs relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID1588907Antihyperglycemic activity in fructose-challenged Sprague-Dawley rat assessed as increase in liver CPT1A mRNA expression at 30 mg/kg, po administered once daily via gavage for 2 weeks measured after 5 hrs fasting by SYBR green dye-based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID597540Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as reduction in serum triglyceride at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID1529850Antihyperlipidemic activity in high fat diet-induced hyperlipidemic mouse model assessed as increase in HDL level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1742330In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARgamma expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID701610Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as increase in HDL-cholesterol level at 25 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1742325In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARalpha expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID776230Antidyslipidemic activity in Charles foster rat assessed as increase in triton WR-1339-reduced lipoprotein lipase level in liver at 100 mg/kg, po relative to triton-treated rat2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
AID252885Effect (100 mpk) on serum cholesterol in hamster2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID305953Decrease in plasma cholesterol levels in dyslipidemic hamster model at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID613805Hypolipidemic activity in Swiss albino mouse assessed as decrease in plasma triglyceride level at 50 mg/kg, po administered daily for 8 days measured on day 9 by spectrophotometry relative to control2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID421163Toxicity in Sprague-Dawley rat assessed as increase albumin/globulin levels at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID613807Octanol-buffer partition coefficient, log P of the compound at pH 7.4 by HPLC2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID1266114Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth at 100 uM after 48 to 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1905847Reduction of lipid accumulation in oleic acid-induced steatosis in human HepaRG cells at 250 uM treated for 2 weeks with media replenishment along with compound and inducer for every 2 days by Oil Red O staining based microscopy2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID194696Activity to induce the elevation of phospholipids in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID701833Antidiabetic activity in sucrose challenged streptozotocin-induced diabetic Sprague-Dawley rat model assessed as reduction in glucose levels at 100 mg/kg, po measured after 24 hrs2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1377503Agonist activity at GAL4-fused PPARgamma LBD (unknown origin) expressed in HEK293 cells assessed as receptor transactivation after 18 hrs by dual luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-29, Volume: 138A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies.
AID156934In vitro activation of human peroxisome proliferator activated receptor gamma (PPAR gamma)2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
AID261955Decrease in triglyceride level in Golden Syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Design and synthesis of potent and subtype-selective PPARalpha agonists.
AID1601338Lipid lowering activity in human HepG2 cells assessed as inhibition of oleic acid-induced lipid accumulation at 10 uM by oil red O staining based microscopic analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Synthesis, biological activities, and docking studies of d-pantolactone derivatives as novel FAS inhibitors.
AID318264Hypolipidemic effect on diabetic KKAy mouse model assessed as increase in HDL cholesterol level at 300 mg/kg, po QD for 4 days2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID427212Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 20 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID551419Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat assessed as blood triglyceride level at 250 mg/kg, po after 7 days (Rvb = 135 +/- 1.592 mg/dl)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
AID91246Agonist activity for Human PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1742312In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in AKT phosphorylation in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID490643Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as increase of blood HDL level at 250 mg/kg, po for 7 days (Rvb = 18.6 +/- 1.36 mg/dl)2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID1905843Reduction of lipid accumulation in oleic acid-induced steatosis in human HepaRG cells at 250 uM treated for 24 hrs by spectrophotometry2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID613806Hypolipidemic activity in Swiss albino mouse assessed as decrease in plasma total cholesterol level at 50 mg/kg, po administered daily for 8 days measured on day 9 by spectrophotometry relative to control2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Synthesis and biological evaluation of orally active hypolipidemic agents.
AID410247Antihyperglycemic activity in po dosed diabetic C57BL/KsJ-db/db mouse model assessed as decrease in postprandial blood glucose level for 10 days2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID261958Decrease in cholesterol level in Beagle dog at 50 mg/kg, po2006Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
Design and synthesis of potent and subtype-selective PPARalpha agonists.
AID427199Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 5 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1269192Effect on body weight in Sprague-Dawley rat at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule measured every 5th day (Rvb = 207.67 +/- 1.2 g)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID1139718Hypolipidemic activity in triton WR-1339 Wistar rat assessed as high-density lipoprotein at 250 mg/kg, po for 7 days (Rvb = 17 +/- 1.70 mg/dl)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID244661Effect at an oral dose of 100 mg/kg/day for 14 days on serum cholesterol level of hamster2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID317702Inhibition of glucose level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID1269191Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as ratio of cholesterol level to HDL level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 1.88 +/- 0.05 No_unit)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID1529845Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic mouse model assessed as decrease in serum MDA level at 13 mg/kg, po for 7 days and co-treated with Triton WR-1339 on day 62018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID84319In vivo percent change in triglyceride in hamsters at 100 mg/kg2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID476394Antiartherosclerosis activity in human ApoA1 transgenic mouse model assessed as reduction of plasma triglyceride level at 100 mg/kg, po qd for 10 days measured 4 hrs after last dose by FPLC method2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
AID701609Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in body weight at 25 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1610312Hypolipidemic activity in Triton WR1339-induced hyperlipidemia mouse model assessed as decrease in serum TG level at 13 mg/kg, ig administered for one week and administered with Triton WR 1339 on day 6 and measured after 24 hrs2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID597539Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as reduction in serum cholesterol at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID690780Antihyperlipidemic activity in Sprague-Dawley rat assessed as decrease in plasma triglyceride level at 100 mg/mL, po administered QD for 8 days relative to vehicle-treated control2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of highly water-soluble fibrate derivatives via BGLation.
AID772438Ratio of total cholesterol level in serum to HDL level in serum in Triton-X-100-induced hyperlipidemia Wistar albino rat model at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID1873502Antidiabetic activity in nicotinamide and streptozotocin induced hyperglycemic mouse model assessed as reduction in triglyceride level at 100 mg/kg, IG administered as single dose and measured on day 3 (Rvb = 95 +/- 5 mg/dl)2022Bioorganic & medicinal chemistry letters, 08-15, Volume: 70Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation.
AID156138In vitro effective concentration for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected KRP-297 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID1529853Antioxidant activity in high fat diet-induced hyperlipidemic mouse model assessed as increase in GSH-PX level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID592753Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as effect on amyloid beta (1 to 38) level at 200 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID421047Inhibition of human PPARgamma receptor by scintillation proximity assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID712725Induction of PPARalpha-mediated upregulation of Acox1 mRNA expression in liver of high fat diet fed-induced obesity and insulin resistance C57Bl/6J mouse model at 100 mg/kg/day, po administered once daily for 2 weeks by real time qPCR analysis2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID701831Antidiabetic activity in sucrose loaded Wistar rat model assessed as reduction in glucose levels at 100 mg/kg, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID427203Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 42 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID421128Antidiabetic activity in Syrian golden hamster assessed as reduction in triglyceride level at 100 mg/kg, po once daily for 9 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1474128Drug concentration at steady state in human at 43 to 130 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID503299Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1742263Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum AST level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID421135AUC in Syrian golden hamster at 100 mg/kg, po once daily for 9 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1742324In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in mTOR phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1761996Hepatoprotective activity against mouse model of HFD-induced hyperlipidemia assessed as decrease in AST level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID1269190Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as HDL level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 37.5 +/- 0.96 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID1377502Agonist activity at GAL4-fused PPARalpha LBD (unknown origin) expressed in HEK293 cells assessed as receptor transactivation after 18 hrs by dual luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-29, Volume: 138A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies.
AID1742262Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum LDL level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1588914Antihyperglycemic activity in fructose-challenged Sprague-Dawley rat assessed as increase in liver SLC25A20 mRNA expression at 30 mg/kg, po administered once daily via gavage for 2 weeks measured after 5 hrs fasting by SYBR green dye-based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists.
AID503336Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID84136In vivo serum cholesterol in hamsters at 100 mg/kg2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
AID280012Increase of HDL/LDL ratio in fat fed hyperlipidemic Golden Syrian hamster at 100 mg/kg, po after 14 days2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID1269193Hypoglycemic activity in Sprague-Dawley rat assessed as blood glucose level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 63.70 +/- 0.7 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID712724Induction of PPARalpha-mediated upregulation of Acadl mRNA expression in liver of high fat diet fed-induced obesity and insulin resistance C57Bl/6J mouse model at 100 mg/kg/day, po administered once daily for 2 weeks by real time qPCR analysis2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID503324Inhibition of mitochondrial membrane potential in human HEK293 cells after 1 hr2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1742273Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in appearance of hepatic lobules at 100 mg/kg, po measured after 24 hrs by Oil Red O staining based assay2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1636479Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 139.9 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID701594Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in NEFA level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1529856Hepatoprotective activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in AST level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID249617Percentage change of non-HDL cholesterol levels in obese female Zucker rats after 2 weeks of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID1546882Agonist activity at PPARalpha (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1529848Antihyperlipidemic activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in atherosclerosis index at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID427216Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 10 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID503332Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1610326Hepatoprotective activity in Met-induced hyperlipidemia rat model assessed as decrease in serum ALT level at 9 mg/kg, po administered with compound for last 30 days during feeding of 0.2% Met solution for 60 days2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1269188Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as VLDL level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 23.48+/- 0.78 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1742283Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as spleen index at 100 mg/kg, po measured after 24 hrs (Rvb = 3.87 +/- 0.05 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1761986Hypolipidemic activity in mouse model of HFD-induced hyperlipidemia assessed as reduction in serum TC level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID317704Inhibition of free fatty acids level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID1529844Antihyperlipidemic activity in Triton WR-1339-induced hyperlipidemic mouse model assessed as decrease in serum triglyceride level at 13 mg/kg, po for 7 days and co-treated with Triton WR-1339 on day 62018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1313521Increase in ApoA1 level in transgenic mouse expressing human ApoA1 at 100 mg/kg administered qd through oral gavage measured after 10 days relative to vehicle-treated control2016ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.
AID1139719Hypolipidemic activity in triton WR-1339 Wistar rat assessed as triglyceride at 250 mg/kg, po for 7 days (Rvb = 190 +/- 1.98 mg/dl)2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
AID772434Hepatotoxicity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as alkaline phosphatase level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID432540Antidyslipidemic activity in high fat diet fed dyslipidemic golden Syrian hamster model assessed as change in plasma triglyceride level at 108 mg/kg, po administered once daily from day 4 to day 10 measured on day 10 after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
AID372086Toxicity in Sprague-Dawley rat assessed as heart weight at 300 mg/kg dosed daily for 2 weeks2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
AID597542Antidyslipidemic activity against high fructose high fat diet fed syrian golden hamster assessed as reduction in serum LDL-cholesterol at 30 mg/kg, po for 7 days relative to untreated control2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and antidyslipidemic activity of chalcone fibrates.
AID662713Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in serum phospholipid level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID662714Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in serum triglyceride level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID427202Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID156298In vitro fold activation of human PPAR alpha relative to maximum activation obtained with Fenofibric acid2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
AID484274Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID317698Binding affinity at PPARgamma2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID317701Inhibition of HDL level in Syrian golden hamster at 300 umol/kg after 10 days2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
AID421157Toxicity in Sprague-Dawley rat assessed as hematocrit at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1742328In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in PPARbeta expression in liver at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1761984Hypolipidemic activity in mouse model of HFD-induced hyperlipidemia assessed as reduction in serum TG level at 13 mg/kg, IG2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID772442Antihyperlipidemic activity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as reduction of triglyceride level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID772441Antihyperlipidemic activity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as reduction of VLDL level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID172907Percent change in high density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 100 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID490645Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of blood VLDL level at 250 mg/kg, po for 7 days (Rvb = 26.2 +/- 1.20 mg/dl)2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID662719Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma VLDL-apoprotein level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID421144AUC in Beagle dog at 50 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID503300Antiproliferative activity against human A549 cells after 120 hrs by MTT assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1347926Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as increase in ABCG5 mRNA expression in eWAT at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID662735Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in deoxycholic acid excretion in feces at 100 mg/kg/day, po administered for 4 weeks measured after 30 days relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1742264Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum ALT level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742317In vivo induction of AMPK in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as increase in CPT-1A phosphorylation in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742327In vivo effect on PPAR signaling in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as decrease in PPARbeta expression in white adipose tissue at 100 mg/kg, po measured after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID701808Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in triglyceride level at 100 mg/kg/day for 7 days2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID427211Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 20 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1742261Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as reduction in serum triglyceride level at 100 mg/kg, po measured after 24 hrs2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID1742281Hypolipidemic activity in tyloxapol-induced Kunming mouse model of hyperlipidemia assessed as liver index at 100 mg/kg, po measured after 24 hrs (Rvb = 65.00 +/- 0.87 No_unit)2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis of natural 3'-Prenylchalconaringenin and biological evaluation of ameliorating non-alcoholic fatty liver disease and metabolic syndrome.
AID540235Phospholipidosis-negative literature compound
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID244673Effect at an oral dose of 100 mg/kg/day for 14 days on serum triglyceride level of hamster2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID592841Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 40) level at 200 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID249607Percentage change of HDL cholesterol levels in obese female Zucker rats after 1 week of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID308342Increase in plasma HDL-C in human apoA1 transgenic mouse at 300 mg/kg after 14 days2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
AID592752Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as effect on amyloid beta (1 to 37) level at 200 uM after 24 hrs by ELISA2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID662734Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in cholic acid excretion in feces at 100 mg/kg/day, po administered for 4 weeks measured after 30 days relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID772439Antihyperlipidemic activity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as increase of HDL level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID662715Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as increase in serum LCAT enzyme level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID305965Increase in ratio of plasma HDL to plasma cholesterol levels at 108 mg/kg after 7 days2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
AID249600Percentage change of triglycerides in obese female Zucker rats after 1 week of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID490641Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of blood LDL level at 250 mg/kg, po for 7 days (Rvb = 51.8 +/- 2.03 mg/dl)2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID1529852Antioxidant activity in high fat diet-induced hyperlipidemic mouse model assessed as reduction in MDA level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1269187Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as triglyceride level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 74.3+/- 0.48 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID662717Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as decrease in plasma VLDL-phospholipid level at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID1269186Hypolipidemic activity in high fat-induced hyperlipidemic Sprague-Dawley rat assessed as cholesterol level at 250 mg/kg, po dosed for last 7 days during 30 day high-fat diet feeding schedule (Rvb = 70.8 +/- 0.5 mg/dl)2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.
AID484275Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-1002010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Colloid formation by drugs in simulated intestinal fluid.
AID421160Toxicity in Sprague-Dawley rat assessed as increase in liver weight at 300 mg/kg, po once daily for 14 days2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
AID209338Screening was performed to determine its plasma triglyceride lowering activity on administration of 30 mg/kg/day dose for 6 days on inbreed colony of Swiss Albino Mice2002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Synthetic studies of cis-4-Amino-L-proline derivatives as novel lipid lowering agents.
AID280010Reduction of VLDL level in fat fed hyperlipidemic Golden Syrian hamster at 100 mg/kg, po after 14 days2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
AID503323Inhibition of mitochondrial membrane potential in human PC3 cells after 1 hr2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID772440Antihyperlipidemic activity in Triton-X-100-induced hyperlipidemia Wistar albino rat model assessed as reduction of LDL level in serum at 250 mg/kg, po qd for 7 days2013European journal of medicinal chemistry, Jul, Volume: 652,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
AID318255Hypolipidemic effect on diabetic KKAy mouse model assessed as reduction of plasma triglyceride level at 300 mg/kg, po QD for 4 days2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID701598Antidyslipidemic activity in high fructose and high-fat diet fed dyslipidemic Syrian golden hamster model assessed as reduction in triglyceride level at 30 mg/kg/day, po for 7 day, po2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Flavone-based novel antidiabetic and antidyslipidemic agents.
AID1905848Reduction of lipid accumulation in oleic acid-induced steatosis in human HepaRG cells at 250 uM treated for 2 weeks with media replenishment along with compound and inducer for every 2 days by spectrophotometry2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID141913Agonist activity for murine PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1347871Induction of reverse cholestrol transport in high fat diet-induced dyslipidemia Syrian Golden hamster model assessed as decrease in NPCL1 mRNA expression in liver at 100 mg/kg, po administered for 1 week by qRT-PCR analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
AID410245Antihyperglycemic activity in diabetic C57BL/KsJ-db/db mouse model assessed as decrease in low-density lipoprotein cholesterol at 50 mg/kg, po for 10 days relative to control2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
AID1529849Antihyperlipidemic activity in high fat diet-induced hyperlipidemic mouse model assessed as LDL level at 13 mg/kg, po administered for last 30 days during 60 days of high fat diet feeding relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
AID1761999Hypolipidemic activity in mouse model of HFD-induced hyperlipidemia assessed as reduction in number of lipid droplets in liver at 13 mg/kg, IG by oil red-O staining based assay2021Bioorganic & medicinal chemistry letters, 07-01, Volume: 431,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID427210Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 25 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID439375Cytotoxicity against HEK293 cells assessed as viable cells at 0.1 uM after 48 hrs by aqueous one solution cell proliferation assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1610334Hypolipidemic activity in Met-induced hyperlipidemia rat model assessed as increase in serum hydrogen sulfide level at 9 mg/kg, po administered with compound for last 30 days during feeding of 0.2% Met solution for 60 days2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents.
AID249614Percentage change of non-HDL cholesterol levels in obese female Zucker rats after 1 week of pre-treatment at a dose of 100 mg/kg/day2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID244642Effect on cholesterol lowering in male Beagle dog at an oral dose of 50 mkd for 3 days2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID439370Agonist activity at human PPARalpha assessed as luciferase activity by transactivation assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID503340Inhibition of p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID427209Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) at 25 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID432542Antidyslipidemic activity in high fat diet fed dyslipidemic golden Syrian hamster model assessed as change in plasma HDL-cholesterol level at 108 mg/kg, po administered once daily from day 4 to day 10 measured on day 10 after 2 hrs of last dose2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
AID407369Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID244650Effect on cholesterol lowering in male Beagle dog at an oral dose of 50 mkd for 15 days2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID490639Antihyperlipidemic activity in high fat diet-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of blood triglyceride level at 250 mg/kg, po for 7 days (Rvb = 142.4 +/- 1.53 mg/dl)2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
AID1905841Cytotoxicity against oleic acid-induced steatosis in human HepaRG cells at 10 times of EC502022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID1143911Antidyslipidemic activity in triton-induced hyperlipidemic Charles Foster rat assessed as reduction in total cholesterol in plasma at 100 mg/kg, po relative to control2014European journal of medicinal chemistry, Jun-23, Volume: 81Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
AID662731Antihyperlipidemic activity in HFD-induced hyperlipidemic Charles Foster rat assessed as reactivation of LPL activity at 100 mg/kg, po administered for 4 weeks relative to control2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
AID503303Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID503302Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1800412ANS Fluorescence Displacement Assay from Article 10.1021/bi401014k: \\The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.\\2013Biochemistry, Dec-23, Volume: 52, Issue:51
The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1801103Fluorophore Displacement Assay from Article 10.1021/cb5005178: \\Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.\\2014ACS chemical biology, Nov-21, Volume: 9, Issue:11
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
AID1801104ITC Titration from Article 10.1021/cb5005178: \\Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.\\2014ACS chemical biology, Nov-21, Volume: 9, Issue:11
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1346004Rat fatty acid binding protein 1 (Fatty acid-binding proteins)2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,966)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990172 (5.80)18.7374
1990's251 (8.46)18.2507
2000's1019 (34.36)29.6817
2010's1239 (41.77)24.3611
2020's285 (9.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 112.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index112.69 (24.57)
Research Supply Index8.19 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index210.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (112.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials529 (17.30%)5.53%
Reviews5 (11.90%)6.00%
Reviews259 (8.47%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies164 (5.36%)4.05%
Observational0 (0.00%)0.25%
Observational9 (0.29%)0.25%
Other37 (88.10%)84.16%
Other2,097 (68.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (182)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diab [NCT01101204]200 participants (Anticipated)Interventional2012-07-31Not yet recruiting
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia [NCT00092560]Phase 3587 participants (Actual)Interventional2002-12-31Completed
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia [NCT03510884]Phase 3153 participants (Actual)Interventional2018-05-31Completed
Randomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis [NCT01141296]Phase 20 participants (Actual)Interventional2011-04-30Withdrawn(stopped due to Lack of funding)
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers [NCT01148004]Phase 125 participants (Actual)Interventional2010-05-13Completed
A Multi-center, Randomized, Double-blind, Parallel Phase Ⅳ Study to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy [NCT03874260]Phase 4180 participants (Anticipated)Interventional2018-07-25Recruiting
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 or Fenofibrate in Subjects With Normal and Impaired Hepatic Function [NCT02891408]Phase 174 participants (Actual)Interventional2016-09-23Completed
Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy [NCT03869931]Phase 3300 participants (Anticipated)Interventional2019-03-08Recruiting
A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercho [NCT02984982]Phase 4206 participants (Actual)Interventional2016-11-15Completed
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia [NCT00092573]Phase 3576 participants (Actual)Interventional2003-04-30Completed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study [NCT02823353]Phase 3117 participants (Actual)Interventional2016-04-08Completed
Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum Deoxysphinganine Levels in Patients With Macular Telangiectasia (MacTel) Type 2 (SAFE Study) [NCT04907084]Phase 260 participants (Anticipated)Interventional2022-04-07Recruiting
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 [NCT04517396]Phase 2701 participants (Actual)Interventional2020-08-18Completed
A Multicenter, Randomized, Active Comparator, Placebo Controlled, Double-blind Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia [NCT01594983]Phase 258 participants (Actual)Interventional2012-06-30Completed
Comparative, Randomized, Single-Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Abbott (TriCor®) 160 mg Fenofibrate Tablets in Healthy Adult Volunteers Under Fed Conditions [NCT00775359]24 participants (Actual)Interventional2002-08-31Completed
Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredri [NCT00145431]Phase 341 participants (Actual)Interventional2005-03-31Terminated
An Open Label, Balanced, Randomized, Two-treatment, Two -Period, Two -Sequence, Crossover Bioequivalence Study Comparing a Single Oral Dose of Fenofibrate 130 mg Capsules of Ohm Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With Anta [NCT02306889]48 participants (Actual)Interventional2010-01-31Completed
A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy [NCT02314533]Phase 4200 participants (Anticipated)Interventional2014-12-31Not yet recruiting
Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia [NCT00934258]0 participants Expanded AccessAvailable
A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin Versus Pitavastatin/Fenofibrate in Complex-dyslipidemia Patients [NCT03618797]Phase 3347 participants (Actual)Interventional2015-11-30Completed
A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Car [NCT01674712]Phase 3575 participants (Actual)Interventional2012-06-30Completed
Safety and Efficacy of Fenofibrate in the Treatment of Pregnant Women With Severe Hypertriglyceridemia [NCT05883865]250 participants (Anticipated)Observational2022-06-01Recruiting
The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial) [NCT02232360]Phase 4106 participants (Anticipated)Interventional2014-01-31Recruiting
A Prospective Observational Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN) [NCT04650152]1,000 participants (Actual)Observational2020-10-27Completed
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease [NCT03515213]Phase 210 participants (Actual)Interventional2017-04-27Completed
Effects of Fenofibrate on Gene Expression Activity and DNA Methylation Profile in Circulating Monocytes of Healthy Volunteers [NCT01109758]Phase 126 participants (Actual)Interventional2008-03-31Completed
Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms [NCT03829514]Phase 410 participants (Actual)Interventional2019-02-04Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study Comparing Fenofibrate Capsule 130 mg of Ohm Laboratories Inc., USA (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With Antara® C [NCT02306902]24 participants (Actual)Interventional2009-10-31Completed
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2 [NCT03011450]Phase 3471 participants (Actual)Interventional2016-11-26Completed
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase [NCT02890992]Phase 242 participants (Actual)Interventional2016-09-15Completed
A Cross-over, Randomized and Open-label Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-337 After a Single Oral Dose in Healthy Male Subjects [NCT03382756]Phase 116 participants (Actual)Interventional2017-10-12Completed
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and < [NCT03001817]Phase 3551 participants (Actual)Interventional2016-11-28Completed
An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia [NCT03510715]Phase 318 participants (Actual)Interventional2018-08-31Completed
PET (Positron Emission Tomography) Detection of the Effects of Aging on the Human Heart (Aim #2 Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function) [NCT00627653]60 participants (Anticipated)Interventional2005-10-31Active, not recruiting
The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia [NCT00754039]Phase 4129 participants (Actual)Interventional2003-02-28Completed
Effect of Choline Fenofibrate (SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects With Diabetic Macular Edema - a One-year, Placebo-Controlled, Randomized Study [NCT00683176]Phase 2110 participants (Actual)Interventional2008-09-30Completed
Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome [NCT00632840]Phase 411 participants (Actual)Interventional2001-06-30Completed
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome. [NCT00703755]Phase 22,288 participants (Actual)Interventional2003-03-31Completed
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study. [NCT00843661]Phase 460 participants (Anticipated)Interventional2009-03-31Recruiting
Open-Label, Randomized, Single-Dose, 3-Arm, Crossover Pharmacokinetic and Bioequivalence Study of One 35 mg Fenofibric Acid Tablet and Three 35 mg Fenofibric Acid Tablets Versus One 105 mg Fenofibric Acid Tablet Under Fasting Conditions [NCT00961259]Phase 154 participants (Actual)Interventional2008-02-29Completed
Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population [NCT02153879]Phase 430 participants (Actual)Interventional2009-02-28Completed
A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy [NCT02166593]Phase 3302 participants (Actual)Interventional2014-05-31Completed
A Multi-Center, Prospective, Longitudinal, Randomized, Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of Daily Administration of Pravastatin 40 mg or Fenofibrate 160 mg or Pravafen (the Combination of Pravastatin and Fenofibrate 40/160 [NCT00459745]Phase 3481 participants (Actual)Interventional2007-04-30Completed
Evaluation of Fenofibrate on Radiation-induced Skin Injury [NCT03557983]30 participants (Anticipated)Interventional2018-06-13Not yet recruiting
An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI [NCT02455336]Phase 2/Phase 323 participants (Actual)Interventional2015-05-18Completed
Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Fenofibrate and Atorvastatin in Healthy Male Volunteers [NCT02066207]Phase 130 participants (Actual)Interventional2014-03-18Completed
The Effect of Altering Myocardial Lipid Content on Cardiac Physiology in Patients With Aortic Stenosis [NCT05256758]67 participants (Actual)Interventional2019-05-29Active, not recruiting
Fenofibrate to Prevent Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation (FICsDCD) [NCT05514119]Phase 2148 participants (Anticipated)Interventional2022-08-17Recruiting
[NCT00719693]Phase 1115 participants (Actual)Interventional2008-07-31Completed
The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate [NCT00732485]Phase 2/Phase 30 participants (Actual)Interventional2008-08-31Withdrawn(stopped due to Principal Investigator Changed)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study [NCT00542178]Phase 33,472 participants (Actual)Interventional2003-10-31Completed
Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males With Klinefelter Syndrome [NCT05498090]Phase 444 participants (Anticipated)Interventional2022-11-03Recruiting
A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia [NCT00664859]Phase 2/Phase 3140 participants (Actual)Interventional2007-10-31Completed
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia [NCT00813527]Phase 2213 participants (Actual)Interventional2006-02-28Completed
A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization [NCT04661930]Phase 355 participants (Anticipated)Interventional2021-01-01Recruiting
A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally. [NCT01320345]Phase 3450 participants (Anticipated)Interventional2016-11-03Recruiting
A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™ [NCT00891293]Phase 493 participants (Actual)Interventional2006-03-31Completed
Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00884819]4 participants (Actual)Interventional2008-12-31Terminated(stopped due to Poor recruitment)
Effect of a Fibrate (Fenofibrate) and a Statin (Atorvastatin) and on Endothelial Dysfunction in Diabetes Mellitus and the Metabolic Syndrome [NCT00491400]28 participants (Actual)Interventional2005-09-30Terminated(stopped due to Insufficient enrollment)
Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia [NCT01010516]Phase 4120 participants (Anticipated)Interventional2009-10-31Recruiting
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance [NCT00470262]27 participants (Actual)Interventional2007-01-31Completed
Pretreatment Genotyping at APOA5 and GCKR Loci and Response to Fenofibrate Therapy [NCT01023750]39 participants (Actual)Observational2010-01-31Completed
A Multicenter, Randomized, Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome [NCT00965315]0 participants Expanded AccessAvailable
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglycerid [NCT00973271]Phase 30 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to Did not continue with development of DCCR in Very High Triglycerides)
A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers. [NCT02651753]Phase 148 participants (Actual)Interventional2016-01-31Completed
A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes [NCT00703482]Phase 2278 participants (Actual)Interventional2003-05-31Completed
[NCT00745407]Phase 40 participants Interventional2005-01-31Completed
Effects of Tibolone and PPARα-agonist on HDL Metabolism in Postmenopausal Women [NCT00809068]Phase 420 participants (Anticipated)Interventional2005-08-31Completed
ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study [NCT00673881]Phase 1/Phase 225 participants (Actual)Interventional2008-03-31Completed
A Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Fenofibrate Formulations Comparing Fenofibrate 160 mg Tablets of Ranbaxy Laboratories With Tricor 160 mg Tablets of in Healthy, Adult, Human Subjects Un [NCT00775827]40 participants (Actual)Interventional2002-11-30Completed
Comparative Study of Effects and Safety of Intermittent Low Dose Therapy of Fenofibrate and Simvastatin on Chronic Hemodialysis Patients [NCT02886299]Phase 460 participants (Actual)Interventional2013-10-31Completed
A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg TriCor® (Fenofibrate) Tablets Under Fed Conditions(Standard Meal) [NCT00960687]Phase 154 participants (Actual)Interventional2007-10-31Completed
Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial [NCT00923676]Phase 4300 participants (Actual)Interventional2008-04-30Active, not recruiting
A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers [NCT00359281]Phase 2125 participants (Actual)Interventional2006-03-31Completed
A Multicenter, Double-Blind, Randomized, Placebo and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of MK0767 in Patients With Metabolic Syndrome and Dyslipidemia [NCT00703690]Phase 2436 participants (Actual)Interventional2002-01-31Terminated
Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) [NCT00819910]Phase 441 participants (Actual)Interventional2008-09-30Terminated(stopped due to Slow recruitment and increase in deployment overseas limiting follow up)
Pilot Study of Fenofibrate for Primary Biliary Cirrhosis [NCT00575042]Phase 220 participants (Actual)Interventional2007-08-31Completed
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening [NCT04661358]Phase 3560 participants (Anticipated)Interventional2021-03-05Recruiting
A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities [NCT00006412]Phase 3630 participants InterventionalCompleted
Insulin Resistance in Non-alcoholic Fatty Liver Disease [NCT00252499]13 participants (Actual)Interventional2005-10-31Terminated(stopped due to Protocol drug change required new clinicaltrails.gov entry)
[NCT01003847]Phase 4150 participants (Actual)Interventional2009-11-30Completed
Atorvastatin Plus Fenofibric Acid in the Reduction of Intermediate [NCT01030328]Phase 318 participants (Actual)Interventional2009-11-30Terminated(stopped due to Lack of patient population)
A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice [NCT00726856]1,200 participants (Anticipated)Observational2007-05-31Completed
Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals. [NCT00186537]47 participants (Actual)Interventional2003-09-30Completed
Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer [NCT00357500]Phase 2101 participants (Actual)Interventional2005-01-31Completed
Randomized Head-to-Head Comparison of Coenzyme A Capsule and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial. [NCT01878227]Phase 3420 participants (Actual)Interventional2010-07-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated With Antara, Followed by an 8-week Extension [NCT00246636]Phase 4167 participants (Actual)Interventional2005-10-31Completed
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study. [NCT01956201]Phase 3476 participants (Anticipated)Interventional2013-12-31Recruiting
An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Rosuvastatin and Fenofibric Acid in Healthy Adult Subjects [NCT01964365]Phase 130 participants (Actual)Interventional2013-09-30Completed
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes [NCT04929379]Phase 240 participants (Anticipated)Interventional2022-01-04Recruiting
Insulin Resistance in Non-alcoholic Fatty Liver Disease (Protocol Drug Change From Project Career Development Award (CDA)-2-044-08S) [NCT01289639]11 participants (Actual)Interventional2005-10-31Terminated(stopped due to Low recruitment in intervention study. Baseline data published.)
Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome [NCT02015988]Phase 460 participants (Anticipated)Interventional2014-01-31Active, not recruiting
Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy [NCT01280604]66 participants (Actual)Interventional2010-10-31Completed
A Phase 3, Multi-Center, Placebo- and Active-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C [NCT04998981]Phase 3350 participants (Anticipated)Interventional2021-09-17Recruiting
Aggressive Treatment of Metabolic Syndrome in Patients Treated With Clozapine for Schizophrenia [NCT00794963]8 participants (Actual)Interventional2008-11-30Terminated(stopped due to Difficulty recruiting)
The Impact of Genetic Determinants of Fenofibrate's Pharmacogenetics on Lipid Response [NCT00613613]56 participants (Actual)Observational2008-01-31Completed
A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia [NCT00504829]Phase 2220 participants (Actual)Interventional2007-07-31Completed
The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans [NCT00872599]Phase 475 participants (Actual)Interventional2009-09-30Completed
A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg Tricor® (Fenofibrate) Tablets Under Fasting Conditions. [NCT00961116]Phase 154 participants (Actual)Interventional2007-10-31Completed
A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid [NCT05751967]Phase 3150 participants (Anticipated)Interventional2023-02-22Recruiting
A Four Arm, Single-Dose, Food Effect Evaluation With 105 mg Fenofibric Acid Tablets Administered in a Fasted State and Three Different Fed Conditions, Low-Fat/Low Calorie Meal, Standard Meal, and High-Fat/High Calorie Meal [NCT00960856]Phase 140 participants (Actual)Interventional2007-11-30Completed
A Double-blind, Cross-over, Placebo-controlled Study Evaluating the Effect of Fenofibrate 160 mg Tablets on Glomerular Filtration Rate and Other Renal Function Test in Healthy Subjects [NCT00543647]Phase 124 participants (Actual)Interventional2002-08-31Completed
Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis [NCT05781698]Phase 260 participants (Anticipated)Interventional2023-03-20Recruiting
The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study [NCT00400231]Phase 2124 participants (Anticipated)Interventional2005-08-31Completed
Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid [NCT05749822]Phase 2/Phase 3104 participants (Anticipated)Interventional2023-02-17Recruiting
Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP). [NCT04882293]Phase 378 participants (Anticipated)Interventional2022-02-15Recruiting
LXRA Gene Polymorphisms and Response to Fenofibrate [NCT00644592]11 participants (Actual)Interventional2008-03-31Terminated(stopped due to supply issues with the formulation of fenofibrate that was used.)
Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females [NCT03615534]Phase 4161 participants (Actual)Interventional2014-10-01Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy [NCT00559962]Phase 2260 participants (Actual)Interventional2007-10-31Completed
An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia [NCT00348725]Phase 369 participants Interventional2005-04-30Completed
Treatment Study for Severe High-Density Lipoprotein Deficiency [NCT00458055]19 participants (Actual)Interventional2006-11-30Completed
Multiple-Dose Pharmacokinetic and Pharmacodynamic Interaction Between ABT-335, Rosuvastatin and Warfarin [NCT00487136]Phase 145 participants (Actual)Interventional2007-06-30Completed
The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal [NCT00552747]Phase 476 participants (Actual)Interventional2007-10-31Completed
A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With Atorvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovasc [NCT00362934]Phase 3516 participants (Actual)Interventional2006-10-31Completed
Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis [NCT05753267]Phase 2/Phase 360 participants (Anticipated)Interventional2023-02-28Recruiting
A Phase II Trial of the Effect of Combination Therapy With Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone [NCT00076518]Phase 2100 participants InterventionalCompleted
A Placebo-Controlled, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in Subjects With Type 2 Diabetes Currently Treated With Lipid-Lowering Therapy [NCT00251680]Phase 3400 participants (Actual)Interventional2005-10-31Completed
A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 D [NCT00261352]Phase 31,000 participants Interventional2005-03-31Terminated(stopped due to The development program has been terminated)
The Comparison of the Efficacy of Ezetimibe and Fenofibrate Versus Atorvastatin Alone in the Lowering of LDL Cholesterol [NCT00299884]45 participants (Actual)Observational2005-01-31Completed
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia [NCT00304993]Phase 430 participants Interventional2001-01-31Completed
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease [NCT00309712]300 participants Interventional2002-08-31Completed
[NCT02823366]Phase 3104 participants (Anticipated)Interventional2016-01-31Recruiting
A Multicenter, Double-Blind, Randomized, Active Comparator, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidem [NCT00349375]Phase 31,040 participants (Actual)Interventional2005-11-30Completed
A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Ad [NCT00352183]Phase 3450 participants (Actual)Interventional2006-01-31Completed
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia [NCT00139061]Phase 3128 participants Interventional2005-03-31Completed
A Multi-center, Three-staged, Randomized, Parallel Group, Sequential, Double-blind, fenofibrate-and Placebo-controlled Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma HDLc and TG of Eight Weeks Treatment With 1µg to 20µg Daily [NCT00169559]Phase 2250 participants (Actual)Interventional2003-11-30Completed
Tissue Lipids and Insulin Resistance [NCT00483210]0 participants (Actual)InterventionalWithdrawn(stopped due to The study goals were accomplished by a similar study at UAMS. (W.J. Evans))
An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia [NCT00490178]Phase 329 participants (Actual)Interventional2007-03-31Completed
A Multicentric Prospective Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia [NCT01539616]Phase 2109 participants (Actual)Interventional2011-11-30Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA [NCT02965911]Phase 1/Phase 20 participants (Actual)Interventional2016-01-31Withdrawn(stopped due to No participants enrolled)
Fenofibrate in Indirect Neonatal Hyperbilirubinemia [NCT04868019]60 participants (Anticipated)Interventional2021-09-30Not yet recruiting
A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome [NCT00195793]Phase 3174 participants (Actual)Interventional2004-08-31Completed
A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome [NCT00816829]Phase 234 participants (Actual)Interventional2005-09-30Terminated(stopped due to The study was prematurely terminated because of slow recruitment)
A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subje [NCT01723735]Phase 179 participants (Actual)Interventional2012-11-30Completed
Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial [NCT00616772]Phase 3682 participants (Actual)Interventional2008-02-29Completed
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia. [NCT00349128]Phase 2/Phase 3382 participants Interventional2004-01-31Completed
A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039 [NCT01501435]Phase 148 participants (Actual)Interventional2011-12-31Completed
Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. [NCT01927315]Phase 441 participants (Actual)Interventional2013-08-31Completed
[NCT01666041]Phase 4120 participants (Anticipated)Interventional2012-01-31Completed
A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia [NCT00300430]Phase 31,911 participants (Actual)Interventional2006-09-30Completed
Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects [NCT01767610]Phase 124 participants (Actual)Interventional2013-01-31Completed
A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I [NCT02354976]Phase 278 participants (Actual)Interventional2015-09-01Completed
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis [NCT06174402]Phase 2/Phase 3184 participants (Anticipated)Interventional2023-08-21Recruiting
A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes [NCT03439345]Phase 41,151 participants (Actual)Interventional2018-07-23Active, not recruiting
Phase 2 Trial to Examine the Metabolic Effects of Fenofibrate in Burned Patients [NCT00361751]Phase 240 participants Interventional2003-05-31Completed
Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination. [NCT00362765]Phase 2/Phase 38 participants (Actual)Interventional2006-10-31Terminated(stopped due to The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion.)
Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients [NCT02262143]Phase 3362 participants (Actual)Interventional2014-11-30Completed
Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis [NCT01142323]Phase 1/Phase 28 participants (Actual)Interventional2010-10-31Terminated
Obesity and Nonalcoholic Fatty Liver Disease [NCT00262964]51 participants (Actual)Interventional2004-10-31Completed
Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia [NCT05365425]Phase 456 participants (Anticipated)Interventional2023-06-01Recruiting
Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume: Assessments on Retinal Endothelial Vascular Dysfunction, Inflammation, and Angiogenesis in Diabetic Retinopathy With Dyslipidemia [NCT04885153]36 participants (Actual)Interventional2016-11-01Completed
Medication Development in Alcoholism: Investigating PPAR Agonists [NCT02158273]Phase 250 participants (Actual)Interventional2014-05-31Completed
Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients [NCT01574131]Phase 43 participants (Actual)Interventional2012-05-31Terminated(stopped due to lost funding; Shriner Burn Hosp has revoked access to study records. No updates or results can be submitted)
Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride [NCT04528212]Phase 460 participants (Actual)Interventional2020-11-01Completed
A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome [NCT00349284]Phase 3181 participants Interventional2005-01-31Completed
A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation o [NCT00349635]Phase 2148 participants Interventional2004-10-31Completed
A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome [NCT00385658]Phase 475 participants (Actual)Interventional2006-08-31Completed
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma [NCT01965834]Phase 26 participants (Actual)Interventional2012-11-19Terminated(stopped due to Lack of adequate accrual.)
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia [NCT00361868]Phase 388 participants (Anticipated)Interventional2006-06-30Terminated(stopped due to The study was discontinued prematurely at the end of March 2007 due to slow enrolment.)
A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin. [NCT00362323]Phase 3482 participants (Actual)Interventional2006-10-31Completed
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis [NCT00422396]60 participants Interventional2001-01-31Completed
A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects [NCT00376285]Phase 10 participants (Actual)Interventional2006-11-30Withdrawn
Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA) [NCT05542147]200 participants (Anticipated)Interventional2022-07-03Recruiting
Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy of Phenofibrate Treatment on the Functions of Beta Cells in Children and Adolescents With Newly Diagnosed of Type 1 Diabetes. [NCT05909800]Phase 2102 participants (Anticipated)Interventional2022-09-29Recruiting
Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients [NCT02452255]Phase 2/Phase 318 participants (Actual)Interventional2015-11-30Terminated(stopped due to Shriner's Burn Hospital closed the study and access to study-related data is unavailable. We are unable to submit the additional information or results-data)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally [NCT02642159]Phase 4413 participants (Actual)Interventional2016-03-15Completed
An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients [NCT01462877]Phase 4506 participants (Actual)Interventional2011-10-31Completed
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study [NCT01048502]100 participants (Actual)Interventional2010-01-31Completed
An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects [NCT00928694]Phase 114 participants (Actual)Interventional2003-02-28Completed
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of Fenofibrate [NCT05080192]40 participants (Anticipated)Observational2021-02-26Recruiting
Lipid Biomarkers for Diabetic Heart Disease [NCT01752842]70 participants (Actual)Interventional2013-03-31Completed
Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients [NCT04140201]Phase 480 participants (Anticipated)Interventional2020-02-29Not yet recruiting
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy [NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients [NCT06155331]Phase 444 participants (Anticipated)Interventional2023-12-31Recruiting
Fibrates: An Adjuvant Therapy for Cholestasis In Pediatric Age Group [NCT03586674]Phase 250 participants (Actual)Interventional2017-11-01Completed
A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia [NCT00639158]Phase 3543 participants (Actual)Interventional2008-02-29Completed
Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate [NCT01426438]Phase 299 participants (Actual)Interventional2011-11-30Completed
A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers [NCT03346187]Phase 160 participants (Actual)Interventional2017-05-19Completed
A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardi [NCT00362206]Phase 3423 participants (Actual)Interventional2006-09-30Completed
Fenofibrate Role Against Chemotherapy Induced Peripheral Neurotoxicity in Breast Cancer Patients [NCT05813145]50 participants (Anticipated)Interventional2023-01-01Recruiting
Fenofibrate as an Adjuvant to Phototherapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants: A Randomized Control Trial. [NCT04418180]0 participants Interventional2016-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00186537 (3) [back to overview]Pre- and Post-Intervention LDL Cholesterol Levels
NCT00186537 (3) [back to overview]Pre- and Post-Intervention Triglyceride Levels
NCT00186537 (3) [back to overview]Pre- and Post-Intervention HDL Cholesterol Levels
NCT00246376 (7) [back to overview]Triglycerides
NCT00246376 (7) [back to overview]Body Composition
NCT00246376 (7) [back to overview]Total Cholesterol
NCT00246376 (7) [back to overview]Non-HDL-C
NCT00246376 (7) [back to overview]HDL-C
NCT00246376 (7) [back to overview]Total Cholesterol : HDL-C Ratio
NCT00246376 (7) [back to overview]Insulin Sensitivity
NCT00252499 (6) [back to overview]Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months
NCT00252499 (6) [back to overview]Change in Hepatic Insulin Sensitivity From Baseline to 6 Months
NCT00252499 (6) [back to overview]Change in Peripheral Insulin Sensitivity From Baseline to 6 Months
NCT00252499 (6) [back to overview]Changes in Intra-abdominal Fat Area From Baseline to 6 Months
NCT00252499 (6) [back to overview]Liver/Spleen Ratio at 6 Months
NCT00252499 (6) [back to overview]Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver
NCT00262964 (12) [back to overview]Change From Baseline in VLDL-Tg Production Rate
NCT00262964 (12) [back to overview]Very Low Density Lipoprotein - Triglyceride Production Rate
NCT00262964 (12) [back to overview]Percent Increase in Skeletal Muscle Insulin Sensitivity During Insulin Infusion.
NCT00262964 (12) [back to overview]Adipose Tissue Insulin Sensitivity
NCT00262964 (12) [back to overview]Hepatic Insulin Sensitivity Index (HISI)
NCT00262964 (12) [back to overview]Change From Baseline in Hepatic Insulin Sensitivity Index
NCT00262964 (12) [back to overview]Adipose Tissue Insulin Sensitivity in Fenofibrate and Niacin Groups
NCT00262964 (12) [back to overview]Change From Baseline in Very Low-density Lipoprotein Triglyceride Concentration
NCT00262964 (12) [back to overview]Change From Baseline in VLDL-Tg Clearance Rate
NCT00262964 (12) [back to overview]Change From Baseline in Skeletal Muscle Insulin Sensitivity
NCT00262964 (12) [back to overview]Change From Baseline in Very Low Density Lipoprotein Apolipoprotein B Production Rate
NCT00262964 (12) [back to overview]Hepatic Fat Content for Fenofibrate and Niacin Groups
NCT00300430 (9) [back to overview]Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study
NCT00300430 (9) [back to overview]Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study
NCT00300430 (9) [back to overview]Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study
NCT00357500 (4) [back to overview]Therapy Completion Rate
NCT00357500 (4) [back to overview]27-Week Overall Survival
NCT00357500 (4) [back to overview]27-Week Progression-Free Survival
NCT00357500 (4) [back to overview]Best Response
NCT00359281 (11) [back to overview]AUC0-t Total Ezetimibe
NCT00359281 (11) [back to overview]AUC0-t Simvastatin Acid
NCT00359281 (11) [back to overview]AUC0-t Rosuvastatin (Lomitapide 60 mg)
NCT00359281 (11) [back to overview]AUC0-t Rosuvastatin (Lomitapide 10 mg)
NCT00359281 (11) [back to overview]AUC0-t Simvastatin
NCT00359281 (11) [back to overview]Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
NCT00359281 (11) [back to overview]AUC0-t Nicotinuric Acid
NCT00359281 (11) [back to overview]AUC0-t Nicotinic Acid
NCT00359281 (11) [back to overview]AUC0-t Fenofibric Acid
NCT00359281 (11) [back to overview]AUC0-t Atorvastatin Acid (Lomitapide 60 mg)
NCT00359281 (11) [back to overview]Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)
NCT00470262 (2) [back to overview]IMCL
NCT00470262 (2) [back to overview]Insulin Sensitivity
NCT00504829 (2) [back to overview]Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy
NCT00504829 (2) [back to overview]Percent Changes From Baseline to End-of-treatment in Non-HDL, HDL and LDL Cholesterol by LCP-AtorFen Versus Fenofibrate Monotherapy
NCT00542178 (4) [back to overview]Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy
NCT00542178 (4) [back to overview]Development or Progression of Macular Edema
NCT00542178 (4) [back to overview]Loss of Visual Acuity
NCT00542178 (4) [back to overview]Cataract Extraction
NCT00559962 (1) [back to overview]Absolute Change From Baseline in Percent Hepatic Fat
NCT00575042 (1) [back to overview]Serum Level of Alkaline Phosphatase
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT)
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)
NCT00616772 (5) [back to overview]Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)
NCT00616772 (5) [back to overview]Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Median Percent Change in Triglycerides From Baseline to Final Visit
NCT00644592 (1) [back to overview]Log(ENA-Period 2 End/ENA Period 1 End)
NCT00664859 (2) [back to overview]Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment
NCT00664859 (2) [back to overview]Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment
NCT00673881 (4) [back to overview]Total Cholesterol
NCT00673881 (4) [back to overview]Mean Change in Plasma Triglycerides
NCT00673881 (4) [back to overview]Mean Change in High Density Lipoprotein Cholesterol
NCT00673881 (4) [back to overview]Mean Change in Calculated Low Density Lipoprotein Cholesterol
NCT00794963 (1) [back to overview]Change in Weight
NCT00816829 (10) [back to overview]Index of Hypopneas
NCT00816829 (10) [back to overview]Sleep Time With Oxygen Saturation Below 90%
NCT00816829 (10) [back to overview]Obstructive Apneas
NCT00816829 (10) [back to overview]Mixed Apneas
NCT00816829 (10) [back to overview]Central Apneas
NCT00816829 (10) [back to overview]Desaturations
NCT00816829 (10) [back to overview]Hypopneas
NCT00816829 (10) [back to overview]Index Apnea/Hypopnea
NCT00816829 (10) [back to overview]Index of Apneas
NCT00816829 (10) [back to overview]Apneas
NCT00819910 (5) [back to overview]Percent Change in Triglyceride (TG) Levels Post Treatment
NCT00819910 (5) [back to overview]Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels
NCT00819910 (5) [back to overview]Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels
NCT00819910 (5) [back to overview]Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit
NCT00819910 (5) [back to overview]Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels
NCT00872599 (2) [back to overview]HDL-cholesterol Measured During High Salt Fenofibrate in Salt-resistant and Salt-sensitive Hypertension
NCT00872599 (2) [back to overview]Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment
NCT00891293 (9) [back to overview]Percent Change in Apo A-1 From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study
NCT00891293 (9) [back to overview]Percent Change in VLDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)
NCT00891293 (9) [back to overview]Percent Change in Total Cholesterol From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study).
NCT00891293 (9) [back to overview]Percent Change in Serum Triglycerides From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension).
NCT00891293 (9) [back to overview]Percent Change in Ratio of Total-C:HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Ext. Study)
NCT00891293 (9) [back to overview]Percent Change in Non-HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)
NCT00891293 (9) [back to overview]Percent Change in LDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)
NCT00891293 (9) [back to overview]Percent Change in HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)
NCT00891293 (9) [back to overview]Percent Change in Apo B From LOV111859/OM5 (Double-blind [DB[ Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)
NCT00928694 (2) [back to overview]Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid
NCT00928694 (2) [back to overview]Maximum Plasma Concentration (Cmax) of Fenofibric Acid
NCT00960687 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00960687 (3) [back to overview]The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
NCT00960687 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00960856 (3) [back to overview]The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
NCT00960856 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00960856 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00961116 (3) [back to overview]The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
NCT00961116 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00961116 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00961259 (3) [back to overview]Maximum Plasma Concentration (Cmax)
NCT00961259 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT00961259 (3) [back to overview]The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
NCT01048502 (2) [back to overview]Changes in Inflammatory Parameter (Plasma TNF-α Levels) After Treatment With Fenofibrate or Placebo.
NCT01048502 (2) [back to overview]The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS).
NCT01142323 (2) [back to overview]Serum Alkaline Phosphatase
NCT01142323 (2) [back to overview]Mayo Risk Score for Primary Sclerosing Cholangitis
NCT01280604 (6) [back to overview]Aspartate Aminotransferase (AST)
NCT01280604 (6) [back to overview]Triglyceride Levels
NCT01280604 (6) [back to overview]Serum Creatinine(SCr)
NCT01280604 (6) [back to overview]Low-density Lipoprotein (LDL)
NCT01280604 (6) [back to overview]High-density Lipoprotein,(HDL)
NCT01280604 (6) [back to overview]Alanine Aminotransferase(ALT)
NCT01289639 (6) [back to overview]Change in Peripheral Insulin Sensitivity
NCT01289639 (6) [back to overview]Change in Hepatic Insulin Sensitivity
NCT01289639 (6) [back to overview]Change in Alanine Aminotransferase (ALT) Levels
NCT01289639 (6) [back to overview]Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan
NCT01289639 (6) [back to overview]Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT
NCT01289639 (6) [back to overview]Change in Intra-abdominal Fat Area by CT Scan
NCT01426438 (14) [back to overview]Change in Triglycerides
NCT01426438 (14) [back to overview]Men: Change in HDL Cholesterol
NCT01426438 (14) [back to overview]Absolute Change in Relative FMD (%)
NCT01426438 (14) [back to overview]Change in C-reactive Protein (CRP)
NCT01426438 (14) [back to overview]Women: Change in HDL Cholesterol
NCT01426438 (14) [back to overview]Change in IL-6
NCT01426438 (14) [back to overview]Change in Cholesterol
NCT01426438 (14) [back to overview]Change in D-Dimer
NCT01426438 (14) [back to overview]Change in HOMA-IR
NCT01426438 (14) [back to overview]Change in HDL Particles
NCT01426438 (14) [back to overview]Change in Large HDL Particles
NCT01426438 (14) [back to overview]Change in LDL Cholesterol
NCT01426438 (14) [back to overview]Change in Non-HDL Cholesterol
NCT01426438 (14) [back to overview]Change in Small LDL Particles
NCT01462877 (11) [back to overview]Change in Serum Creatine Kinase
NCT01462877 (11) [back to overview]Change in Serum Creatinine
NCT01462877 (11) [back to overview]Change in Serum High-density Lipoprotein Cholesterol
NCT01462877 (11) [back to overview]Change in Serum Low-density Lipoprotein Cholesterol
NCT01462877 (11) [back to overview]Change in Serum Non-high-density Lipoprotein Cholesterol
NCT01462877 (11) [back to overview]Change in Serum Total Cholesterol
NCT01462877 (11) [back to overview]Percentage of Triglyceride (TG) Change
NCT01462877 (11) [back to overview]Change in Serum Alanine Aminotransferase
NCT01462877 (11) [back to overview]Change in Serum Apolipoprotein A1
NCT01462877 (11) [back to overview]Change in Serum Apolipoprotein B
NCT01462877 (11) [back to overview]Change in Serum Aspartate Aminotransferase
NCT01674712 (3) [back to overview]Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)
NCT01674712 (3) [back to overview]Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)
NCT01674712 (3) [back to overview]Percentage of Change of TG (Triglyceride)
NCT01752842 (3) [back to overview]Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent
NCT01752842 (3) [back to overview]Change in Cardiac Diastolic Function as Measured by E' (cm/s)
NCT01752842 (3) [back to overview]Change in C24:0/C16:0 Ceramide Ratio
NCT01965834 (3) [back to overview]Number of Subjects Experiencing Adverse Events
NCT01965834 (3) [back to overview]Proportion of Participants Achieving Progression-Free Survival
NCT01965834 (3) [back to overview]Rate of Response in Participants Receiving Fenofibrate Therapy
NCT02158273 (2) [back to overview]Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period
NCT02158273 (2) [back to overview]Change From Baseline in Standard Drinks Per Week at 1 Week
NCT02354976 (2) [back to overview]Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate)
NCT02354976 (2) [back to overview]Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)
NCT02455336 (3) [back to overview]Triglyceride Concentration (Percent Change From Baseline)
NCT02455336 (3) [back to overview]Triglyceride Concentration (Percent Change From Baseline)
NCT02455336 (3) [back to overview]Adverse Event Profile
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis
NCT02890992 (20) [back to overview]Percent Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Apolipoprotein B at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8
NCT02890992 (20) [back to overview]Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4
NCT02890992 (20) [back to overview]Percent Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in HDL-C at Week 8
NCT02891408 (24) [back to overview]PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)
NCT02891408 (24) [back to overview]Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
NCT02891408 (24) [back to overview]Percentage of Participants Experiencing Laboratory Abnormalities
NCT02984982 (24) [back to overview]Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]Number of Participants With Cardiovascular (CV) Adverse Events
NCT02984982 (24) [back to overview]Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Total Cholesterol at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Apolipoprotein A-1 at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Apolipoprotein B at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in External Elastic Membrane Volume at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Lipoprotein (a) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Non-HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Remnant Cholesterol
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Total Cholesterol
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
NCT03001817 (114) [back to overview]Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in TC
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Remnant Cholesterol
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Non-HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in hsCRP
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in LDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo E
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo C3
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo C2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B48
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B100
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo A1
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in hsCRP
NCT03001817 (114) [back to overview]Change From Baseline to Week 52 in FGF21
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium
NCT03001817 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo A1
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo A2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo A2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B100
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B48
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo C2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo C3
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo E
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Fasting TG
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in FFAs
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in HDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in LDL-C
NCT03001817 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Cholesterol)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (Triglyceride)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Remnant Cholesterol
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in TC
NCT03011450 (114) [back to overview]Percent Change in Fasting TG From Baseline to Week 12
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 3 and 2a)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in FGF21
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in hsCRP
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Medium)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Small)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (IDL Particles)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Small)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Medium)
NCT03011450 (114) [back to overview]Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Small)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in FGF21
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in hsCRP
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Medium)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Small)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (IDL Particles)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Small)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Medium)
NCT03011450 (114) [back to overview]Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Small)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Non-HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo A1
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo A2
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B100
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo B48
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo C2
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo C3
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Apo E
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in FFAs
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Diameter of the Major LDL Particle (Å))
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 2b)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 1)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 2)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins I)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVc)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Intermediate)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Large)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Small)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in LDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TC:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (Triglyceride)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particle Size)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Lipoprotein Fraction HDL Cholesterol (Total)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Non-HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Remnant Cholesterol
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 12 in Total Cholesterol
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo A1
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo A2
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B100
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo B48
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo C2
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo C3
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Apo E
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Fasting TG
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in FFAs
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in HDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Diameter of the Major LDL Particle (Å))
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 2b)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 3 and 2a)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 1)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 2)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins I)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVa)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVb)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVc)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Intermediate)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Large)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Small)
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in LDL-C
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
NCT03011450 (114) [back to overview]Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
NCT03510715 (13) [back to overview]Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis
NCT03510715 (13) [back to overview]Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48
NCT03510715 (13) [back to overview]Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand
NCT03510884 (44) [back to overview]OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03515213 (7) [back to overview]Changes in Unified Huntington Disease Rating Scale - Behavioral
NCT03515213 (7) [back to overview]Change in Unified Huntington Disease Rating Scale Motor Score.
NCT03515213 (7) [back to overview]Change in PGC-1alpha RNA Expression
NCT03515213 (7) [back to overview]Change in PGC-1alpha Protein Abundance.
NCT03515213 (7) [back to overview]Change in Montreal Cognitive Assesment Score.
NCT03515213 (7) [back to overview]Change in Functional Assessment Scores
NCT03515213 (7) [back to overview]Change in Fenofibric Acid Level.
NCT03615534 (9) [back to overview]Adverse Events
NCT03615534 (9) [back to overview]Changes in Estimated Glomerular Filtration Rate (eGFR)
NCT03615534 (9) [back to overview]Changes in Serum Apolipoprotein Levels
NCT03615534 (9) [back to overview]Changes in Serum Enzymes Levels
NCT03615534 (9) [back to overview]Changes in Serum Fasting Glucose Levels.
NCT03615534 (9) [back to overview]Changes in Serum Lipoprotein Cholesterol Levels
NCT03615534 (9) [back to overview]Changes in Serum Uric Acid Levels
NCT03615534 (9) [back to overview]Changes in Systolic and Diastolic Blood Pressure
NCT03615534 (9) [back to overview]Changes Serum Triglyceride Levels
NCT03829514 (1) [back to overview]Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry
NCT04517396 (7) [back to overview]Seven-category Ordinal Scale
NCT04517396 (7) [back to overview]Secondary Hierarchical Composite Endpoint
NCT04517396 (7) [back to overview]Primary Hierarchical Composite Endpoint
NCT04517396 (7) [back to overview]Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization
NCT04517396 (7) [back to overview]Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization
NCT04517396 (7) [back to overview]Exploratory Hierarchical Composite Endpoint
NCT04517396 (7) [back to overview]All-Cause Death

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

Pre- and Post-Intervention LDL Cholesterol Levels

Compare the change in mean LDL Cholesterol levels between groups after the interventions (NCT00186537)
Timeframe: Baseline, 12 weeks

,,
Interventionmg/dL (Mean)
pre treatmentpost treatment
Calorie Restricted Diet144128
Fenofibrate114111
Rosiglitazone119129

[back to top]

Pre- and Post-Intervention Triglyceride Levels

Compare the change in mean triglyceride levels between groups after the interventions (NCT00186537)
Timeframe: Baseline, 12 weeks

,,
Interventionmg/dL (Mean)
pre treatmentpost treatment
Calorie Restricted Diet201143
Fenofibrate231140
Rosiglitazone209232

[back to top]

Pre- and Post-Intervention HDL Cholesterol Levels

Compare the change in mean HDL Cholesterol levels between groups after the interventions (NCT00186537)
Timeframe: Baseline, 12 weeks

,,
Interventionmg/dL (Mean)
pre treatmentPost treatment
Calorie Restricted Diet3838
Fenofibrate3536
Rosiglitazone4042

[back to top]

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

[back to top]

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

[back to top]

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

[back to top]

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

[back to top]

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

[back to top]

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

[back to top]

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

[back to top]

Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months

(NCT00252499)
Timeframe: 6 months

InterventionU/L (Mean)
Arm 1-11.5
Arm 2-35.0
Arm 3-15.2

[back to top]

Change in Hepatic Insulin Sensitivity From Baseline to 6 Months

Hepatic insulin sensitivity was determined as the percent suppression of endogenous glucose production (EGP) at the end of the low dose insulin clamp. (NCT00252499)
Timeframe: 6 months

Interventionpercent of baseline EGP (Mean)
Arm 123.3
Arm 2-4.09
Arm 34.91

[back to top]

Change in Peripheral Insulin Sensitivity From Baseline to 6 Months

A two-step stable isotope labeled, hyperinsulinemic-euglycemic clamp procedure was performed with a low dose insulin infusion (20 mU/m2/min) for 3 hours followed by a primed high dose insulin infusion (160 mU/m2/min x 5 minutes then 80 mU/m2/min) for two hours. D20 was infused and adjusted to maintain the blood glucose at 90 mg/dl. Samples for glucose, insulin and 6,6 2d glucose were drawn every 15 minutes during the final half hour of the basal, low dose and high dose insulin periods. Whole body insulin sensitivity was calculated as the rate of glucose disposal (Rd)/lean body mass during the high dose insulin infusion. (NCT00252499)
Timeframe: 6 months

Interventionmg/min/kg (Mean)
Arm 11.65
Arm 20.123
Arm 3-0.24

[back to top]

Changes in Intra-abdominal Fat Area From Baseline to 6 Months

Unenhanced CT scan images were obtained on a General Electric Discovery HD750 CT scanner. Intra-abdominal (IAF) areas were measured at the top of the iliac crest and quantified using the Tomovision program (SliceOMatic V4.3) by one trained technologist. (NCT00252499)
Timeframe: 6 months

Interventionmm2 (Mean)
Arm 1885
Arm 2440
Arm 3108

[back to top]

Liver/Spleen Ratio at 6 Months

Liver fat was estimated by non-contrast CT scan measuring the density ratio between the liver and spleen by Hounsfield units (liver/spleen ratio), which has been previously correlated with liver fat quantification by magnetic resonance spectroscopy.Ten separate measurements equally distributed throughout the liver and spleen were obtained and the Hounsfield units averaged. In subjects with more than one slice through the liver and spleen, the values for all slices were averaged. (NCT00252499)
Timeframe: 6 months

Interventionratio (Mean)
Arm 10.85
Arm 20.96
Arm 30.60

[back to top]

Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver

(NCT00252499)
Timeframe: 6 months

Interventionratio (Mean)
Arm 1.09
Arm 2.34
Arm 3-.16

[back to top]

Change From Baseline in VLDL-Tg Production Rate

VLDL-TG production rate, a measure of hepatic secretion of VLDL-triglyceride per liter of plasma per minute. (NCT00262964)
Timeframe: baseline to end of treatment: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Intervention(μmol/L/min) (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate6.46.0
NAFLD - Niacin7.74.5

[back to top]

Very Low Density Lipoprotein - Triglyceride Production Rate

Very low density lipoprotein triglyceride (VLDL-TG) production rate, a measure of hepatic secretion of VLDL-triglyceride per liter of plasma per minute (μmol/L/min). (NCT00262964)
Timeframe: baseline cross-sectional data

Interventionμmol/L/min (Mean)
NAFLD6.7
Controls3.8

[back to top]

Percent Increase in Skeletal Muscle Insulin Sensitivity During Insulin Infusion.

A precise measure of the ability of insulin to stimulate glucose uptake by skeletal muscle. Skeletal muscle insulin sensitivity, measured as the increase from baseline in skeletal muscle glucose uptake during insulin infusion(percentage)as part of a nine hour euglycemic hyperinsulinemic clamp study. (NCT00262964)
Timeframe: baseline cross-sectional data pre and post nine hour euglycemic clamp

Interventionpercent increase (Mean)
NAFLD173
Controls303

[back to top]

Adipose Tissue Insulin Sensitivity

The ability of insulin to suppress the release of fatty acids from adipose tissue: Adipose tissue insulin sensitivity, measured as the suppression from baseline of free fatty acid release from adipose tissue (lipolysis) during insulin infusion as part of a nine hour euglycemic hyperinsulinemic clamp study. (NCT00262964)
Timeframe: baseline cross-sectional data pre and post nine hour euglycemic clamp

Interventionpercent decrease (Mean)
NAFLD66
Controls75

[back to top]

Hepatic Insulin Sensitivity Index (HISI)

Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration. The Hepatic Insulin Sensitivity Index(HISI) is the reciprocal of glucose rate of appearance [10000/(μmol/min)] multiplied by insulin concentration[mU/L]. The 10000 in the formula is a conventional adjustment so that insulin sensitivity measures are more readable. As yet there is no normal range for HISI, since is a surrogate marker for hepatic insulin sensitivity that has not yet been validated. (NCT00262964)
Timeframe: baseline cross-sectional data

Intervention[10000/(μmol/min)x(mU/L)] (Mean)
NAFLD0.8
Controls1.4

[back to top]

Change From Baseline in Hepatic Insulin Sensitivity Index

Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration. The Hepatic Insulin Sensitivity Index (HISI) is measured as the reciprocal of glucose rate of appearance [10000/(μmol/min)] multiplied by insulin concentration[mU/L]. The 10000 in the formula is a conventional adjustment so that insulin sensitivity measures are more readable. As yet there is no normal range for HISI, since is a surrogate marker for hepatic insulin sensitivity that has not yet been validated. (NCT00262964)
Timeframe: baseline to end of treatment: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Intervention[10000/(μmol/min)x(mU/L)] (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate0.70.8
NAFLD - Niacin0.80.5

[back to top]

Adipose Tissue Insulin Sensitivity in Fenofibrate and Niacin Groups

The baseline and post-treatment measures of adipose tissue insulin sensitivity (ATIS) were compared. ATIS at both timepoints is the suppression from fasting levels of free fatty acid release from adipose tissue (lipolysis) during an insulin infusion as part of a euglycemic clamp study. It is the percent decrease from time zero to the end of the nine hour euglycemic hyperinsulinemic clamp (NCT00262964)
Timeframe: baseline to post intervention: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Interventionpercent decrease (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate6869
NAFLD - Niacin6335

[back to top]

Change From Baseline in Very Low-density Lipoprotein Triglyceride Concentration

Change from baseline in very low-density lipoprotein triglyceride concentration (VLDL-Tg) (NCT00262964)
Timeframe: baseline to end of treatment: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Interventionmmol/l (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate1.090.50
NAFLD - Niacin1.040.64

[back to top]

Change From Baseline in VLDL-Tg Clearance Rate

Very low density lipoprotein triglyceride (VLDL-Tg) clearance rate, a measure of VLDL-triglyceride removal from plasma per minute. (NCT00262964)
Timeframe: baseline to end of treatment: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Intervention(ml/min) (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate3556
NAFLD - Niacin3452

[back to top]

Change From Baseline in Skeletal Muscle Insulin Sensitivity

Changes in skeletal muscle insulin sensitivity (SMIS). SMIS was measured as the increase in skeletal muscle glucose uptake from time zero to the end of a nine hour euglycemic clamp and insulin infusion study. This increase is the percentage change from time zero to end of insulin infusion at nine hours. (NCT00262964)
Timeframe: baseline to end of treatment: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Interventionpercent increase (Mean)
Baseline8 weeks (fenofibrate) or 16 weeks (niacin)
NAFLD - Fenofibrate188169
NAFLD - Niacin183142

[back to top]

Change From Baseline in Very Low Density Lipoprotein Apolipoprotein B Production Rate

VLDL-apolipoprotein B (apoB) concentrations were measured as part of a VLDL metabolism study utilizing stable isotope tracers. VLDL apoB production rate, a measure of hepatic secretion of VLDL-apolipoproteinB-100 per liter of plasma per minute. (NCT00262964)
Timeframe: baseline to post intervention: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Interventionnmol/l/min (Mean)
Baseline8 wk (fenofibrate), 16 wk (niacin)
NAFLD - Fenofibrate0.50.4
NAFLD - Niacin0.40.4

[back to top]

Hepatic Fat Content for Fenofibrate and Niacin Groups

Hepatic fat content as measured by magnetic resonance spectroscopy. A PRESS sequence was used. The results from three 10 cubic centimeter voxels positioned within the liver were averaged. The measure is a ratio of triglyceride signal to total signal. (NCT00262964)
Timeframe: baseline to post intervention: 8 weeks (fenofibrate), 16 weeks (niacin)

,
Interventionratio (Mean)
Baseline8 wk (fenofibrate), 16 wk (niacin)
NAFLD - Fenofibrate23.223.6
NAFLD - Niacin21.019.7

[back to top]

Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 in this open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin-48.8
ABT-335 + 40 mg Simvastatin-36.6
ABT-335 + 40 mg Atorvastatin-44.3

[back to top]

Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin25.2
ABT-335 + 40 mg Simvastatin25.1
ABT-335 + 40 mg Atorvastatin19.4

[back to top]

Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin-41.6
ABT-335 + 40 mg Simvastatin-30.2
ABT-335 + 40 mg Atorvastatin-38.1

[back to top]

Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study

(NCT00300430)
Timeframe: Anytime after initiation of combination therapy (either in the double-blind or open-label study) to within 30 days after the last dose of combination therapy

Interventionpercentage of participants (Number)
ABT-335 + 20 mg Rosuvastatin83
ABT-335 + 40 mg Simvastatin86
ABT-335 + 40 mg Atorvastatin85

[back to top]

Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Median)
ABT-335 + 20 mg Rosuvastatin-53.0
ABT-335 + 40 mg Simvastatin-47.7
ABT-335 + 40 mg Atorvastatin-56.2

[back to top]

Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Median)
ABT-335 + 20 mg Rosuvastatin-38.87
ABT-335 + 40 mg Simvastatin-27.72
ABT-335 + 40 mg Atorvastatin-39.13

[back to top]

Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin-44.8
ABT-335 + 40 mg Simvastatin-35.5
ABT-335 + 40 mg Atorvastatin-42.9

[back to top]

Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin-56.9
ABT-335 + 40 mg Simvastatin-37.7
ABT-335 + 40 mg Atorvastatin-52.2

[back to top]

Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study

(NCT00300430)
Timeframe: Baseline to Week 52 of the open-label study

Interventionpercent change (Mean)
ABT-335 + 20 mg Rosuvastatin-37.9
ABT-335 + 40 mg Simvastatin-27.5
ABT-335 + 40 mg Atorvastatin-35.0

[back to top]

Therapy Completion Rate

Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks

Interventionproportion of patients (Number)
5-drug Metronomic Antiangiogenic Regimen.25

[back to top]

27-Week Overall Survival

27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

InterventionProbability (Number)
5-drug Metronomic Antiangiogenic Regimen0.61

[back to top]

27-Week Progression-Free Survival

27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

InterventionProbability (Number)
5-drug Metronomic Antiangiogenic Regimen0.31

[back to top]

Best Response

As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.

Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot Evaluable
5-drug Metronomic Antiangiogenic Regimen11236471

[back to top]

AUC0-t Total Ezetimibe

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Ezetimibe 10 mg + Lomitapide 10 mg105.71

[back to top]

AUC0-t Simvastatin Acid

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Simvastatin 20 mg + Lomitapide 10 mg138.76

[back to top]

AUC0-t Rosuvastatin (Lomitapide 60 mg)

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg) (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Rosuvastatin 20 mg + Lomitapide 60 mg132.21

[back to top]

AUC0-t Rosuvastatin (Lomitapide 10 mg)

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg) (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Rosuvastatin 20 mg + Lomitapide 10 mg102.05

[back to top]

AUC0-t Simvastatin

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Simvastatin 20 mg + Lomitapide 10 mg162.25

[back to top]

Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Percent change from Baseline in LDL-C (NCT00359281)
Timeframe: Baseline to Day 8

InterventionPercent Change (Mean)
Atorvastatin 20 mg + Lomitapide 10 mg-30.99
Simvastatin 20 mg + Lomitapide 10 mg-26.43
Ezetimibe 10 mg + Lomitapide 10 mg-28.36
Rosuvastatin 20 mg + Lomitapide 10 mg-41.74
Fenofibrate 145 mg + Lomitapide 10 mg-20.12
Atorvastatin 20 mg + Lomitapide 60 mg-66.02
Rosuvastatin 20 mg + Lomitapide 60 mg-63.20
Dextrometh-rophan 30 mg + Lomitapide 60 mg-46.07
ER Niacin 1000 mg + Lomitapide 10 mg-20.89

[back to top]

AUC0-t Nicotinuric Acid

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
ER Niacin 1000 mg + Lomitapide 10 mg79.15

[back to top]

AUC0-t Nicotinic Acid

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
ER Niacin 1000 mg + Lomitapide 10 mg110.22

[back to top]

AUC0-t Fenofibric Acid

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Fenofibrate 145 mg + Lomitapide 10 mg89.62

[back to top]

AUC0-t Atorvastatin Acid (Lomitapide 60 mg)

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg) (NCT00359281)
Timeframe: 0 to 24 hours

InterventionRatio (Geometric Mean)
Atorvastatin 20 mg + Lomitapide 60 mg152.32

[back to top]

Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)

Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg) (NCT00359281)
Timeframe: 0 to 24 hour

InterventionRatio (Geometric Mean)
Atorvastatin 20 mg + Lomitapide 10 mg110.97

[back to top]

IMCL

Intramyocellular lipid was measured using immunohistochemistry (using oil Red O staining) in muscle biopsy specimens. Oil red O-stained muscle sections were magnified with an Olympus Provis (Tokyo, Japan) light microscope, and images were digitally captured by using a connected charge-coupled device camera (Sony, Tokyo, Japan). Fiber-typed and oil red O-stained fibers were matched. The oil red O staining intensity of either type 1 or 2 muscle fibers was quantified using National Institutes of Health Image program (http://rsb.info.nih.gov/nih-image/). By adjusting a density threshold, the software was set to recognize the presence of one fat droplet only if its highlighted surface was exceeding 0.40 μm2 or larger. Muscle lipid content was calculated by total area of lipid droplets in a given muscle fiber divided by the total area of the same fiber. The mean number of fibers analyzed per sample was 40 for type 1 and 2 muscle fibers (NCT00470262)
Timeframe: 3 months

,
Intervention% of lipid area stained (Mean)
prepost
Fenofibrate 145mg PO QD3.673.46
Fenofibrate 145mg PO QD + Pioglitazone 45mg PO BID5.322.82

[back to top]

Insulin Sensitivity

Insulin sensitivity was measure through frequently sampled intravenous glucose tolerance test. Subjects presented to research center fasting. Blood samples were collected at -21, -11, and -1 minutes. At time t=0 initiates the start of the IVGTT and the injection of glucose into the non-sampling arm. The glucose dose was calculated as 11.4g/m2 of body surface area, given as a 50% dextrose solution. This glucose injection was administered over 60 seconds or less. At time t=20 minutes, an insulin dose of 0.04u/kg was administered over 30 seconds. Blood samples were collected at times t=2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 70, 90, 100, 120, 140, 160, and 180. If blood sugar did not return to a steady state the test was continued to t= 210 or t= 240. (NCT00470262)
Timeframe: 3 months

,
Interventionmg*kg^-1*min^-1 (Mean)
prepost
Fenofibrate 145 mg PO QD + Pioglitazone1.732.93
Fenofibrate 145mg PO QD1.481.89

[back to top]

Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy

Mean percent change from baseline to end-of-treatment (12 weeks) for non-HDL cholesterol and triglycerides and the mean percent change from baseline to end-of-treatment for HDL cholesterol for AtorFen 40/100mg fixed-dose combination tablet versus atorvastatin 40mg tablet. (NCT00504829)
Timeframe: baseline(randomization) to 12 weeks

,
Interventionpercent change from baseline (Mean)
non-HDLtriglyceridesHDL
Atorvastatin 40mg-40.2-28.96.5
LCP-AtorFen 40/100mg-44.8-49.119.7

[back to top]

Percent Changes From Baseline to End-of-treatment in Non-HDL, HDL and LDL Cholesterol by LCP-AtorFen Versus Fenofibrate Monotherapy

Mean percent changes from baseline (Visit 3, Week 0) to end-of-treatment (Visit 6; Week 12) in non-HDL, HDL and LDL cholesterol by LCP-AtorFen versus fenofibrate monotherapy (NCT00504829)
Timeframe: baseline (week 0) to 12 weeks

,
Interventionpercent change from baseline (Mean)
non-HDLLDLHDL
Fenofibrate 145mg-16.1-13.918.2
LCP-AtorFen 40/100mg-44.8-42.319.7

[back to top]

Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy

Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4

Interventionparticipants (Number)
Intensive Glycemia Control104
Standard Glycemia Control149
Intensive Blood Pressure Control67
Standard Blood Pressure Control54
Fenofibrate + Simvastatin Therapy52
Placebo + Simvastatin Therapy80

[back to top]

Development or Progression of Macular Edema

(NCT00542178)
Timeframe: Measured at Year 4

InterventionParticipants (Count of Participants)
Intensive Glycemia Control44
Standard Glycemia Control40
Intensive Blood Pressure Control18
Standard Blood Pressure Control20
Fenofibrate + Simvastatin Therapy24
Placebo + Simvastatin Therapy22

[back to top]

Loss of Visual Acuity

(NCT00542178)
Timeframe: Measured at Year 4

InterventionParticipants (Count of Participants)
Intensive Glycemia Control744
Standard Glycemia Control752
Intensive Blood Pressure Control367
Standard Blood Pressure Control382
Fenofibrate + Simvastatin Therapy354
Placebo + Simvastatin Therapy393

[back to top]

Cataract Extraction

(NCT00542178)
Timeframe: Measured at Year 4

InterventionParticipants (Count of Participants)
Intensive Glycemia Control547
Standard Glycemia Control623
Intensive Blood Pressure Control266
Standard Blood Pressure Control300
Fenofibrate + Simvastatin Therapy305
Placebo + Simvastatin Therapy299

[back to top]

Absolute Change From Baseline in Percent Hepatic Fat

Absolute change from Baseline in percent hepatic fat (NCT00559962)
Timeframe: Baseline and 12 weeks on study drug

,
InterventionPercent of Hepatic Fat (Mean)
Placebo0.03
AEGR-733 5 mg4.72
Placebo0.03
AEGR-733 2.5 mg4.95
AEGR-733 5 mg4.72
AEGR-733 7.5 mg3.94
AEGR-733 10 mg7.86
AEGR-733 5 mg + Atorvastatin 20 mg3.68
AEGR-733 5 mg + Fenofibrate 145 mg7.70
AEGR-733 5 mg + Ezetimibe 10 mg7.55

[back to top]

Serum Level of Alkaline Phosphatase

We analyzed whether there was a difference in median ALP at 1 year compared to baseline values. (NCT00575042)
Timeframe: 1 year

InterventionU/L (Median)
Patients Before Treatment With Fenofibrate351
Patients Treated With Fenofibrate175

[back to top]

Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.014
Placebo + Atorvastatin-0.008

[back to top]

Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall and anterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.003
Placebo + Atorvastatin-0.019

[back to top]

Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of the mean posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.010
Placebo + Atorvastatin-0.004

[back to top]

Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)

Rate of change (mm/year) from baseline in mean of posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.006
Placebo + Atorvastatin0.000

[back to top]

Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)

Rate of change (mm/year) from baseline in mean of maximal posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.005
Placebo + Atorvastatin-0.003

[back to top]

Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit

[(Week 12 apoAI minus baseline apoAI)/baseline apoAI] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe1.8
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-1.3

[back to top]

Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit

[(Week 12 apoB minus baseline apoB)/baseline apoB] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-49.1
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-44.7

[back to top]

Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit

[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-42.5
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-25.3

[back to top]

Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit

[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe13.0
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe4.2

[back to top]

Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit

[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-55.6
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-51.0

[back to top]

Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit

[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (final visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-57.8
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-41.1

[back to top]

Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit

[(Week 12 hsCRP minus baseline hsCRP)/baseline hSCRP] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Median)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-52.1
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-40.3

[back to top]

Median Percent Change in Triglycerides From Baseline to Final Visit

[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00639158)
Timeframe: Baseline to 12 Weeks (Final Visit)

InterventionPercent change (Median)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-57.3
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-39.7

[back to top]

Log(ENA-Period 2 End/ENA Period 1 End)

"Log of the ratio of Period end ENA-78 Period 2:Period 1. Once the confidence interval is obtained, we take antilogs to obtain a ratio of effects.~Natural logs used" (NCT00644592)
Timeframe: week 12 to week 4

InterventionLog of Ratio (Mean)
1-Fenofibrate Then Placebo-0.298
2 Placebo Then Fenofibrate0.178

[back to top]

Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment

Mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12 of DB study) to end of treatment (Week 52) (NCT00664859)
Timeframe: 52 weeks from DB baseline and 40 weeks from OL baseline

,,
Interventionpercent change (Mean)
Non-HDL cholesterol, change from DB baselineNon-HDL cholesterol change from OL baselineTriglycerides change from DB baselineTriglycerides change from OL baselineHDL cholesterol change from DB baselineHDL cholesterol change from OL baseline
Atorvastatin 40 mg-43.62.8-51.2-19.116.310.1
Fenofibrate 145 mg-42.0-29.6-42.1-5.217.5-2.4
LCP-AtorFen 40/100mg-48.22.6-53.111.422.12.1

[back to top]

Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment

Mean percent changes in LDL cholesterol, VLDL, total cholesterol, Apo A-1, and Apo B from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12) to end-of-treatment (Week 52) (NCT00664859)
Timeframe: 52 weeks from DB baseline and 40 weeks from OL baseline

,,
InterventionPercent change (Mean)
LDL-C change from DB baselineLDL-C change from OL baselineVLDL-C change from DB baselineVLDL-C change from OL baselineTotal-C change from DB baselineTotal-C change from OL baselineApo A-1 change from DB baselineApo-A-1 change from OL baselineApo B change from DB baselineApo B change from OL baseline
Atorvastatin 40 mg-39.314-51.1-18.7-33.84.61.01.9-38.9-1.5
Fenofibrate 145 mg-40.9-33.6-42.0-5.5-32.8-24.40.4-5.1-36.8-25.5
LCP-AtorFen 40/100mg-44.82.1-53.612.7-36.51.53.2-1.4-42.43.1

[back to top]

Total Cholesterol

Mean Change in total cholesterol from baseline to End-of-treatment (Day 95) (NCT00673881)
Timeframe: 12 weeks

Interventionmg/dL (Mean)
ABT 335-54.0

[back to top]

Mean Change in Plasma Triglycerides

Change in plasma triglyceride, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95) (NCT00673881)
Timeframe: baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-138.0

[back to top]

Mean Change in High Density Lipoprotein Cholesterol

Mean change in plasma high density plasma lipoprotein cholesterol (HDL-C)baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95) (NCT00673881)
Timeframe: Baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-1.6

[back to top]

Mean Change in Calculated Low Density Lipoprotein Cholesterol

Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95) (NCT00673881)
Timeframe: baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-22.7

[back to top]

Change in Weight

(NCT00794963)
Timeframe: baseline and 8 months

Interventionpounds (Mean)
Integrated Care11

[back to top]

Index of Hypopneas

Average number of hypopneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber per hour of sleep (Median)
Placebo11.0
Fenofibrate9.5

[back to top]

Sleep Time With Oxygen Saturation Below 90%

Percentage of Sleep time with oxygen saturation below 90% (measured by oximetry). Marker of consequences of apneas/hypopneas on arterial oxygenation during sleep during one night after one month of treatment. Higher percentage are worst for the patients. (NCT00816829)
Timeframe: at one month of treatment

InterventionPercentage of sleep time (Median)
Placebo11.5
Fenofibrate3.5

[back to top]

Obstructive Apneas

Total number of obstructive apneas during sleep during one night after one month of treatment (i.e. an occlusion of the airways accompanied by ineffective respiratory efforts). (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of obstructive apneas (Median)
Placebo30.5
Fenofibrate15.0

[back to top]

Mixed Apneas

Total number of mixed apneas (i.e. sleep apneas that have both obstructive and central component) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of mixed apneas (Median)
Placebo0.0
Fenofibrate1.0

[back to top]

Central Apneas

Total number of central apneas (i.e. apneas with no respiratory effort present) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of central apneas (Median)
Placebo0.0
Fenofibrate1.0

[back to top]

Desaturations

Total number of desaturation events (i.e. defined as a decrease by 3 - 4% in oxygen saturation) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of desaturations (Median)
Placebo171.0
Fenofibrate130.0

[back to top]

Hypopneas

Total number of episodes of hypopneas (i.e. 50% to 80% reduction in airflow with a decrease of 3-4% in arterial oxygen saturation) during sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of hypopneas (Median)
Placebo69.5
Fenofibrate63.0

[back to top]

Index Apnea/Hypopnea

Average number of apneas and/or hypopneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber per hour of sleep (Median)
Placebo22.5
Fenofibrate17.0

[back to top]

Index of Apneas

Average number of apneas per hour of sleep during one night after one month of treatment. (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber per hour of sleep (Median)
Placebo4.0
Fenofibrate2.5

[back to top]

Apneas

Total number of episodes of apneas (i.e. cessation of breathing for at least 10 seconds) from central, obstructive or mixed origin during sleep during one night after one month of treatment (NCT00816829)
Timeframe: at one month of treatment

InterventionNumber of apneas (Median)
Placebo31.0
Fenofibrate20.5

[back to top]

Percent Change in Triglyceride (TG) Levels Post Treatment

The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone + Placebo7.4
Fenofibrate + Placebo-2.2
Rosiglitazone +Fenofibrate20
Placebo Therapy Daily7.6

[back to top]

Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels

The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone and Placebo1.9
Fenofibrate + Placebo14.5
Rosiglitazone +Fenofibrate5.8
Placebo Therapy Daily1.7

[back to top]

Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels

Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

,,,
Intervention% Change (Median)
Apo AIApo AIIApo CIII
Fenofibrate + Placebo133.4-4.35
Placebo Therapy Daily5-3.5-2.3
Rosiglitazone + Placebo-1.0010.250.30
Rosiglitazone +Fenofibrate17.2-5.3

[back to top]

Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit

The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

,,,
Interventionmg/dl (Mean)
AST 1 (aspartate aminotransferase [10-35 U/L])AST 12 (aspartate aminotransferase [15-37 U/L])ALT 1 (alanine aminotransferase [6-60 U/L])ALT 12 (alanine aminotransferase [6-60 U/L])
Fenofibrate + Placebo25.2526.5025.8826.38
Placebo Therapy Daily19.8817.8820.8814.88
Rosiglitazone + Placebo24.0030.2928.1427.43
Rosiglitazone +Fenofibrate24.3019.7024.1021.10

[back to top]

Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels

The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone + Placebo-0.5
Fenofibrate + Placebo2.6
Rosiglitazone + Fenofibrate37.3
Placebo Therapy Daily13.7

[back to top]

HDL-cholesterol Measured During High Salt Fenofibrate in Salt-resistant and Salt-sensitive Hypertension

HDL-cholesterol concentration measured on the last day of fenofibrate treatment in salt-resistant and salt-sensitive hypertensive patients (NCT00872599)
Timeframe: Measured on day 6 of high salt intake and fenofibrate treatment

Interventionmg/dL (Mean)
Salt-resistant Hypertension54.1
Salt-sensitive Hypertension52.1

[back to top]

Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment

"Difference in blood pressure (mean arterial pressure) measured on the last day of high salt intake and fenofibrate treatment minus blood pressure (mean arterial pressure) measured during high salt intake and placebo treatment in participants classified as being salt-sensitive versus salt-resistant.~Participants were classified as salt-sensitive if the average study day mean arterial pressure (MAP) was at least 5 mmHg higher during the high salt placebo arm than during low salt intake." (NCT00872599)
Timeframe: pressure measured on day 6 of high salt fenofibrate minus pressure measured on day 6 of high salt placebo

Interventionmm Hg (Mean)
Salt-resistant Hypertension2.0
Salt-sensitive Hypertension-3.4

[back to top]

Percent Change in Apo A-1 From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study

Median Percent Change in apolipoprotein (apo) A-1 from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of apo A-1 from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate1.72.9

[back to top]

Percent Change in VLDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)

Median Percent Change in very low density lipoprotein-cholesterol (VLDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of VLDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-58.3-54.6

[back to top]

Percent Change in Total Cholesterol From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study).

Median Percent Change in Total Cholesterol (Total-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of Total-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-6.7-13.2

[back to top]

Percent Change in Serum Triglycerides From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension).

Median Percent Change in Serum Triglycerides from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of Serum Triglycerides from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-60.6-62.0

[back to top]

Percent Change in Ratio of Total-C:HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Ext. Study)

Median Percent Change in the ratio of total cholesterol (Total-C) to high density lipoprotein-cholesterol (HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change for the ratio of Total-C to HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-4.80

[back to top]

Percent Change in Non-HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)

Median Percent Change of non- high density lipoprotein-cholesterol (non-HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of non-HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-7.2-13.3

[back to top]

Percent Change in LDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)

Median Percent Change in low density lipoprotein-cholesterol (LDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of LDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate52.837.5

[back to top]

Percent Change in HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)

Median Percent Change in high density lipoprotein-cholesterol (HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate-3.0-11.1

[back to top]

Percent Change in Apo B From LOV111859/OM5 (Double-blind [DB[ Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)

Median Percent Change in apolipoprotein (apo) B from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of apo B from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24

InterventionPercentage change (Median)
LOV111859/OM5 Baseline to LOV111860/OM5X EOTLOV111859/OM5 Baseline to LOV111821/OM5XX EOT
Lovaza (Formerly Known as Omacor) and Fenofibrate0.0-7.3

[back to top]

Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid

(NCT00928694)
Timeframe: Predose and up to 168 hours postdose

Interventionμg·hr/mL (Least Squares Mean)
U.S. Formulation (TRICOR™)116
UK Formulation (SUPRALIP™)121

[back to top]

Maximum Plasma Concentration (Cmax) of Fenofibric Acid

(NCT00928694)
Timeframe: Predose and up to 168 hours postdose

Interventionμg/mL (Least Squares Mean)
U.S. Formulation (TRICOR™)6.35
UK Formulation (SUPRALIP™)6.48

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00960687)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng/mL (Mean)
Fenofibric Acid 105 mg Tablets8,545.50
Fenofibrate 145 mg Tablets9,456.66

[back to top]

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00960687)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Fenofibric Acid 105 mg Tablets134,576.33
Fenofibrate 145 mg Tablets146,847.53

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00960687)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Fenofibric Acid 105 mg Tablets121,974.07
Fenofibrate 145 mg Tablets132,463.37

[back to top]

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00960856)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Low-fat Meal - Treatment A145,827.10
Standard Meal - Treatment B148,367.21
High-Fat, High-Calorie Meal - Treatment C148,488.53
Fasted - Treatment D152,571.61

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00960856)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

Interventionng/mL (Mean)
Low-fat Meal - Treatment A9,806.74
Standard Meal - Treatment B9,854.39
High-Fat, High-Calorie Meal - Treatment C7,950.75
Fasted - Treatment D12,061.67

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00960856)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

Interventionng-hr/mL (Mean)
Low-fat Meal - Treatment A132,636.84
Standard Meal - Treatment B134,928.11
High-Fat, High-Calorie Meal - Treatment C134,814.42
Fasted - Treatment D139,975.28

[back to top]

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. (NCT00961116)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Fenofibric Acid 105 mg Tablets176,816.78
Fenofibrate 145 mg Tablets188,331.49

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. (NCT00961116)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng/mL (Mean)
Fenofibric Acid 105 mg Tablets12,344.00
Fenofibrate 145 mg Tablets10,940.05

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT00961116)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Fenofibric Acid 105 mg Tablets159,866.23
Fenofibrate 145 mg Tablets170,727.10

[back to top]

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that the drug reaches in the plasma. For the dosing group, Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg), the Cmax values were dose-adjusted in order to assess pharmacokinetic linearity. (NCT00961259)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

Interventionng/mL (Mean)
Fenofibric Acid 35 mg (1 x 35 mg Tablet) - Treatment A3,569.47
Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg)10,708.40
Fenofibric Acid 105 mg (3 x 35 mg Tablet) - Treatment B11,014.93
Fenofibric Acid 105 mg (1 x 105 mg Tablet) - Treatment C11,202.87

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. For the dosing group, Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg), the [AUC(0-t)] values were dose-adjusted in order to assess pharmacokinetic linearity. (NCT00961259)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

Interventionng-hr/mL (Mean)
Fenofibric Acid 35 mg (1 x 35 mg Tablet) - Treatment A49,419.89
Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg)148,259.66
Fenofibric Acid 105 mg (3 x 35 mg Tablet) - Treatment B131,976.95
Fenofibric Acid 105 mg (1 x 105 mg Tablet) - Treatment C135,119.10

[back to top]

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant. For the dosing group, Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg), the AUC(0-∞) values were dose-adjusted in order to assess pharmacokinetic linearity. (NCT00961259)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

Interventionng-hr/mL (Mean)
Fenofibric Acid 35 mg (1 x 35 mg Tablet) - Treatment A58,304.35
Fenofibric Acid 35 mg (35 mg Dose-adjusted to 105 mg)174,913.04
Fenofibric Acid 105 mg (3 x 35 mg Tablet) - Treatment B142,858.88
Fenofibric Acid 105 mg (1 x 105 mg Tablet) - Treatment C147,555.58

[back to top]

Changes in Inflammatory Parameter (Plasma TNF-α Levels) After Treatment With Fenofibrate or Placebo.

(NCT01048502)
Timeframe: baseline and 6-8 weeks

,
Interventionpg/mL (Median)
TNF-α at randomizationTNF-α 6-8 weeks post randomization
Fenofibrate (Tricor) (145 mg/Day)1.21.1
Placebo1.50.2

[back to top]

The Effect of Omega-3 Fatty Acid Supplementation on Cytokine Production (Plasma Levels of TNFα) During an in Vivo Inflammatory Challenge (LPS).

(NCT01048502)
Timeframe: randomization and 8 weeks post

,,
Interventionpg/mL (Median)
TNF-α at randomizationTNF-α 8 weeks post randomization
Lovaza (3,600 mg/Day)1.140.99
Lovaza (900 mg/Day)1.261.25
Placebo0.951.12

[back to top]

Serum Alkaline Phosphatase

Serum alkaline phosphatase will be measured at entry and end of study (NCT01142323)
Timeframe: 6 months

InterventionU/L (Median)
Baseline290
At 6 Months165

[back to top]

Mayo Risk Score for Primary Sclerosing Cholangitis

"The Mayo risk score (MRS), which is a composite of several variables (age, bilirubin, albumin, aspartate aminotransferase[AST] and h/o variceal bleeding), will be measured at entry and end of study. The MRS is a mathematically calculated risk score.~MRS does not have a theoretical lower/upper bound (that is, no theoretical minimum and maximum values).~Mayo risk score <=0 indicates low risk of death. MRS between 0 and 2 indicates intermediate risk, and greater than 2 indicates high risk.~There is no known range for this score." (NCT01142323)
Timeframe: 6 months

Interventionscore (Median)
BaselineAfter 6 months
Fenofibrate-0.41-0.46

[back to top]

Aspartate Aminotransferase (AST)

AST levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventioninternational units/liter (Mean)
Baseline Aspartate AminotransferaseFollow-up Aspartate Aminotransferase
Control27.5926.36
Intervention27.4825.5

[back to top]

Triglyceride Levels

Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventionmilligram/deciliter (Mean)
Baseline Triglyceride LevelsFollow-Up Triglyceride Levels
Control108.3109
Intervention135.5152.7

[back to top]

Serum Creatinine(SCr)

SCr levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventionmilligram/deciliter (Mean)
Baseline Serum CreatinineFollow-up Serum Creatinine
Control1.141.13
Intervention0.98801

[back to top]

Low-density Lipoprotein (LDL)

LDL levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventionmilligram/deciliter (Mean)
Baseline Low-density lipoproteinFollow-up Low-density lipoprotein
Control83.2978.71
Intervention95.3284.42

[back to top]

High-density Lipoprotein,(HDL)

HDL levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventionmilligram/deciliter (Mean)
Baseline High-density lipoproteinFollow-up High-density lipoprotein
Control41.7938.79
Intervention41.8843.21

[back to top]

Alanine Aminotransferase(ALT)

ALT levels will be assessed in study participants 6-10 weeks after entry into study. (NCT01280604)
Timeframe: 6-10 weeks

,
Interventioninternational units/liter (Mean)
Baseline Alanine aminotransferaseFollow-up Alanine aminotransferase
Control30.6629.96
Intervention29.7627.38

[back to top]

Change in Peripheral Insulin Sensitivity

Change in the rate of glucose disposal (Rd) during the low dose clamp. During a clamp procedure, insulin is infused at a dose based on body size and a glucose solution is infused and the rate adjusted every 5 minutes based on a blood glucose reading to maintain the blood glucose stable at 90 mg/dl (normal level). Using glucose isotopes and the rate of the glucose infusion, we are then able to calculate how much glucose the liver is producing and how much glucose is being taken up into tissues. This provides a measure of insulin sensitivity. (NCT01289639)
Timeframe: 0-6 months

Interventionmg/minute/kg lean mass (Mean)
Arm 10.21
Arm 2-0.42

[back to top]

Change in Hepatic Insulin Sensitivity

Hepatic insulin sensitivity was determined using stable glucose isotope measurements during the low dose hyperinsulinemic euglycemic clamp to determine the rate of endogenous glucose production in the fasting state and in response to a low dose glucose infusion. The ability of insulin to suppress glucose, which is mainly produced by the liver, thus provides a measure of hepatic insulin sensitivity and is expressed as a percentage of the basal state. Change in the ability of low dose insulin to suppress endogenous glucose production during a labeled hyperinsulinemic euglycemic clamp. (NCT01289639)
Timeframe: 0-6 months

Intervention% change from baseline (Mean)
Arm 123.3
Arm 24.9

[back to top]

Change in Alanine Aminotransferase (ALT) Levels

(NCT01289639)
Timeframe: 0-6 months

InterventionU/L (Mean)
Arm 1-11.5
Arm 2-15.2

[back to top]

Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan

(NCT01289639)
Timeframe: 6 months

Interventionratio (Mean)
Arm 1.85
Arm 2.60

[back to top]

Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT

(NCT01289639)
Timeframe: 0-6 months

Interventionratio (Mean)
Arm 1.09
Arm 2-0.16

[back to top]

Change in Intra-abdominal Fat Area by CT Scan

(NCT01289639)
Timeframe: 0-6 months

Interventionmm2 (Mean)
Arm 1885
Arm 2108

[back to top]

Change in Triglycerides

Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-65
Arm B: Fenofibrate-54

[back to top]

Men: Change in HDL Cholesterol

Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin3
Arm B: Fenofibrate6.5

[back to top]

Absolute Change in Relative FMD (%)

The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Intervention% FMD (Median)
Arm A: Extended-release Niacin With Aspirin0.60
Arm B: Fenofibrate0.50

[back to top]

Change in C-reactive Protein (CRP)

Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin-0.6
Arm B: Fenofibrate0.7

[back to top]

Women: Change in HDL Cholesterol

Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin16
Arm B: Fenofibrate8

[back to top]

Change in IL-6

Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionpg/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.1
Arm B: Fenofibrate0.2

[back to top]

Change in Cholesterol

Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-9
Arm B: Fenofibrate-2

[back to top]

Change in D-Dimer

Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.06
Arm B: Fenofibrate0.06

[back to top]

Change in HOMA-IR

Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks

InterventionHOMA IR Score (Median)
Arm A: Extended-release Niacin With Aspirin1.3
Arm B: Fenofibrate0.3

[back to top]

Change in HDL Particles

Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-1.7
Arm B: Fenofibrate4.3

[back to top]

Change in Large HDL Particles

Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin0.9
Arm B: Fenofibrate-0.3

[back to top]

Change in LDL Cholesterol

Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-1
Arm B: Fenofibrate7

[back to top]

Change in Non-HDL Cholesterol

Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-17
Arm B: Fenofibrate-4

[back to top]

Change in Small LDL Particles

Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-176
Arm B: Fenofibrate-119

[back to top]

Change in Serum Creatine Kinase

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of CK change (Median)
Fenofibrate Arm8.02

[back to top]

Change in Serum Creatinine

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of Creatinine change (Median)
Fenofibrate Arm12.99

[back to top]

Change in Serum High-density Lipoprotein Cholesterol

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of HDL-C change (Mean)
Fenofibrate Arm17.40

[back to top]

Change in Serum Low-density Lipoprotein Cholesterol

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of LDL-C change (Mean)
Fenofibrate Arm14.91

[back to top]

Change in Serum Non-high-density Lipoprotein Cholesterol

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of Non-HDL-C change (Mean)
Fenofibrate Arm-1.30

[back to top]

Change in Serum Total Cholesterol

Blood tests (NCT01462877)
Timeframe: Baseline and up to 8 weeks after intervention

Interventionpercentage of TC change (Mean)
Fenofibrate Arm2.75

[back to top]

Percentage of Triglyceride (TG) Change

Blood tests (NCT01462877)
Timeframe: Baseline and up to 8 weeks after intervention

Interventionpercentage of TG change (Mean)
Fenofibrate Arm-38.12

[back to top]

Change in Serum Alanine Aminotransferase

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of ALT change (Median)
Fenofibrate Arm0.00

[back to top]

Change in Serum Apolipoprotein A1

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of apoA1 change (Mean)
Fenofibrate Arm12.41

[back to top]

Change in Serum Apolipoprotein B

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of apoB change (Mean)
Fenofibrate Arm2.42

[back to top]

Change in Serum Aspartate Aminotransferase

Blood tests (NCT01462877)
Timeframe: Baseline up to 8 weeks after intervention

Interventionpercentage of AST change (Median)
Fenofibrate Arm10.91

[back to top]

Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)

Collection and measurement of blood samples. (NCT01674712)
Timeframe: from baseline to 12 weeks of treatment

Interventionpercentage of change (Mean)
Fenofibrate/Simvastatin 145/20 mg9.0
Simvastatin 20 mg0.3
Fenofibrate/Simvastatin 145/40 mg8.8
Simvastatin 40 mg2.2
Fenofibrate 145 mg7.6

[back to top]

Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)

Collection and measurement of blood samples. (NCT01674712)
Timeframe: from baseline to 12 weeks of treatment

Interventionpercentage of change (Mean)
Fenofibrate/Simvastatin 145/20 mg1.9
Simvastatin 20 mg-2.0
Fenofibrate/Simvastatin 145/40 mg-6.1
Simvastatin 40 mg-8.1
Fenofibrate 145 mg30.3

[back to top]

Percentage of Change of TG (Triglyceride)

Collection and measurement of blood samples. (NCT01674712)
Timeframe: from baseline to 12 weeks of treatment

Interventionpercentage of change (Mean)
Fenofibrate/Simvastatin 145/20 mg-30.6
Simvastatin 20 mg10.7
Fenofibrate/Simvastatin 145/40 mg-27.3
Simvastatin 40 mg-2.9
Fenofibrate 145 mg-21.6

[back to top]

Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent

Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline. (NCT01752842)
Timeframe: Baseline and 12 weeks

Interventionpercent (Mean)
Fenofibrate0.025
Placebo for Fenofibrate0.030

[back to top]

Change in Cardiac Diastolic Function as Measured by E' (cm/s)

Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline. (NCT01752842)
Timeframe: Baseline and 12 weeks

Interventioncm/s (Mean)
Fenofibrate-0.02
Placebo for Fenofibrate0.55

[back to top]

Change in C24:0/C16:0 Ceramide Ratio

Mass spectrometry-based quantification of the ratio of C24:0 ceramide to C16:0 ceramide in plasma. (NCT01752842)
Timeframe: Baseline and 12 weeks

Interventionratio (Mean)
Fenofibrate-1.6
Placebo for Fenofibrate-0.03

[back to top]

Number of Subjects Experiencing Adverse Events

To evaluate safety and tolerability of fenofibrate therapy in patients with multiple myeloma. (NCT01965834)
Timeframe: Up to 8 months

Interventionparticipants (Number)
Fenofibrate Therapy5

[back to top]

Proportion of Participants Achieving Progression-Free Survival

Proportion of participants achieving progression-free survival. Measured from date of initiation of treatment (Day 1) to the earliest occurrence of any of the following events: documented disease progression, or death from any cause. Patients who are alive and progression-free will be censored at the date of last documented progression-free status. (NCT01965834)
Timeframe: 6 months, 12 months

Interventionparticipants (Number)
6 months12 months
Fenofibrate Therapy00

[back to top]

Rate of Response in Participants Receiving Fenofibrate Therapy

To determine response rate (Strict Complete Response (sCR), Complete response (CR), Very Good Partial Response (VgPR), and Partial Response (PR)) in multiple myeloma patients receiving oral fenofibrate therapy. Response will be measured by serum and urine protein electrophoresis and immunofixation, as well as by percentage of plasma cells present on bone marrow biopsy. (NCT01965834)
Timeframe: After two cycles, about 2 months

Interventionparticipants (Number)
Strict Complete Response (sCR)Complete response (CR)Very Good Partial Response (VgPR)Partial Response (PR)
Fenofibrate Therapy0000

[back to top]

Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period

The four Visual Analog Scale (VAS) questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. Each VAS scale item score ranges from 1-20 where a one indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four VAS item scores (i.e. Intent, Impulse, Relief, Strength) and ranges in value from 4-80 with higher scores indicative of a worse outcome. (NCT02158273)
Timeframe: 1 week following administration of fenofibrate

,
Interventionunits on a scale (Mean)
StrengthIntentImpulseReliefTotal
Fenofibrate8.949.836.876.9232.56
Placebo10.3711.036.988.8637.24

[back to top]

Change From Baseline in Standard Drinks Per Week at 1 Week

Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 1 - Baseline). More negative values indicate less use of alcohol. (NCT02158273)
Timeframe: 1 week

,
Interventiondrinks/week (Mean)
Drinks/week BaselineDrinks/week Week 1Drinks/week Change
Fenofibrate51.2131.77-19.44
Placebo47.2228.24-18.98

[back to top]

Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate)

To evaluate the efficacy of Epanova compared to Fenofibrate with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. (NCT02354976)
Timeframe: 12 weeks

Interventionratio of % liver fat (Geometric Mean)
Epanova0.98
Fenofibrate1.17

[back to top]

Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)

To evaluate the efficacy of Epanova compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. (NCT02354976)
Timeframe: Baseline and 12 weeks

Interventionratio of % liver fat (Geometric Mean)
Epanova0.98
Placebo1.04

[back to top]

Triglyceride Concentration (Percent Change From Baseline)

To determine the efficacy of fenofibrate monotherapy to lower TG concentration at 4 months of treatment, when the peak therapeutic efficacy to drug treatment has been reported to occur. (NCT02455336)
Timeframe: four months from initiating drug treatment

Interventionpercent change from baseline (Mean)
Fenofibrate-40
No Intervention7

[back to top]

Triglyceride Concentration (Percent Change From Baseline)

To determine the efficacy of fenofibrate monotherapy after 2 months of treatment to improve the lipoprotein profile; a successful response will be defined as a 25% reduction in the serum TG concentration at 2 months. (NCT02455336)
Timeframe: two months from initiating drug treatment

Interventionpercent change from baseline (Mean)
Fenofibrate-40
No Intervention-2

[back to top]

Adverse Event Profile

Documentation and description of adverse events will be obtained in subjects who have received drug treatment compared to events occurring in the control group. (NCT02455336)
Timeframe: 4 months

,
InterventionParticipants (Count of Participants)
Elevated liver enzymesGastrointestinal discomfort
Fenofibrate22
No Intervention00

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis). (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-37.3
Usual Care-4.7

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.7
Usual Care: Intent to Prescribe Fenofibrate-8.5

[back to top]

Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis

Absolute change = HbA1c value at specified week minus HbA1c value at baseline. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
Interventionmmol/mol (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.592.84
Usual Care0.432.40

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-35.5
Usual Care-9.4

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-34.7
Usual Care: Intent to Prescribe Fenofibrate-7.3

[back to top]

Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-43.3
Usual Care-0.3

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-47.0
Usual Care: Intent to Prescribe Fenofibrate8.7

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.7
Usual Care-7.0

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-44.3
Usual Care: Intent to Prescribe Fenofibrate5.4

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-18.9
Usual Care: Intent to Prescribe Fenofibrate3.9

[back to top]

Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W13.5
Usual Care: Intent to Prescribe Fenofibrate12.3

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis

Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were included in the imputation model. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-23.7
Usual Care3.7

[back to top]

Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis

LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.6
Usual Care-3.9

[back to top]

Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

LDL-C particle number was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-45.4
Usual Care: Intent to Prescribe Fenofibrate-2.9

[back to top]

Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W14.5
Usual Care8.2

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-13.0
Usual Care-8.8

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-15.4
Usual Care: Intent to Prescribe Fenofibrate-24.4

[back to top]

Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-33.8
Usual Care-1.6

[back to top]

Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-38.9
Usual Care: Intent to Prescribe Fenofibrate-3.8

[back to top]

Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis

Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified week minus baseline value. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
InterventionGlucose lowering treatments (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.040.07
Usual Care0.040.04

[back to top]

Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis

Absolute change = FPG value at specified week minus FPG value at baseline. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
Interventionmmol/L (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.450.68
Usual Care0.210.03

[back to top]

Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-30.9
Usual Care: Intent to Prescribe Fenofibrate-5.7

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-27.4
Usual Care-2.8

[back to top]

Percent Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-4.0
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-7.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg14.5
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg19.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-3.1
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-32.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-7.1

[back to top]

Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmilligram per deciliter (mg/dL) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-83.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-27.6
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-55.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-88.3
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-32.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg0.1
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-55.9
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-104.3

[back to top]

Absolute Change From Baseline in Apolipoprotein B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-51.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-18.5
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-35.3
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-53.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-15.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-5.4
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-34.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-63.5

[back to top]

Absolute Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg17.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg11.3
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg10.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg8.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg7.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg11.0

[back to top]

Absolute Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmmol/L (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.121
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.076
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg0.168
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg0.111
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg0.117
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.045
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.402
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.107

[back to top]

Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: At Week 8

Interventionpercentage of participants (Number)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg100.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg33.3
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg97.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg83.0
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg33.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg20.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg66.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg80.0

[back to top]

Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: At Week 8

Interventionpercentage of participants (Number)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg0.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg0.0
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg93.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg65.7
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg16.7
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg20.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg66.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg80.0

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-29.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-4.1
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-28.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-34.2
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-10.7
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.2
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-24.0
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-41.8

[back to top]

Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-39.6
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-7.1
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-39.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-43.9
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-14.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg3.2
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-31.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-54.6

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.5
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-26.9
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg1.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-25.2
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg2.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-7.7
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg0.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-7.7

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg9.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg16.5
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg14.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg10.6
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg5.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg13.8
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg4.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg2.8

[back to top]

Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Percent change in calculated LDL-C was defined as 100*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period & within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 & 2) or +35 days (for Cohorts 3 & 4). Adjusted Least-squares (LS) mean & standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W [<50 kg], 40 mg Q2W [<50 kg], 50 mg Q2W [>=50 kg], 75 mg Q2W [>=50 kg], 75 mg Q4W [<50 kg],150 mg Q4W [>=50 kg], 150 mg Q4W [<50 kg] and 300 mg Q4W ([>=50 kg] dose), time point & dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-41.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-7.9
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-40.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-49.8
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-17.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg4.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-31.9
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-59.8

[back to top]

Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4

Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-29.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-49.2

[back to top]

Percent Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg14.8
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg10.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg1.8
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg8.9
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg7.4
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg5.8
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg7.2

[back to top]

Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-38.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-9.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-36.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-40.1
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-12.6
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.9
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-27.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-51.4

[back to top]

Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-80.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-20.8
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-57.1
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-84.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-27.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.3
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-60.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-105.1

[back to top]

Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.363
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.262
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-0.370
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.402
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-0.190
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.086
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.282
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.473

[back to top]

Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-86.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-28.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-62.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-88.5
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-29.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.6
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-63.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-106.4

[back to top]

Absolute Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventiongram/Liter (g/L) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg0.003
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.021
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg0.007
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.025
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg0.023
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.031
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.002
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.120

[back to top]

Absolute Change From Baseline in HDL-C at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg5.9
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg7.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg5.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg4.9
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg2.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.9
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg2.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg1.2

[back to top]

PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Tmax is defined as the time (observed time point) of Cmax. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionhours (Median)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg1.001.50
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg1.001.00
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg1.001.00
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg1.001.50
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg2.502.50
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg1.502.00

[back to top]

PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Intervention1/hour (Mean)
FirsocostatGS-834773
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg0.0960.105
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg0.1360.209
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg0.1930.300
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg0.0770.103
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg0.1320.133
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg0.1550.214

[back to top]

PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Intervention1/hour (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg0.034
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg0.038

[back to top]

PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Tmax is defined as the time (observed time point) of Cmax. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionhours (Median)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg3.00
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg2.50

[back to top]

PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Vz/F is defined as the apparent volume of distribution of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
InterventionmL (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg2896998.515576712.2
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg2846198.819236747.1
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg592810.82126366.5
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg3797739.423635388.6
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg3079474.820312673.6
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg230242.5501512.3

[back to top]

PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Vz/F is defined as the apparent volume of distribution of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
InterventionmL (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg25908.5
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg28290.3

[back to top]

PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

AUCinf is defined as the concentration of drug extrapolated to infinite time. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionhr*ng/mL (Mean)
FirsocostatGS-834773
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg686.6399.0
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg65.85.9
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg10.61.6
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg313.6155.9
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg165.248.5
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg70.58.2

[back to top]

PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionpercentage of AUC (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg7.11
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg5.38

[back to top]

PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Tlast is defined as the time (observed time point) of Clast. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionhours (Median)
FirsocostatGS-834773
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg24.0012.00
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg72.0048.02
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg24.0011.00
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg16.007.00
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg48.0036.04
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg24.0024.00

[back to top]

PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Tlast is defined as the time (observed time point) of Clast. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionhours (Median)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg96.00
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg84.25

[back to top]

PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionhours (Median)
FirsocostatGS-834773
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg11.2012.82
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg5.043.28
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg3.932.49
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg9.548.51
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg5.235.24
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg4.393.32

[back to top]

PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionhours (Median)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg21.33
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg18.27

[back to top]

PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Cmax is defined as the maximum observed concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionng/mL (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg50.912.9
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg25.42.3
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg197.777.3
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg20.11.4
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg3.00.5
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg73.831.3

[back to top]

PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Cmax is defined as the maximum observed concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionng/mL (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg2723.0
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg2451.0

[back to top]

PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Clast is defined as the last observed quantifiable concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionng/mL (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg0.200.11
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg0.100.12
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg0.260.18
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg0.100.11
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg0.080.07
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg0.230.22

[back to top]

PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

Clast is defined as the last observed quantifiable concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionng/mL (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg133.04
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg90.71

[back to top]

PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

CL/F is defined as the apparent oral clearance following administration of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
InterventionmL/hour (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg259318.91467352.6
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg376896.23966285.6
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg59482.2239748.5
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg395572.34795605.6
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg509793.44656562.3
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg16969.744379.6

[back to top]

PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

CL/F is defined as the apparent oral clearance following administration of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
InterventionmL/hour (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg909.4
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg1060.8

[back to top]

PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

AUCinf is defined as the concentration of drug extrapolated to infinite time. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionhr*ng/mL (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg65530.7
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg50754.1

[back to top]

PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionpercentage of AUC (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg2.547.16
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg1.3613.16
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg0.631.71
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg1.9213.59
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg4.6825.94
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg1.352.21

[back to top]

Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,,,,,
Interventionhr*ng/mL (Mean)
FirsocostatGS-834773
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg160.646.2
Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg69.87.4
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg682.1395.8
Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg64.55.1
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg10.21.4
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg310.4153.3

[back to top]

Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)

AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4). (NCT02891408)
Timeframe: Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)

,
Interventionhr*ng/mL (Mean)
Fenofibric Acid
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg61207.4
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg48128.0

[back to top]

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)

"Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following:~Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates are the same, the AE will be considered treatment emergent.~Any AEs leading to premature discontinuation of study drug." (NCT02891408)
Timeframe: First dose date plus 30 days

Interventionpercentage of participants (Number)
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg20.0
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg10.0
Cohort 1 & 2 (Normal Hepatic Function): Firsocostat 20 mg7.1
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg30.0
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg10.0
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg0
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg10.0

[back to top]

Percentage of Participants Experiencing Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. The most severe graded abnormality from all tests was counted for each participant. (NCT02891408)
Timeframe: First dose date plus 30 days

InterventionPercentage of participants (Number)
Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg100.0
Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg90.0
Cohort 1 & 2 (Normal Hepatic Function): Firsocostat 20 mg50.0
Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg100.0
Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg50.0
Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg90.0
Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg60.0

[back to top]

Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmm^3 (Mean)
Standard of Care-8.23
Alirocumab-10.01

[back to top]

Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 12, Week 36

,
Interventionmg/dL (Least Squares Mean)
Week 12Week 36
Alirocumab-62.4-63.2
Standard of Care-9.6-15.5

[back to top]

Number of Participants With Cardiovascular (CV) Adverse Events

The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure. (NCT02984982)
Timeframe: Up to 36 weeks

,
InterventionParticipants (Count of Participants)
Cardiovascular deathMyocardial infarctionIschemic strokeUnstable angina requiring hospitalizationCongestive heart failure requiring hospitalizationIschemia led coronary revascularization procedure
Alirocumab022004
Standard of Care030002

[back to top]

Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 12, Week 36

,
Interventionpercent change (Least Squares Mean)
Week 12Week 36
Alirocumab-64.53-63.94
Standard of Care-7.57-13.40

[back to top]

Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Mean)
Standard of Care-10.3
Alirocumab-15.5

[back to top]

Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-16.8
Alirocumab-51.0

[back to top]

Percent Change From Baseline in Total Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-7.59
Alirocumab-35.43

[back to top]

Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36

Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) and the continuous fixed covariate of baseline fasting TGs value. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Mean)
Standard of Care-26.2
Alirocumab-35.3

[back to top]

Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care4.7
Alirocumab8.1

[back to top]

Absolute Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmm^3 (Mean)
Standard of Care-1.25
Alirocumab-0.93

[back to top]

Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-20.3
Alirocumab-69.2

[back to top]

Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventioncubic millimeter (mm^3) (Least Squares Mean)
Standard of Care-4.73
Alirocumab-5.77

[back to top]

Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care3.8
Alirocumab12.0

[back to top]

Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent atheroma volume (Least Squares Mean)
Standard of Care-1.28
Alirocumab-1.42

[back to top]

Absolute Change From Baseline in Total Cholesterol (TC) at Week 36

LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-15.2
Alirocumab-61.7

[back to top]

Percent Change From Baseline in Apolipoprotein A-1 at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care4.61
Alirocumab11.75

[back to top]

Percent Change From Baseline in Apolipoprotein B at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-16.61
Alirocumab-55.13

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 36

Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) and the continuous fixed covariate of baseline fasting TGs value. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-8.85
Alirocumab-18.37

[back to top]

Percent Change From Baseline in External Elastic Membrane Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-0.86
Alirocumab-3.18

[back to top]

Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care12.19
Alirocumab21.04

[back to top]

Percent Change From Baseline in Lipoprotein (a) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-17.23
Alirocumab-55.76

[back to top]

Percent Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care1.20
Alirocumab-0.86

[back to top]

Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-14.06
Alirocumab-54.50

[back to top]

Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36

Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-3.14
Alirocumab-4.79

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-0.11
Placebo-4.63

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-1.14
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8772.87
Placebo-1.07

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8777.08
Placebo-2.42

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8771.00
Placebo0.01

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-48.78
Placebo8.43

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-37.93
Placebo5.37

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-48.58
Placebo7.54

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-49.06
Placebo6.71

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium

(NCT03001817)
Timeframe: 12 Weeks

Interventionμmol/L (Median)
K-877-0.97
Placebo0.02

[back to top]

Percent Change From Baseline to Week 12 in Non-HDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-16.07
Placebo0.81

[back to top]

Percent Change From Baseline to Week 12 in Remnant Cholesterol

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-52.95
Placebo-3.36

[back to top]

Percent Change From Baseline to Week 12 in Total Cholesterol

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-11.26
Placebo1.55

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-48.38
Placebo/Fenofibrate-47.69

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-51.64
Placebo/Fenofibrate-51.23

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-39.09
Placebo/Fenofibrate-30.29

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-48.01
Placebo/Fenofibrate-48.29

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8770.99
Placebo/Fenofibrate0.51

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8779.01
Placebo/Fenofibrate6.37

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8771.07
Placebo/Fenofibrate1.38

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-1.15
Placebo/Fenofibrate-1.11

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-3.88
Placebo/Fenofibrate-2.63

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-63.46
Placebo/Fenofibrate-65.21

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-27.21
Placebo/Fenofibrate-27.59

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-30.63
Placebo/Fenofibrate-32.36

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87728.03
Placebo/Fenofibrate24.73

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-20.98
Placebo/Fenofibrate-13.99

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8771.05
Placebo/Fenofibrate-1.76

[back to top]

Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent of Change (Median)
K-877-56.00
Placebo-7.97

[back to top]

Percent Change From Baseline to Week 52 in TC

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-11.84
Placebo/Fenofibrate-9.93

[back to top]

Percent Change From Baseline to Week 52 in Remnant Cholesterol

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-53.98
Placebo/Fenofibrate-49.11

[back to top]

Percent Change From Baseline to Week 52 in Non-HDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-17.24
Placebo/Fenofibrate-15.71

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-6.12
Placebo/Fenofibrate-6.70

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-87727.54
Placebo0.00

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877209.41
Placebo51.43

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-5.70
Placebo0.80

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877-5.52
Placebo-0.21

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large

(NCT03001817)
Timeframe: 12 Weeks

Interventionμmol/L (Median)
K-8770.27
Placebo0.05

[back to top]

Change From Baseline to Week 12 in hsCRP

(NCT03001817)
Timeframe: 12 Weeks

Interventionmg/L (Median)
K-877-0.051
Placebo-0.100

[back to top]

Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)

(NCT03001817)
Timeframe: 12 Weeks

Interventionpg/mL (Median)
K-877196.97
Placebo3.88

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-24.84
Placebo7.50

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8770.73
Placebo2.47

[back to top]

Percent Change From Baseline to Week 12 in LDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87731.93
Placebo1.01

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87730.90
Placebo-0.49

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-4.13
Placebo1.86

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-27.89
Placebo5.99

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-30.79
Placebo-4.49

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8772.38
Placebo-0.06

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-21.68
Placebo4.65

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-34.81
Placebo5.60

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-24.88
Placebo-0.26

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-1.50
Placebo1.11

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-17.32
Placebo4.70

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87733.08
Placebo0.85

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87761.87
Placebo1.26

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87759.36
Placebo0.75

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87745.24
Placebo1.04

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87715.50
Placebo3.06

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8774.47
Placebo2.10

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a

Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-2.01
Placebo1.76

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-7.34
Placebo2.04

[back to top]

Percent Change From Baseline to Week 12 in HDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87716.25
Placebo4.00

[back to top]

Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Chage (Median)
K-877-19.07
Placebo10.29

[back to top]

Percent Change From Baseline to Week 12 in Apo E

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-28.48
Placebo0.56

[back to top]

Percent Change From Baseline to Week 12 in Apo C3

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-39.56
Placebo5.11

[back to top]

Percent Change From Baseline to Week 12 in Apo C2

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8770.00
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Apo B48

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-31.35
Placebo22.62

[back to top]

Percent Change From Baseline to Week 12 in Apo B100

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8773.09
Placebo2.76

[back to top]

Percent Change From Baseline to Week 12 in Apo B

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8772.41
Placebo3.73

[back to top]

Percent Change From Baseline to Week 12 in Apo A1

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8771.21
Placebo2.13

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-8770.00
Placebo/Fenofibrate3.85

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-34.20
Placebo/Fenofibrate-20.70

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-87781.00
Placebo/Fenofibrate138.00

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-87725.50
Placebo/Fenofibrate50.50

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877193.00
Placebo/Fenofibrate213.50

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles

(NCT03001817)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-9.00
Placebo/Fenofibrate-6.50

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium

(NCT03001817)
Timeframe: 52 Weeks

Interventionumol/L (Median)
K-877-0.80
Placebo/Fenofibrate-1.15

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large

(NCT03001817)
Timeframe: 52 Weeks

Interventionumol/L (Median)
K-8770.10
Placebo/Fenofibrate-0.10

[back to top]

Change From Baseline to Week 52 in hsCRP

(NCT03001817)
Timeframe: 52 Weeks

Interventionmg/L (Median)
K-8770.000
Placebo/Fenofibrate-0.200

[back to top]

Change From Baseline to Week 52 in FGF21

(NCT03001817)
Timeframe: 52 Weeks

Interventionpg/mL (Median)
K-877259.20
Placebo/Fenofibrate207.50

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-8770.90
Placebo-1.87

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877-33.57
Placebo7.58

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small

(NCT03001817)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-87787.75
Placebo23.85

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-62.64
Placebo-11.22

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-25.84
Placebo-3.86

[back to top]

Percent Change From Baseline to Week 52 in Apo A1

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-8771.63
Placebo/Fenofibrate3.48

[back to top]

Percent Change From Baseline to Week 52 in Apo A2

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-8779.26
Placebo/Fenofibrate12.31

[back to top]

Percent Change From Baseline to Week 12 in Apo A2

(NCT03001817)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-87715.30
Placebo2.89

[back to top]

Percent Change From Baseline to Week 52 in Apo B100

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-8771.48
Placebo/Fenofibrate1.97

[back to top]

Percent Change From Baseline to Week 52 in Apo B48

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-14.04
Placebo/Fenofibrate-5.22

[back to top]

Percent Change From Baseline to Week 52 in Apo C2

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-8.70
Placebo/Fenofibrate-1.80

[back to top]

Percent Change From Baseline to Week 52 in Apo C3

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-36.70
Placebo/Fenofibrate-30.77

[back to top]

Percent Change From Baseline to Week 52 in Apo E

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-29.94
Placebo/Fenofibrate-30.67

[back to top]

Percent Change From Baseline to Week 52 in Fasting TG

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-57.93
Placebo/Fenofibrate-55.45

[back to top]

Percent Change From Baseline to Week 52 in FFAs

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-877-18.08
Placebo/Fenofibrate-13.64

[back to top]

Percent Change From Baseline to Week 52 in HDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-87717.65
Placebo/Fenofibrate19.35

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8772.38
Placebo/Fenofibrate1.56

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-9.54
Placebo/Fenofibrate-8.99

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a

Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction. (NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-3.58
Placebo/Fenofibrate-3.06

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8774.44
Placebo/Fenofibrate8.23

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87721.05
Placebo/Fenofibrate21.09

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87748.52
Placebo/Fenofibrate38.99

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87764.54
Placebo/Fenofibrate44.52

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87758.07
Placebo/Fenofibrate42.18

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-87731.63
Placebo/Fenofibrate30.84

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-8770.34
Placebo/Fenofibrate4.31

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-24.86
Placebo/Fenofibrate-15.38

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-35.58
Placebo/Fenofibrate-27.86

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-24.00
Placebo/Fenofibrate-22.02

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-21.71
Placebo/Fenofibrate-11.70

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-33.43
Placebo/Fenofibrate-24.44

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent Change (Median)
K-877-4.28
Placebo/Fenofibrate-3.23

[back to top]

Percent Change From Baseline to Week 52 in LDL-C

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-87731.15
Placebo/Fenofibrate36.84

[back to top]

Percent Change From Baseline to Week 52 in Apo B

(NCT03001817)
Timeframe: 52 Weeks

InterventionPercent of Change (Median)
K-8770.93
Placebo/Fenofibrate2.46

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-36.49
Placebo/Fenofibrate-27.67

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-31.53
Placebo/Fenofibrate-23.70

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-66.38
Placebo/Fenofibrate-56.61

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Cholesterol)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8772.90
Placebo/Fenofibrate-1.19

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particle Size)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-1.14
Placebo/Fenofibrate-1.15

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8774.96
Placebo/Fenofibrate0.00

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particle Size)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8771.03
Placebo/Fenofibrate0.51

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87714.43
Placebo/Fenofibrate12.79

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (Triglyceride)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-55.03
Placebo/Fenofibrate-42.76

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-40.10
Placebo/Fenofibrate-28.98

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-54.30
Placebo/Fenofibrate-41.55

[back to top]

Percent Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particle Size)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-7.15
Placebo/Fenofibrate-5.46

[back to top]

Percent Change From Baseline to Week 52 in Remnant Cholesterol

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-58.39
Placebo/Fenofibrate-43.31

[back to top]

Percent Change From Baseline to Week 52 in TC

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-15.28
Placebo/Fenofibrate-8.64

[back to top]

Percent Change in Fasting TG From Baseline to Week 12

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-58.89
Placebo-22.94

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 3 and 2a)

Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-2.13
Placebo-0.53

[back to top]

Change From Baseline to Week 12 in FGF21

(NCT03011450)
Timeframe: 12 Weeks

Interventionpg/mL (Median)
K-877277.97
Placebo12.15

[back to top]

Change From Baseline to Week 12 in hsCRP

(NCT03011450)
Timeframe: 12 Weeks

Interventionmg/L (Median)
K-877-0.201
Placebo-0.100

[back to top]

Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B

(NCT03011450)
Timeframe: 12 Weeks

InterventionRatio (Median)
K-8770.219
Placebo0.026

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Large)

(NCT03011450)
Timeframe: 12 Weeks

Interventionµmol/L (Median)
K-8770.22
Placebo0.00

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Medium)

(NCT03011450)
Timeframe: 12 Weeks

Interventionµmol/L (Median)
K-877-0.21
Placebo-0.23

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles-Small)

(NCT03011450)
Timeframe: 12 Weeks

Interventionµmol/L (Median)
K-8771.54
Placebo0.16

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (IDL Particles)

(NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877-17.06
Placebo-2.74

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Large)

(NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-87754.52
Placebo0.00

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles-Small)

(NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-87783.88
Placebo12.43

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877-12.62
Placebo-3.75

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Medium)

(NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-877-41.27
Placebo-9.13

[back to top]

Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particles-Small)

(NCT03011450)
Timeframe: 12 Weeks

Interventionnmol/L (Median)
K-8770.46
Placebo0.07

[back to top]

Change From Baseline to Week 52 in FGF21

(NCT03011450)
Timeframe: 52 Weeks

Interventionpg/mL (Median)
K-877371.80
Placebo/Fenofibrate194.40

[back to top]

Change From Baseline to Week 52 in hsCRP

(NCT03011450)
Timeframe: 52 Weeks

Interventionmg/L (Median)
K-877-0.100
Placebo/Fenofibrate-0.225

[back to top]

Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B

(NCT03011450)
Timeframe: 52 Weeks

InterventionRatio (Median)
K-8770.210
Placebo/Fenofibrate0.150

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Large)

(NCT03011450)
Timeframe: 52 Weeks

Interventionumol/L (Median)
K-8770.20
Placebo/Fenofibrate0.30

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Medium)

(NCT03011450)
Timeframe: 52 Weeks

Interventionumol/L (Median)
K-877-0.20
Placebo/Fenofibrate-0.40

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (HDL Particles-Small)

(NCT03011450)
Timeframe: 52 Weeks

Interventionumol/L (Median)
K-8771.80
Placebo/Fenofibrate1.40

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (IDL Particles)

(NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-12.00
Placebo/Fenofibrate-6.00

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Large)

(NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-87753.00
Placebo/Fenofibrate8.00

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (LDL Particles-Small)

(NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-87759.00
Placebo/Fenofibrate97.00

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL & Chylomicron Particles-Large)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-13.00
Placebo/Fenofibrate-8.60

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Medium)

(NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-41.95
Placebo/Fenofibrate-26.90

[back to top]

Change From Baseline to Week 52 in Lipoprotein Fraction (VLDL Particles-Small)

(NCT03011450)
Timeframe: 52 Weeks

Interventionnmol/L (Median)
K-877-0.15
Placebo/Fenofibrate0.00

[back to top]

Percent Change From Baseline to Week 52 in Non-HDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-21.80
Placebo/Fenofibrate-14.22

[back to top]

Percent Change From Baseline to Week 12 in Apo A1

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8774.05
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Apo A2

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87719.34
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Apo B

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8770.57
Placebo-1.67

[back to top]

Percent Change From Baseline to Week 12 in Apo B100

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8772.05
Placebo-2.33

[back to top]

Percent Change From Baseline to Week 12 in Apo B48

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-36.64
Placebo19.91

[back to top]

Percent Change From Baseline to Week 12 in Apo C2

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-4.70
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Apo C3

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-41.97
Placebo-3.10

[back to top]

Percent Change From Baseline to Week 12 in Apo E

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-29.09
Placebo-5.98

[back to top]

Percent Change From Baseline to Week 12 in FFAs

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-25.25
Placebo-5.51

[back to top]

Percent Change From Baseline to Week 12 in HDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87723.50
Placebo7.33

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Diameter of the Major LDL Particle (Å))

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8772.67
Placebo0.14

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (High Density Lipoproteins 2b)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-10.65
Placebo0.91

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 1)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-0.22
Placebo2.42

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Intermediate Density Lipoproteins 2)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87717.52
Placebo3.21

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins I)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87744.20
Placebo4.81

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIa)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87753.94
Placebo4.24

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIb)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87748.44
Placebo1.89

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIa)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87723.79
Placebo-0.80

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IIIb)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-5.73
Placebo0.71

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVa)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-30.48
Placebo-2.89

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVb)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-35.08
Placebo-0.74

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (Low Density Lipoproteins IVc)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-23.39
Placebo0.89

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Intermediate)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-23.23
Placebo0.07

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Large)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-36.45
Placebo-5.95

[back to top]

Percent Change From Baseline to Week 12 in Ion Mobility (VLDL Cholesterol-Small)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-6.07
Placebo4.16

[back to top]

Percent Change From Baseline to Week 12 in LDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87731.49
Placebo2.30

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-1.68
Placebo-1.25

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-27.76
Placebo-0.47

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-32.36
Placebo-9.02

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TC:HDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-32.36
Placebo-9.02

[back to top]

Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-66.21
Placebo-26.81

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particle Size)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-877-1.19
Placebo-0.14

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (HDL Particles)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8775.96
Placebo-1.60

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particle Size)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-8771.02
Placebo0.00

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (LDL Particles)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-87717.58
Placebo4.97

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (Triglyceride)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-54.86
Placebo-15.24

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Particles)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-42.76
Placebo-5.59

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL & Chylomicron Triglyceride)

Two types of lipoprotein particles were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-55.19
Placebo-16.20

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction (VLDL Particle Size)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-5.02
Placebo-2.26

[back to top]

Percent Change From Baseline to Week 12 in Lipoprotein Fraction HDL Cholesterol (Total)

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent Change (Median)
K-8775.51
Placebo-2.20

[back to top]

Percent Change From Baseline to Week 12 in Non-HDL-C

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-20.98
Placebo-3.43

[back to top]

Percent Change From Baseline to Week 12 in Remnant Cholesterol

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-55.51
Placebo-13.29

[back to top]

Percent Change From Baseline to Week 12 in Total Cholesterol

(NCT03011450)
Timeframe: 12 Weeks

InterventionPercent change (Median)
K-877-14.55
Placebo-2.05

[back to top]

Percent Change From Baseline to Week 52 in Apo A1

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8773.29
Placebo/Fenofibrate2.56

[back to top]

Percent Change From Baseline to Week 52 in Apo A2

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87715.92
Placebo/Fenofibrate8.33

[back to top]

Percent Change From Baseline to Week 52 in Apo B

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-1.73
Placebo/Fenofibrate0.00

[back to top]

Percent Change From Baseline to Week 52 in Apo B100

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-1.32
Placebo/Fenofibrate-0.87

[back to top]

Percent Change From Baseline to Week 52 in Apo B48

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-19.43
Placebo/Fenofibrate-15.19

[back to top]

Percent Change From Baseline to Week 52 in Apo C2

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-9.56
Placebo/Fenofibrate0.00

[back to top]

Percent Change From Baseline to Week 52 in Apo C3

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-42.80
Placebo/Fenofibrate-26.25

[back to top]

Percent Change From Baseline to Week 52 in Apo E

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-30.82
Placebo/Fenofibrate-30.00

[back to top]

Percent Change From Baseline to Week 52 in Fasting TG

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-59.96
Placebo/Fenofibrate-49.55

[back to top]

Percent Change From Baseline to Week 52 in FFAs

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-21.61
Placebo/Fenofibrate-21.41

[back to top]

Percent Change From Baseline to Week 52 in HDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87718.78
Placebo/Fenofibrate15.59

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Diameter of the Major LDL Particle (Å))

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8772.69
Placebo/Fenofibrate1.54

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 2b)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-11.67
Placebo/Fenofibrate-5.62

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (High Density Lipoproteins 3 and 2a)

Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction. (NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-4.62
Placebo/Fenofibrate-3.71

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 1)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-8770.69
Placebo/Fenofibrate3.54

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Intermediate Density Lipoproteins 2)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87717.33
Placebo/Fenofibrate15.87

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins I)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87746.51
Placebo/Fenofibrate25.53

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIa)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87761.36
Placebo/Fenofibrate33.66

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIb)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87745.61
Placebo/Fenofibrate27.29

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIa)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87718.50
Placebo/Fenofibrate19.64

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IIIb)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-6.92
Placebo/Fenofibrate1.17

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVa)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-25.63
Placebo/Fenofibrate-24.80

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVb)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-37.26
Placebo/Fenofibrate-24.22

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (Low Density Lipoproteins IVc)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-26.81
Placebo/Fenofibrate-17.41

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Intermediate)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-25.03
Placebo/Fenofibrate-13.31

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Large)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-36.60
Placebo/Fenofibrate-22.03

[back to top]

Percent Change From Baseline to Week 52 in Ion Mobility (VLDL Cholesterol-Small)

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-12.96
Placebo/Fenofibrate-2.31

[back to top]

Percent Change From Baseline to Week 52 in LDL-C

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-87731.90
Placebo/Fenofibrate22.96

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-3.56
Placebo/Fenofibrate-2.94

[back to top]

Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2

(NCT03011450)
Timeframe: 52 Weeks

InterventionPercent change (Median)
K-877-27.81
Placebo/Fenofibrate-13.17

[back to top]

Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-4.2-11.80.9

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab13.08.910.1

[back to top]

Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on-or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Mean)
Week 12Week 24Week 48
Alirocumab7.4-5.2-6.4

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 24 and 48

Interventionpercent change (Least Squares Mean)
Week 24Week 48
Alirocumab-10.14.2

[back to top]

Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-3.9-9.25.7

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-1.9-6.35.5

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis

Adjusted least square (LS) means and standard errors were obtained from the mixed model analysis with repeated measures (MMRM) to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). (NCT03510715)
Timeframe: Baseline to Week 12

Interventionpercent change (Least Squares Mean)
Alirocumab-4.1

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline on-treatment data from Week 4 to Week 48 (on-treatment Analysis). (NCT03510715)
Timeframe: Baseline to Week 12

Interventionpercent change (Least Squares Mean)
Alirocumab-4.1

[back to top]

Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionmg/dL (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-33.4-43.0-15.0

[back to top]

Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48

Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males), and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty). (NCT03510715)
Timeframe: Baseline, Weeks 12, 24 and 48

,
InterventionParticipants (Count of Participants)
Baseline: PrepubescentBaseline: PubescentBaseline: Post-pubescentWeek 12: PrepubescentWeek 12: PubescentWeek 12: Post-pubescentWeek 24: PrepubescentWeek 24: PubescentWeek 24: Post-pubescentWeek 48: PrepubescentWeek 48: PubescentWeek 48: Post-pubescent
Alirocumab 150 mg Q2W090081081072
Alirocumab 75 mg Q2W/up to 150 mg Q2W360360260170

[back to top]

Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted Percentage were obtained from a multiple imputation approach for handling of missing data including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercentage of participants (Number)
Week 12Week 24Week 48
Alirocumab50.050.039.0

[back to top]

Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab11.314.611.3

[back to top]

Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Mean)
Week 12Week 24Week 48
Alirocumab2.85.210.0

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.1
DB Period: Alirocumab Q2W1.0
DB Period: Placebo Q4W-4.5
DB Period: Alirocumab Q4W4.4

[back to top]

DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response

Anti-drug (alirocumab) antibodies samples were analyzed using a validated non-quantitative, titer-based bridging immunoassay. Number of participants with positive ADA during 24-week treatment period is reported. Treatment-emergent positive ADA response was defined as 1) participants with no ADA positive response at baseline but with any positive response in the post-baseline period or 2) participants with a positive ADA response at baseline and at least a 4- fold increase in titer in the post-baseline period. A persistent positive response was defined as a TE ADA positive response detected in at least 2 consecutive post-baseline samples separated by at least a 12-week period. Persistent positive response was only analyzed for participants with positive TE ADA response. (NCT03510884)
Timeframe: Up to 24 weeks

,,
InterventionParticipants (Count of Participants)
TE ADA positive response
DB Period: Alirocumab Q4W0
DB Period: Placebo Q2W0
DB Period: Placebo Q4W0

[back to top]

DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-0.2-0.2
DB Period: Alirocumab Q4W-0.3-0.3
DB Period: Placebo Q2W0.10.1
DB Period: Placebo Q4W0.00.0

[back to top]

DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 and Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-0.2-0.2
DB Period: Alirocumab Q4W-0.3-0.3
DB Period: Placebo Q2W0.10.1
DB Period: Placebo Q4W0.00.0

[back to top]

Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104

Cogstate battery test (cognitive testing system) consisted of detection test (DET), identification test (IDN), one card learning test (OCL) and Groton maze learning test (GML) to assess processing speed, attention, visual learning and executive functioning, respectively. For each test, Z-scores were computed based on participant's age at Baseline and Weeks 24, 68 and 104. Composite score: calculated as mean of Z-scores equally weighted, provided that at least 3 of 4 tests were available and if all of these domains were covered as: attention, through either DET or IDN, visual learning, through OCL and executive function, through GML. There is not minimum/maximum since values were reported as z-score but z-score of 0 means result equals to mean with negative numbers indicating values lower than mean and positive values higher. Positive change in z-score = an improvement in cognition, i.e., a better outcome; and negative change in z-score = worsening in cognition, i.e., a worse outcome. (NCT03510884)
Timeframe: Baseline, Weeks 24, 68 and 104

,,,
InterventionZ-score (Mean)
Week 24Week 68Week 104
Alirocumab Q2W-0.313-0.334-0.439
Alirocumab Q4W-0.136-0.263-0.638
Placebo/Alirocumab Q2W-0.403-0.421-0.601
Placebo/Alirocumab Q4W-0.218-0.272-0.393

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.1
DB Period: Alirocumab Q2W-1.7
DB Period: Placebo Q4W-0.7
DB Period: Alirocumab Q4W5.0

[back to top]

OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand

Percent Change in LDL-C from Baseline to Week 104 was reported in this outcome measure. (NCT03510884)
Timeframe: Baseline, Week 104

Interventionpercent change (Least Squares Mean)
OL Period: Placebo/Alirocumab Q2W-22.8
OL Period: Alirocumab Q2W-25.8
OL Period: Placebo/Alirocumab Q4W-27.6
OL Period: Alirocumab Q4W-23.4

[back to top]

OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand

Percent Change in LDL-C from Baseline to Week 104 was reported in this outcome measure. (NCT03510884)
Timeframe: Baseline, Week 104

Interventionpercent change (Least Squares Mean)
OL Period: Placebo/Alirocumab Q2W-23.3
OL Period: Alirocumab Q2W-22.2
OL Period: Placebo/Alirocumab Q4W-27.1
OL Period: Alirocumab Q4W-23.7

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand

Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Week 24

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W8.0
DB Period: Alirocumab Q2W73.3
DB Period: Placebo Q4W22.2
DB Period: Alirocumab Q4W76.3

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand

Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 12 were included in the imputation model. (NCT03510884)
Timeframe: At Week 12

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W16.4
DB Period: Alirocumab Q2W70.6
DB Period: Placebo Q4W12.9
DB Period: Alirocumab Q4W72.6

[back to top]

DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand

Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Week 24

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W4.0
DB Period: Alirocumab Q2W57.2
DB Period: Placebo Q4W9.0
DB Period: Alirocumab Q4W67.2

[back to top]

DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand

Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data for Q4W. All available post-baseline data up to Week 12 were included in the imputation model. For Q2W, adjusted percentages at Week 12 were obtained from last observation carried forward approach (LOCF) to handle missing on-treatment LDL-C values as well as missing post-treatment LDL-C values in participants who discontinued treatment due to the coronavirus disease-2019 pandemic. Other post-treatment missing values were considered as failure. (NCT03510884)
Timeframe: At Week 12

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W0.0
DB Period: Alirocumab Q2W61.2
DB Period: Placebo Q4W4.3
DB Period: Alirocumab Q4W57.0

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W7.5
DB Period: Alirocumab Q2W-25.3
DB Period: Placebo Q4W0.9
DB Period: Alirocumab Q4W-27.0

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W7.4
DB Period: Alirocumab Q2W-23.4
DB Period: Placebo Q4W-4.4
DB Period: Alirocumab Q4W-27.7

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.8
DB Period: Alirocumab Q2W-33.0
DB Period: Placebo Q4W2.8
DB Period: Alirocumab Q4W-34.7

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.7
DB Period: Alirocumab Q2W-31.0
DB Period: Placebo Q4W-3.7
DB Period: Alirocumab Q4W-35.6

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W10.7
DB Period: Alirocumab Q2W-34.8
DB Period: Placebo Q4W2.3
DB Period: Alirocumab Q4W-39.2

[back to top]

Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104

Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males) and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty). (NCT03510884)
Timeframe: Baseline, Weeks 24, 68 and 104

,,,
InterventionParticipants (Count of Participants)
Baseline: Boys - PrepubescentBaseline: Boys - PubescentBaseline: Boys - PostpubescentBaseline: Girls - PrepubescentBaseline: Girls - PubescentBaseline: Girls - PostpubescentWeek 24: Boys - PrepubescentWeek 24: Boys - PubescentWeek 24: Boys - PostpubescentWeek 24: Girls - PrepubescentWeek 24: Girls - PubescentWeek 24: Girls - PostpubescentWeek 68: Boys - PrepubescentWeek 68: Boys - PubescentWeek 68: Boys - PostpubescentWeek 68: Girls - PrepubescentWeek 68: Girls - PubescentWeek 68: Girls - PostpubescentWeek 104: Boys - PrepubescentWeek 104: Boys - PubescentWeek 104: Boys - PostpubescentWeek 104: Girls - PrepubescentWeek 104: Girls - PubescentWeek 104: Girls - Postpubescent
Alirocumab Q2W41324161031134159196314918601011
Alirocumab Q4W01447131401252169096116908711711
Placebo/Alirocumab Q2W11331610134152074061067042
Placebo/Alirocumab Q4W543186173165153155152155

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand

Adjusted least square (LS) means and standard errors (SE) were obtained from mixed-effect model with repeated measures (MMRM) model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.7
DB Period: Alirocumab Q2W-33.6
DB Period: Placebo Q4W-4.4
DB Period: Alirocumab Q4W-38.2

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 24. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Mean)
DB Period: Placebo Q2W0.5
DB Period: Alirocumab Q2W-14.7
DB Period: Placebo Q4W2.5
DB Period: Alirocumab Q4W-22.4

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 12. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Mean)
DB Period: Placebo Q2W-7.1
DB Period: Alirocumab Q2W-12.7
DB Period: Placebo Q4W-2.5
DB Period: Alirocumab Q4W-16.0

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-2.2
DB Period: Alirocumab Q2W3.5
DB Period: Placebo Q4W-3.5
DB Period: Alirocumab Q4W4.0

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.8
DB Period: Alirocumab Q2W5.6
DB Period: Placebo Q4W-1.1
DB Period: Alirocumab Q4W3.4

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 24. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Mean)
DB Period: Placebo Q2W7.7
DB Period: Alirocumab Q2W11.9
DB Period: Placebo Q4W12.2
DB Period: Alirocumab Q4W-6.8

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 12. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Mean)
DB Period: Placebo Q2W6.5
DB Period: Alirocumab Q2W-2.2
DB Period: Placebo Q4W7.8
Db Period: Alirocumab Q4W-0.3

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W8.9
DB Period: Alirocumab Q2W-30.0
DB Period: Placebo Q4W1.1
DB Period: Alirocumab Q4W-31.7

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W10.4
DB Period: Alirocumab Q2W-27.4
DB Period: Placebo Q4W-3.6
DB Period: Alirocumab Q4W-34.3

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W70.673.3
DB Period: Alirocumab Q4W72.676.3
DB Period: Placebo Q2W16.48.0
Db Period: Placebo Q4W12.922.2

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W61.757.2
DB Period: Alirocumab Q4W57.067.2
DB Period: Placebo Q2W0.14.0
DB Period: Placebo Q4W4.39.0

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W25.221.6
DB Period: Alirocumab Q4W31.932.4
DB Period: Placebo Q2W0.00.0
DB Period: Placebo Q4W0.19.1

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W25.221.6
DB Period: Alirocumab Q4W31.932.4
DB Period: Placebo Q2W0.00.0
DB Period: Placebo Q4W0.19.1

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week12Week 24
DB Period: Alirocumab Q2W65.866.7
DB Period: Alirocumab Q4W70.872.5
DB Period: Placebo Q2W0.84.0
DB Period: Placebo Q4W4.218.5

[back to top]

DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W65.866.7
DB Period: Alirocumab Q4W70.872.5
DB Period: Placebo Q2W0.84.0
DB Period: Placebo Q4W4.218.5

[back to top]

DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 8, Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Baseline to Weeks 8, 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 8Week 12Week 24
DB Period: Alirocumab Q2W-35.4-34.8-33.6
DB Period: Alirocumab Q4W-42.0-39.2-38.2
DB Period: Placebo Q2W7.110.79.7
DB Period: Placebo Q4W-3.82.3-4.4

[back to top]

DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 8, Week 12 and Week 24 were used and missing data were accounted for by the MMRM model. (NCT03510884)
Timeframe: Baseline to Weeks 8, 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 8Week 12Week 24
DB Period: Alirocumab Q2W-35.4-34.8-33.6
DB Period: Alirocumab Q4W-42.0-39.2-38.2
DB Period: Placebo Q2W7.110.79.7
DB Period: Placebo Q4W-3.82.3-4.4

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-25.3-23.4
DB Period: Alirocumab Q4W-27.0-27.7
DB Period: Placebo Q2W7.57.4
DB Period: Placebo Q4W0.9-4.4

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-33.0-31.0
Db Period: Alirocumab Q4W-34.7-35.6
DB Period: Placebo Q2W9.89.7
DB Period: Placebo Q4W2.8-3.7

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st investigational medicinal product (IMP) injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-34.8-33.6
DB Period: Alirocumab Q4W-39.2-38.2
DB Period: Placebo Q2W10.79.7
DB Period: Placebo Q4W2.3-4.4

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline on-treatment data up to Week 12 and Week 24, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-12.746-14.748
DB Period: Alirocumab Q4W-16.042-22.418
DB Period: Placebo Q2W-7.0990.492
DB Period: Placebo Q4W-2.5452.468

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 day otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W3.55.6
DB Period: Alirocumab Q4W4.03.4
DB Period: Placebo Q2W-2.2-0.8
DB Period: Placebo Q4W-3.5-1.1

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline on-treatment data up to Week 12 and Week 24, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-2.211.9
DB Period: Alirocumab Q4W-0.3-6.8
DB Period: Placebo Q2W6.57.7
DB Period: Placebo Q4W7.812.2

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-30.0-27.4
DB Period: Alirocumab Q4W-31.7-34.3
DB Period: Placebo Q2W8.910.4
DB Period: Placebo Q4W1.1-3.6

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM mode, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-1.71.0
DB Period: Alirocumab Q4W5.04.4
DB Period: Placebo Q2W-0.1-0.1
DB Period: Placebo Q4W-0.7-4.5

[back to top]

DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response

Anti-drug (alirocumab) antibodies samples were analyzed using a validated non-quantitative, titer-based bridging immunoassay. Number of participants with positive ADA during 24-week treatment period is reported. Treatment-emergent positive ADA response was defined as 1) participants with no ADA positive response at baseline but with any positive response in the post-baseline period or 2) participants with a positive ADA response at baseline and at least a 4- fold increase in titer in the post-baseline period. A persistent positive response was defined as a TE ADA positive response detected in at least 2 consecutive post-baseline samples separated by at least a 12-week period. Persistent positive response was only analyzed for participants with positive TE ADA response. (NCT03510884)
Timeframe: Up to 24 weeks

InterventionParticipants (Count of Participants)
TE ADA positive responsePersistent positive response
DB Period: Alirocumab Q2W30

[back to top]

Changes in Unified Huntington Disease Rating Scale - Behavioral

Unified Huntington Disease Rating Scale (UHDRS) Behavioral Scale (total score range 0-100 where 100 = 100% independent) (NCT03515213)
Timeframe: Baseline, Month 3 and 6 months

,
Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Active9.7788.3338.444
Placebo898

[back to top]

Change in Unified Huntington Disease Rating Scale Motor Score.

Unified Huntington Disease Rating Scale (UHDRS) Motor (total score range 0-124 where higher score = greater impairment) (NCT03515213)
Timeframe: Baseline and 6 months

,
Interventionscore on a scale (Mean)
BaselineMonth 6
Active19.5621.22
Placebo3427

[back to top]

Change in PGC-1alpha RNA Expression

Change in PGC-1alpha RNA expression from Baseline, Month 3 and Month 6 (NCT03515213)
Timeframe: Baseline compared to 3 and 6 months.

,
InterventionLog 2 fold change (Mean)
Month 3Month 6
Active-0.021907160.07414876
Placebo0.31605620.4800263

[back to top]

Change in PGC-1alpha Protein Abundance.

Mean change in PGC-1alpha protein abundance. (NCT03515213)
Timeframe: Baseline compared to 3 and 6 months.

,
InterventionLog 2 fold change (Mean)
Month 3Month 6
Active0.26091230.02375246
Placebo-0.020297920.3185422

[back to top]

Change in Montreal Cognitive Assesment Score.

Montreal Cognitive Assessment (total score range 0-30, higher score = less impairment) (NCT03515213)
Timeframe: Baseline compared to 3 and 6 months.

,
Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Active24.22225.77825.667
Placebo181622

[back to top]

Change in Functional Assessment Scores

Clinical Global Impression (CGI-I); (total score range 1-7 where higher score = greater impairment), and Unified Huntington Disease Rating Scale (UHDRS) Total Functional Capacity Assessment ( total score range 0-13, higher score = less impairment) (NCT03515213)
Timeframe: Baseline compared to 3 and 6 months.

,
Interventionscore on a scale (Mean)
BaselineMonth 3Month 6
Active3.2223.5713.571
Placebo333

[back to top]

Change in Fenofibric Acid Level.

Change in Fenofibric acid abundance from Baseline to 3 and 6 months. (NCT03515213)
Timeframe: Baseline to 3 and 6 months.

,
InterventionNg/ml (Mean)
BaselineMonth 3Month 6
Active64903710905
Placebo51019

[back to top]

Adverse Events

"Assessments comprise the total number of participants complicating and reporting muscle pain,flushing, nausea, vomiting, and dizziness.~As part of the complete safety profile of each arm,other specific reported adverse event are presented in the Adverse Event Module." (NCT03615534)
Timeframe: Changes from baseline were assessed at the end of the eighth week of treatments.

,,,
InterventionParticipants (Count of Participants)
Muscle PainFlushingNausea/VomitingDizziness
Combination Therapy1011
Fenofibrate Monotherapy0000
Placebo0000
WMER Niacin Monotherapy0130

[back to top]

Changes in Estimated Glomerular Filtration Rate (eGFR)

Assessments involve the measurement of serum creatinine which is used to calculate eGFR using the CKD-EPI equation (2009) . (NCT03615534)
Timeframe: Changes from baseline were assessed at the end of the eighth week of treatments.

,,,
Interventionml/min per 1.73 m^2 (Mean)
Baseline eGFRAdjusted End line eGFR
Combination Therapy85.279.2
Fenofibrate Monotherapy86.583.2
Placebo89.883.1
WMER Niacin Monotherapy91.082.9

[back to top]

Changes in Serum Apolipoprotein Levels

Assessments involve the measurement of serum Apolipoprotein A1 (Apo A1) and B (Apo B) levels. (NCT03615534)
Timeframe: Treatments effects were assessed by two events, baseline investigations conducted before randomization and end line investigations at the end of the eighth week of treatments.

,,,
Interventionmg/dl (Mean)
Baseline Apo A1Baseline Apo BAdjusted End line Apo A1Adjusted End line Apo B
Combination Therapy150.0133.1162.3101.7
Fenofibrate Monotherapy143.8141.8155.9106.7
Placebo130.8134.1130.2124.7
WMER Niacin Monotherapy150.1123.0134.2111.1

[back to top]

Changes in Serum Enzymes Levels

Assessments involve the measurement of serum enzymes including Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) levels. (NCT03615534)
Timeframe: Changes from baseline were assessed at the end of the eighth week of treatments.

,,,
InterventionIU/L (Mean)
Baseline ASTBaseline ALTBaseline CKAdjusted End line ASTAdjusted End line ALTAdjusted End line CK
Combination Therapy18.917.828.019.616.228.2
Fenofibrate Monotherapy18.816.329.117.314.434.9
Placebo17.113.128.018.915.427.3
WMER Niacin Monotherapy17.016.026.918.016.427.4

[back to top]

Changes in Serum Fasting Glucose Levels.

Assessments involve the measurement of serum fasting glucose levels. (NCT03615534)
Timeframe: Changes from baseline were assessed at the end eighth week of treatments.

,,,
Interventionmg/dl (Mean)
Baseline serum fasting glucoseAdjusted End line serum fasting glucose
Combination Therapy94.787.3
Fenofibrate Monotherapy98.991.7
Placebo93.591.3
WMER Niacin Monotherapy94.6100.1

[back to top]

Changes in Serum Lipoprotein Cholesterol Levels

"Assessments involve the measurement of serum Total (TC), High density lipoprotein (HDL-C) and direct Low density lipoprotein (d-LDL-C) cholesterol levels.~Serum non HDL-C levels is calculated by subtracting HDL-C from TC. Serum Remnant cholesterol (RC) is calculated by subtracting HDL-C and d-LDL-C from TC." (NCT03615534)
Timeframe: Treatments effects were assessed by two events, baseline investigations conducted before randomization and end line investigations at the end of the eighth week of treatments.

,,,
Interventionmg/dl (Mean)
Baseline TCBaseline HDL-CBaseline d-LDL-CBaseline non HDL-CBaseline RCAdjusted End line TCAdjusted End line HDL-CAdjusted End line d-LDL-CAdjusted End line non HDL-CAdjusted End line RC
Combination Therapy219.529.7129.3189.760.5179.942.8115.0136.322.1
Fenofibrate Monotherapy190.732.1108.9158.649.7171.137.2103.6134.130.3
Placebo203.130.9120.0172.352.3198.432.0115.7166.450.7
WMER Niacin Monotherapy189.134.2120.1154.934.9177.338.3103.3138.735.7

[back to top]

Changes in Serum Uric Acid Levels

Assessments involve the measurement of serum uric acid levels (NCT03615534)
Timeframe: Changes from baseline were assessed at the end of the eighth week of treatments.

,,,
Interventionmg/dl (Mean)
Baseline serum uric acidAdjusted End line serum uric acid
Combination Therapy5.283.9
Fenofibrate Monotherapy5.214.0
Placebo4.454.80
WMER Niacin Monotherapy4.875.6

[back to top]

Changes in Systolic and Diastolic Blood Pressure

Assessments involve the measurement of systolic and diastolic blood pressure. Patients were allowed to rest for 15 minutes in sitting position, and Walgreens Homedics WGNBPA-540 upper arm blood pressure monitor (Walgreens, China), was used for the measurement of blood pressure. Three consecutive readings were taken at 1 minute interval, and systolic and diastolic blood pressure were calculated as the mean of the last two readings. (NCT03615534)
Timeframe: Changes from baseline were assessed at the end of the eighth week of treatments.

,,,
InterventionmmHg (Mean)
Baseline diastolic blood pressureBaseline systolic blood pressureAdjusted End line diastolic blood pressureAdjusted End line systolic blood pressure
Combination Therapy77.3119.580.9118.8
Fenofibrate Monotherapy83.5125.478.6117.4
Placebo80.7120.779.5118.3
WMER Niacin Monotherapy76.1118.580.3117.8

[back to top]

Changes Serum Triglyceride Levels

Assessments involve the measurement of serum Triglyceride (TG) level. (NCT03615534)
Timeframe: Treatments effects were assessed by two events, baseline investigations conducted before randomization and end line investigations at the end of the eighth week of treatments.

,,,
Interventionmg/dl (Mean)
Baseline TG levelsAdjusted End line TG levels
Combination Therapy267.2136.1
Fenofibrate Monotherapy241.2133.7
Placebo223.1220.2
WMER Niacin Monotherapy227.0164.0

[back to top]

Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry

Protein exclusive intensity values (counts/second) were normalized using cyclic loess normalization. Mean protein abundance as determined by the intensity for each protein was determined. 95% confidence intervals were calculated as a measure of dispersion. Paired means were compared using a Limma T-test and the p-value was adjusted for multiple comparisons using the Benjamini-Hochberg method. Mean Log2 Fold Change was calculated for each protein compared between 6 weeks and baseline. The number of proteins that changed between 6 weeks and baseline was zero. (NCT03829514)
Timeframe: Six weeks, from baseline visit to study completion visit

InterventionProteins (Mean)
Fenofibrate0

[back to top]

Seven-category Ordinal Scale

A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care1
Placebo + Usual Care1

[back to top]

Secondary Hierarchical Composite Endpoint

The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.05
Placebo + Usual Care5.05

[back to top]

Primary Hierarchical Composite Endpoint

The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days

InterventionRanked Severity Score (Median)
Fenofibrate + Usual Care5.32
Placebo + Usual Care5.33

[back to top]

Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization

Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Mean)
Fenofibrate + Usual Care28.8
Placebo + Usual Care28.3

[back to top]

Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization

Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Median)
Fenofibrate + Usual Care30
Placebo + Usual Care30

[back to top]

Exploratory Hierarchical Composite Endpoint

The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.03
Placebo + Usual Care5.03

[back to top]

All-Cause Death

Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Fenofibrate + Usual Care19
Placebo + Usual Care22

[back to top]